tazobactam profile

Tazobactam: A penicillanic acid and sulfone derivative and potent BETA-LACTAMASE inhibitor that enhances the activity of other anti-bacterial agents against beta-lactamase producing bacteria. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

tazobactam : A member of the class of penicillanic acids that is sulbactam in which one of the exocyclic methyl hydrogens is replaced by a 1,2,3-triazol-1-yl group; used (in the form of its sodium salt) in combination with ceftolozane sulfate for treatment of complicated intra-abdominal infections and complicated urinary tract infections. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	123630
CHEMBL ID	404
CHEBI ID	9421
SCHEMBL ID	122302
MeSH ID	M0127405

Synonym
AC-7620
BIDD:GT0212
tazobactam acid
(2s,3s,5r)-3-methyl-4,4,7-trioxo-3-[1,2,3]triazol-1-ylmethyl-4lambda6-thia-1-aza-bicyclo[3.2.0]heptane-2-carboxylic acid
(2s,3s,5r)-3-methyl-4,4,7-trioxo-3-[1,2,3]triazol-1-ylmethyl-4lambda 6-thia-1-aza-bicyclo[3.2.0]heptane-2-carboxylic acid
(2s,3s,5r)-3-methyl-4,4,7-trioxo-3-[1,2,3]triazol-1-ylmethyl-4-thia-1-aza-bicyclo[3.2.0]heptane-2-carboxylic acid
3-methyl-4,4,7-trioxo-3-[1,2,3]triazol-1-ylmethyl-4lambda6-thia-1-aza-bicyclo[3.2.0]heptane-2-carboxylic acid
bdbm50053173
cl-298741
ytr-830h
(2s,3s,5r)-3-methyl-7-oxo-3-(1h-1,2,3-triazol-1-ylmethyl)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid 4,4-dioxide
89785-84-2
ytr830h
4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3-methyl-7-oxo-3-(1h-1,2,3-triazol-1-ylmethyl)-, 4,4-dioxide, (2s,3s,5r)-
(2s,3s,5r)-3-methyl-4,4,7-trioxo-3-(triazol-1-ylmethyl)-4$l^{6}-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
cl298741
C07771
89786-04-9
tazobactam
DB01606
D00660
tazobactam (jp17/usp/inn)
cl 298741
ytr 830h
cl 298,741
ytr 830
ytr 830 h
brn 4787943
ccris 2203
(2s,3s,5r)-3-methyl-7-oxo-3-(1h-1,2,3-triazol-1-ylmethyl)-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 4,4-dioxide
tazobactamum [inn-latin]
4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3-methyl-7-oxo-3-(1h-1,2,3-triazol-1-ylmethyl)-, 4,4-dioxide, (2s-(2alpha,3beta,5alpha))-
CHEMBL404 ,
chebi:9421 ,
nsc-759887
A843310
(2s,3s,5r)-3-methyl-4,4,7-trioxo-3-(1-triazolylmethyl)-4$l^{6}-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
(2s,3s,5r)-3-methyl-4,4,7-tris(oxidanylidene)-3-(1,2,3-triazol-1-ylmethyl)-4$l^{6}-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
se10g96m8w ,
tazobactamum
nsc 759887
ec 618-303-7
tazobactam [usan:usp:inn:ban]
unii-se10g96m8w
(2s,3s,5r)-3-methyl-7-oxo-3-(1h-1,2,3-triazol-1-ylmethyl)-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid 4,4-dioxide
AKOS015960801
tazobactam [who-dd]
tazobactam [usp monograph]
tazobactam [usp-rs]
tazobactam [usp impurity]
tazobactam [usan]
tazobactam [jan]
tazobactam [mi]
tazobactam [inn]
S3077 ,
BRD-K14312455-001-01-6
CCG-207890
SCHEMBL122302
T3732
LPQZKKCYTLCDGQ-WEDXCCLWSA-N
CS-4914
T-1445
tazobactam, antibiotic for culture media use only
(2s,3s,5s)-3-methyl-7-oxo-3-(1h-1,2,3-triazol-1-ylmethyl)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid 4,4-dioxide
(2s,3s,5r)-3-methyl-4,4,7-trioxo-3-[(1h-1,2,3-triazol-1-yl)methyl]-4lambda(6)-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
HY-B1418
DTXSID8023634
(2s,3s,5r)-3-methyl-4,4,7-trioxo-3-(1h-1,2,3-triazol-1-ylmethyl)-4$l^{6}-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
(2s,3s,5r)-3-methyl-4,4,7-trioxo-3-[1,2,3]triazol-1-ylmethyl-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
mfcd00867002
SR-01000872598-2
SR-01000872598-1
sr-01000872598
(2s,3s,5r)-3-((1h-1,2,3-triazol-1-yl)methyl)-3-methyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid 4,4-dioxide
D78146
HMS3714G17
(2s,3s,5r)-3-methyl-4,4,7-trioxo-3-(triazol-1-ylmethyl)-4lambda6-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
cl-298741;ytr-830h
DS-8301
Q423376
89786-04-9 (free acid)
89786-04-9, 89785-84-2 (sodium salt)
EX-A1377
tazobactam,(s)
BCP09757
ytr830
(2s,3s,5r)-3-methyl-4,4,7-trioxo-3-(1h-1,2,3-triazol-1-ylmethyl)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
gtpl10789
tazobactam, free acid
(2s,3s,5r)-3-((1h-1,2,3-triazol-1-yl)methyl)-3-methyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylicacid4,4-dioxide

Excerpt	Reference	Relevance
"Tazobactam is a sulfone β-lactamase inhibitor with in vitro inhibitory activity against common ESBLs in Enterobacterales, including CTX-M."	( The role of tazobactam-based combinations for the management of infections due to extended-spectrum β-lactamase-producing Enterobacterales: Insights from the Society of Infectious Diseases Pharmacists. Aitken, SL; Heil, EL; Monogue, ML; Pogue, JM, 2021)	1.72
"Tazobactam/ceftolozane is a combination of a β-lactamase inhibitor and a cephalosporin antibiotic, with recommended dosage for patients with normal renal function of tazobactam 0.5 g/ceftolozane 1 g administered as a 1-h intravenous infusion every 8 h. "	( Population pharmacokinetics of tazobactam/ceftolozane in Japanese patients with complicated urinary tract infection and complicated intra-abdominal infection. Feng, HP; Kakara, M; Larson, K; Rizk, ML; Shiomi, M; Yoshitsugu, H, 2019)	2.24
"Tazobactam is an ESBL inhibitor and is combined with ceftolozane to broaden its activity."	( Plasma and epithelial lining fluid pharmacokinetics of ceftolozane and tazobactam alone and in combination in mice. Lagarde, C; Mavridou, E; Melchers, MJ; Mouton, JW; Seyedmousavi, S; van Mil, AC, 2015)	1.37
"Tazobactam is a clinically used inhibitor of class A β-lactamases, which inhibits the GES-2 enzyme effectively, restoring susceptibility to β-lactam antibiotics."	( Identification of products of inhibition of GES-2 beta-lactamase by tazobactam by x-ray crystallography and spectrometry. Champion, MM; Frase, H; Mobashery, S; Smith, CA; Toth, M; Vakulenko, SB, 2011)	1.33
"Tazobactam/Piperacillin is a combination of a broad-spectrum penicillin and a beta-lactamase inhibitor with increased toxicity against staph."	( [Antibiotic prophylaxis in cesarean section -- piperacillin versus piperacillin/tazobactam in 300 cesarean sections]. Bier, U; Callies, R; Regidor, PA; Schindler, AE; Wagner, KJ, 2006)	1.28
"Tazobactam is a new derivative of penicillinic acid sulfone, which functions as an irreversible inhibitor of many beta-lactamases. "	( Pharmacokinetics of tazobactam M1 metabolite after administration of piperacillin/tazobactam in subjects with renal impairment. Bansal, S; Doepner, M; Halstenson, CE; Johnson, CA; Keane, WF; Onorato, JJ; Sia, L; Tantillo, K; Wong, MO; Zimmerman, SW, 1994)	2.05
"Tazobactam (TAZ) is a newly developed beta-lactamase inhibitor. "	( [Single-dose toxicity studies of tazobactam/piperacillin and tazobactam]. Anai, M; Anai, S; Hayashi, T; Kawazu, K; Kaziwara, T; Umano, T; Yada, H; Yamasaki, K, 1994)	2.01
"Tazobactam (TAZ) is a newly developed beta-lactamase inhibitor. "	( [A six-month intraperitoneal repeated dose toxicity study of tazobactam/piperacillin and tazobactam in rats]. Auletta, CS; Cockrell, BY; Daly, IW; Hayashi, T; Knezevich, AL; Yada, H, 1994)	1.97
"Tazobactam (TAZ) is a newly developed beta-lactamase inhibitor. "	( [A six-month intravenous repeated dose toxicity study of tazobactam/piperacillin and tazobactam in dogs]. Blair, M; Blanchard, GL; Geil, RG; Hayashi, T; Laughlin, KA; Tucek, PC; Yada, H, 1994)	1.98
"Tazobactam (TAZ) is a newly developed beta-lactamase inhibitor and piperacillin (PIPC) is an antibiotics which is used in clinical field widely. "	( [Reproductive and developmental toxicity studies of tazobactam/piperacillin or tazobactam (2)--Teratological study in rats with intravenously administration]. Christian, MS; Hoberman, AM; Lochry, EA; Sato, T, 1994)	1.98
"Tazobactam (TAZ) is a newly developed beta-lactamase inhibitor and piperacillin (PIPC) is an antibiotics which is used in clinical field widely. "	( [Reproductive and developmental toxicity studies of tazobactam/piperacillin or tazobactam(1)--Fertility and general reproduction study in rats with intraperitoneal administration]. Christian, MS; Hoberman, AM; Lochry, EA; Sato, T, 1994)	1.98
"Tazobactam (TAZ) is a newly developed beta-lactamase inhibitor and piperacillin (PIPC) is an antibiotics which is used in clinical field widely. "	( [Reproductive and developmental toxicity studies of tazobactam/piperacillin or tazobactam (3)--Perinatal and postnatal study in rats with intraperitoneal administration]. Christian, MS; Hoberman, AM; Sato, T, 1994)	1.98
"Tazobactam is a highly potent inhibitor of beta-lactamases. "	( Interaction of tazobactam with Staphylococcus aureus PC1 beta-lactamase: a molecular modelling and enzyme kinetics study. Denny, BJ; Lambert, PA; Toomer, CA, 1994)	2.08
"Tazobactam was shown to be a potent inhibitor of group 1, 2a, 2b, and 2b' beta-lactamases. "	( Kinetic interactions of tazobactam with beta-lactamases from all major structural classes. Bush, K; Lee, VJ; Macalintal, C; Rasmussen, BA; Yang, Y, 1993)	2.04
"Tazobactam is a new, irreversible inhibitor of bacterial beta-lactamases of staphylococci, plasmid-mediated beta-lactamases of the TEM and SHV types found in Escherichia coli and Klebsiella species and beta-lactamases of anerobes such as Bacteroides species. "	( An evaluation of the in vitro activity of piperacillin/tazobactam. Daley, D; Dimech, W; Mulgrave, L; Munro, R; Neville, S; Smith, H, 1996)	1.98
"Tazobactam is an irreversible inhibitor of many beta-lactamases. "	( Single-dose pharmacokinetics of piperacillin and tazobactam in patients with renal disease. Dutta, A; Faulkner, R; Greene, DS; Halstenson, CE; Haynes, J; Johnson, CA; Kelloway, JS; Shapiro, BE; Tonelli, A; Zimmerman, SW, 1992)	1.98

Excerpt	Reference	Relevance
"Tazobactam has an intrinsic activity against B."	( Turbidimetric and microscopic analysis of Bacteroides fragilis exposed to tazobactam and piperacillin alone and in combination. Crokaert, F; Lismont, MJ; Van der Linden, MP; Yourassowsky, E, 1990)	1.23
"Tazobactam has a good potential for enhancing the clinical efficacy of piperacillin."	( Comparative in vitro and in vivo activities of piperacillin combined with the beta-lactamase inhibitors tazobactam, clavulanic acid, and sulbactam. Jacobus, NV; Kuck, NA; Petersen, PJ; Testa, RT; Weiss, WJ, 1989)	1.21
"Tazobactam has inhibitory activity, and therefore protects piperacillin against Richmond and Sykes types II, III, IV and V beta-lactamases, staphylococcal penicillinase and extended-spectrum beta-lactamases."	( Piperacillin/tazobactam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential. Brogden, RN; Bryson, HM, 1994)	1.38
"Tazobactam has an intrinsic activity against B."	( Turbidimetric and microscopic analysis of Bacteroides fragilis exposed to tazobactam and piperacillin alone and in combination. Crokaert, F; Lismont, MJ; Van der Linden, MP; Yourassowsky, E, 1990)	1.23
"Tazobactam has a good potential for enhancing the clinical efficacy of piperacillin."	( Comparative in vitro and in vivo activities of piperacillin combined with the beta-lactamase inhibitors tazobactam, clavulanic acid, and sulbactam. Jacobus, NV; Kuck, NA; Petersen, PJ; Testa, RT; Weiss, WJ, 1989)	1.21

Excerpt	Reference	Relevance
"Tazobactam was able to inactivate intracellular beta-lactamase in Prot."	( Inhibition of beta-lactamases by tazobactam and in-vitro antibacterial activity of tazobactam combined with piperacillin. Higashitani, F; Hyodo, A; Inoue, M; Ishida, N; Mitsuhashi, S, 1990)	1.28

Excerpt	Reference	Relevance
" The incidence of adverse reactions was similar in both groups."	( Efficacy and safety of piperacillin/tazobactam in skin and soft tissue infections. File, TM; Tan, JS, 1994)	0.56
" TAZ/PIPC or TAZ caused adverse change in reproductive performance of the F0 generation only at doses that caused maternal toxicity."	( [Reproductive and developmental toxicity studies of tazobactam/piperacillin or tazobactam(1)--Fertility and general reproduction study in rats with intraperitoneal administration]. Christian, MS; Hoberman, AM; Lochry, EA; Sato, T, 1994)	0.54
" In all trials, piperacillin/tazobactam was found to be safe and well tolerated."	( Safety profile of piperacillin/tazobactam in phase I and III clinical studies. DeVries, VG; Kuye, O; Morrow, CA; Tally, FP; Teal, J, 1993)	0.86
" Nine patients (4%) had severe adverse events related to piperacillin/tazobactam and requiring discontinuation of therapy."	( Efficacy, safety and tolerance of parenteral piperacillin/tazobactam in the treatment of patients with lower respiratory tract infections. Ajana, F; Beuscart, C; Chidiac, C; Lecocq, P; Leroy, O; Mouton, Y; Senneville, E, 1993)	0.76
" Side-effects were mild; the commonest adverse events noted were mild elevations of liver enzymes."	( The efficacy and safety of piperacillin/tazobactam in the therapy of bacteraemia. Wise, R, 1993)	0.55
" No serious adverse drug reaction was found during the treatment with piperacillin/tazobactam."	( [Multicentre clinical trial on efficacy and safety of domestic piperacillin/tazobactam for treatment of acute bacterial infections]. Liu, Y; Wang, R; Yu, B, 2001)	0.77
"Domestic piperacillin/tazobactam is effective and safe for the treatment of acute bacterial infections."	( [Multicentre clinical trial on efficacy and safety of domestic piperacillin/tazobactam for treatment of acute bacterial infections]. Liu, Y; Wang, R; Yu, B, 2001)	0.85
" No clinical adverse events considered related to the study drug were noted, in particular, no cases of phlebitis, rash or stool changes."	( Safety evaluation of piperacillin/tazobactam in very low birth weight infants. Apfalter, P; Berger, A; Kretzer, V; Pollak, A; Rohrmeister, K; Zaknun, D, 2004)	0.6
"6% of patients receiving doripenem and piperacillin/tazobactam, respectively, had a drug-related adverse event."	( Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study. Friedland, I; Kaniga, K; Ketter, N; Lee, M; Lobo, SM; Niederman, M; Prokocimer, P; Réa-Neto, A; Schroeder, E, 2008)	0.85
"Piperacillin/tazobactam therapy is effective and safe empirical antibacterial therapy in febrile neutropenic patients with hematological malignancies."	( [Clinical effects and safety of piperacillin/tazobactam in treating neutropenic febrile patients with malignant hematopathy]. Hu, LD; Huang, XJ; Jia, JS; Li, J; Lu, KY; Wang, C; Wu, DP, 2009)	0.98
" Ceftolozane-tazobactam was well tolerated and systemic adverse events were uncommon."	( Pharmacokinetics and safety of intravenous ceftolozane-tazobactam in healthy adult subjects following single and multiple ascending doses. Benziger, D; Friedland, I; Hershberger, E; Miller, B; Trinh, M, 2012)	1
" A causality assessment of the adverse reaction identified the antibiotic as the most probable cause of the observation."	( A case of severe toxicity during coadministration of vincristine and piperacillin: are drug transporters involved in vincristine hypersensitivity and drug-drug interactions? Andres, CR; Benz-de Bretagne, I; Gendrot, C; Jonville-Bera, AP; Jourdain, A; Le Guellec, C; Tarfaoui, N, 2012)	0.38
" A similar proportion of patients (ITT population) experienced any adverse events in both treatment groups (MXF: 30."	( Efficacy and safety of IV/PO moxifloxacin and IV piperacillin/tazobactam followed by PO amoxicillin/clavulanic acid in the treatment of diabetic foot infections: results of the RELIEF study. Alder, J; Arvis, P; Dryden, M; Gyssens, IC; Kujath, P; Nathwani, D; Reimnitz, P; Schaper, NC, 2013)	0.63
" No significant difference of adverse effect was found between two groups."	( Effectiveness and safety of generic formulation of piperacillin/tazobactam (Astaz-P) for treatment of infected patients at Siriraj Hospital. Charoenpong, L; Thamlikitkul, V; Tongsai, S, 2013)	0.63
" The adverse event rates were similar in the groups (50."	( Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane-tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections. Friedland, I; Hershberger, E; Lucasti, C; Miller, B; Solomkin, J; Steenbergen, J; Yankelev, S, 2014)	0.62
" No deaths, study drug-related serious adverse events, or clinically significant laboratory abnormalities were observed after administration of ceftolozane/tazobactam."	( Pharmacokinetics and Safety of Single Intravenous Doses of Ceftolozane/Tazobactam in Children With Proven or Suspected Gram-Negative Infection. Ang, JY; Arrieta, AC; Bradley, JS; Caro, L; Johnson, MG; Larson, KB; Rhee, EG; Rizk, ML; Yang, S; Yu, B, 2018)	0.91
" No serious adverse events (AEs), treatment-related AEs, severe AEs, or clinically significant laboratory abnormalities were reported."	( Ceftolozane/Tazobactam in Neonates and Young Infants: The Challenges of Collecting Pharmacokinetics and Safety Data in This Vulnerable Patient Population. Ang, JY; Arrieta, A; Bradley, JS; Johnson, MG; Rhee, EG; Rizk, ML; Yu, B; Zhang, Z, 2021)	1
" The most common adverse event was hypokalaemia (4."	( Ceftolozane/tazobactam for difficult-to-treat Pseudomonas aeruginosa infections: A systematic review of its efficacy and safety for off-label indications. Buonomo, AR; Gentile, I; Maraolo, AE; Mazzitelli, M; Torti, C; Trecarichi, EM, 2020)	0.94
" All patients were successfully treated without worsening of renal function and without any other adverse events."	( Efficacy and safety of ceftolozane/tazobactam as therapeutic option for complicated skin and soft tissue infections by MDR/XDR Pseudomonas aeruginosa in patients with impaired renal function: a case series from a single-center experience. Buonomo, AR; Congera, P; Foggia, M; Gentile, I; Maraolo, AE; Parente, S; Scotto, R; Zappulo, E, 2020)	0.84
" There were no deaths or adverse event-related study discontinuations."	( Lung penetration, bronchopulmonary pharmacokinetic/pharmacodynamic profile and safety of 3 g of ceftolozane/tazobactam administered to ventilated, critically ill patients with pneumonia. Adedoyin, A; Caro, L; De Waele, JJ; Gadzicki, E; Kuti, JL; Larson, KB; Nicolau, DP; Rhee, EG; Yu, B; Zeng, Z, 2020)	0.77
" Serious adverse events (AEs) occurred in 26."	( A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study). Boucher, HW; Brown, ML; Butterton, JR; Chen, LF; David-Wang, A; Du, J; Kartsonis, NA; Kaye, KS; Losada, MC; Paschke, A; Patel, M; Rizk, ML; Rodríguez Gonzalez, D; Roquilly, A; Tipping, R; Titov, I; Wunderink, RG; Young, K, 2021)	0.83
"The purpose of this study is to characterize adverse events (AEs) of clinical interest reported with ceftolozane-tazobactam and ceftazidime-avibactam, as an aid in monitoring patients affected by severe multidrug-resistant Gram-negative infections."	( Serious adverse events with novel beta-lactam/beta-lactamase inhibitor combinations: a large-scale pharmacovigilance analysis. De Ponti, F; Gatti, M; Raschi, E, 2021)	0.83
" Secondary endpoints included clinical and microbiologic responses at the TOC and end-of-treatment (≤24 hours after last dose) visits and adverse event rates."	( A phase III, multicenter, double-blind, randomized clinical trial to evaluate the efficacy and safety of ceftolozane/tazobactam plus metronidazole versus meropenem in Chinese participants with complicated intra-abdominal infections. Bensaci, M; Bruno, CJ; Chen, G; Chen, X; Du, X; Fan, J; Huntington, JA; Johnson, MG; Sun, F; Sun, Y; Wang, H; Wang, Y, 2022)	0.93
" Rates of adverse events were similar between treatment groups (any: ceftolozane/tazobactam, 59."	( Safety and Efficacy of Ceftolozane/Tazobactam Versus Meropenem in Neonates and Children With Complicated Urinary Tract Infection, Including Pyelonephritis: A Phase 2, Randomized Clinical Trial. Ashouri, N; Bensaci, M; Bradley, JS; Bruno, CJ; De Anda, C; Huntington, JA; Johnson, MG; Lonchar, J; Popejoy, MW; Rhee, EG; Roilides, E; Su, FH, 2023)	1.41
" Ceftolozane/tazobactam is a safe and effective new treatment option for children with cUTI, especially due to antibacterial-resistant Gram-negative pathogens."	( Safety and Efficacy of Ceftolozane/Tazobactam Versus Meropenem in Neonates and Children With Complicated Urinary Tract Infection, Including Pyelonephritis: A Phase 2, Randomized Clinical Trial. Ashouri, N; Bensaci, M; Bradley, JS; Bruno, CJ; De Anda, C; Huntington, JA; Johnson, MG; Lonchar, J; Popejoy, MW; Rhee, EG; Roilides, E; Su, FH, 2023)	1.56
" Adverse events (AEs) occurred in 80."	( Safety and Efficacy of Ceftolozane/Tazobactam Plus Metronidazole Versus Meropenem From a Phase 2, Randomized Clinical Trial in Pediatric Participants With Complicated Intra-abdominal Infection. Bensaci, M; Bruno, CJ; De Anda, C; Dementieva, N; Huntington, JA; Jackson, CA; Johnson, MG; Lonchar, J; Newland, J; Popejoy, MW; Rhee, EG; Su, FH, 2023)	1.19
" Statistically significant trends were observed favoring cefotaxime plus metronidazole, which exhibited fewer discontinuations because of adverse events (AEs) when compared with eravacycline, meropenem and ceftolozane/tazobactam plus metronidazole (OR = 0."	( Efficacy, safety, and tolerability of antimicrobial agents for complicated intra-abdominal infection: a systematic review and network meta-analysis. Deng, T; Kong, W; Li, S; Shu, Y; Wu, Y, 2023)	1.1
"This observational study demonstrated that TAZ/CTLZ in combination with metronidazole has a favorable effect without major drug-related adverse events for intraabdominal infection in the hepato-biliary-pancreatic field in clinical practice although the efficacy of TAZ/CTLZ may decrease in compromised patients."	( Efficacy and safety of tazobactam/ceftolozane in combination with metronidazole for intraabdominal infection in a hepato-biliary-pancreatic field in clinical practice. Ishizawa, T; Kimura, K; Kinoshita, M; Kubo, S; Nishio, K; Ohira, G; Okada, T; Shinkawa, H; Shirai, D; Tanaka, S; Tani, N; Tauchi, J, 2023)	1.22
"In vivo microdialysis was well tolerated in piglets and children, with no significant adverse events reported."	( Microdialysis as a safe and feasible method to study target-site piperacillin-tazobactam disposition in septic piglets and children. Colman, R; De Cock, PA; De Paepe, P; Devreese, M; Dhont, E; Hermans, E; Vande Walle, J; Verougstraete, N; Zeitlinger, M, 2023)	1.14
"Microdialysis is a safe and applicable method for the measurement of tissue drug concentrations in piglets and children."	( Microdialysis as a safe and feasible method to study target-site piperacillin-tazobactam disposition in septic piglets and children. Colman, R; De Cock, PA; De Paepe, P; Devreese, M; Dhont, E; Hermans, E; Vande Walle, J; Verougstraete, N; Zeitlinger, M, 2023)	1.14

Excerpt	Reference	Relevance
" Noncompartmental methods were used for pharmacokinetic analysis."	( Single-dose pharmacokinetics of piperacillin and tazobactam in patients with renal disease. Dutta, A; Faulkner, R; Greene, DS; Halstenson, CE; Haynes, J; Johnson, CA; Kelloway, JS; Shapiro, BE; Tonelli, A; Zimmerman, SW, 1992)	0.54
" On the basis of concentrations in plasma, the following pharmacokinetic parameter values were obtained (values are means +/- standard deviations): maximum concentration of drug in serum, tazobactam, 27."	( Pharmacokinetics and tissue penetration of tazobactam and piperacillin in patients undergoing colorectal surgery. Brismar, B; Kinzig, M; Nord, CE; Sörgel, F, 1992)	0.74
"To determine the appropriate compartmental and noncompartmental pharmacokinetic parameters for intravenous piperacillin and tazobactam."	( Piperacillin-tazobactam pharmacokinetics in patients with intraabdominal infections. Burm, JP; Gill, MA; Jhee, SS; Kern, JW; Yellin, AE, )	0.71
"The estimated noncompartmental pharmacokinetic parameters (mean +/- SD) for piperacillin and tazobactam, respectively, were as follows: maximum concentration in plasma 218."	( Piperacillin-tazobactam pharmacokinetics in patients with intraabdominal infections. Burm, JP; Gill, MA; Jhee, SS; Kern, JW; Yellin, AE, )	0.72
" Pharmacokinetic variables of both components after they have been given together have been studied in healthy volunteers and in patients."	( Pharmacokinetics and tissue penetration of piperacillin/tazobactam with particular reference to its potential in abdominal and soft tissue infections. Kinzig, M; Sörgel, F, 1994)	0.53
"Pharmacokinetic and pharmacodynamic considerations in in vitro susceptibility testing are described, and the integration of pharmacokinetic and pharmacodynamic concepts in dosage-regimen design is explored."	( Combination beta-lactam and beta-lactamase-inhibitor therapy: pharmacokinetic and pharmacodynamic considerations. Dudley, MN, 1995)	0.29
" The pharmacokinetic behavior of tazobactam was very similar to that observed for piperacillin, supporting the use of these two agents in a fixed-dose combination."	( Single-dose pharmacokinetics of piperacillin and tazobactam in infants and children. Blumer, JL; Goldfarb, J; Lemon, E; Reed, MD; Yamashita, TS, 1994)	0.82
" The pharmacokinetic parameters of piperacillin and tazobactam were evaluated and were similar to previous reports."	( Pharmacokinetics of tazobactam M1 metabolite after administration of piperacillin/tazobactam in subjects with renal impairment. Bansal, S; Doepner, M; Halstenson, CE; Johnson, CA; Keane, WF; Onorato, JJ; Sia, L; Tantillo, K; Wong, MO; Zimmerman, SW, 1994)	0.86
"To evaluate the pharmacokinetic and clinical effects of the newly developed combination antibiotic tazobactam/piperacillin (TAZ/PIPC, YP-14) on various infections in pediatric field, a study group was organized, and a joint research by 17 institutions and their related hospitals was conducted."	( [Comprehensive evaluation of pharmacokinetic and clinical studies on tazobactam/piperacillin in pediatric field]. Fujii, R; Fujita, K; Fukushima, N; Inyaku, F; Ishikawa, A; Okuno, A; Saijo, M; Takimoto, M; Wagatsuma, S; Yoshikawa, M, 1995)	0.74
" In contrast, tazobactam administered with piperacillin achieved higher plasma concentrations and had a longer half-life than tazobactam administered alone."	( Pharmacokinetic characteristics of piperacillin/tazobactam. Kinzig, M; Sörgel, F, 1994)	0.9
"The pharmacokinetic properties of piperacillin/tazobactam are summarized."	( The chemistry, pharmacokinetics and tissue distribution of piperacillin/tazobactam. Kinzig, M; Sörgel, F, 1993)	0.78
"An in vitro pharmacokinetic model was used to study the pharmacodynamics of piperacillin-tazobactam and piperacillin-sulbactam against gram-negative bacilli producing plasmid-encoded beta-lactamases."	( Importance of beta-lactamase inhibitor pharmacokinetics in the pharmacodynamics of inhibitor-drug combinations: studies with piperacillin-tazobactam and piperacillin-sulbactam. Lister, PD; Prevan, AM; Sanders, CC, 1997)	0.72
" The fixed drug preparation appeared to have ideal pharmacokinetic properties if renal function was normal or slightly impaired, but no data are available for critically ill patients in anuric renal failure."	( Pharmacokinetics of piperacillin and tazobactam in critically ill patients with renal failure, treated with continuous veno-venous hemofiltration (CVVH). Mulder, PO; Stegeman, CA; Uges, DR; van der Werf, TS; Zijlstra, JG, 1997)	0.57
"A modified Emax model was used to describe the pharmacodynamic effect."	( Pharmacokinetic-pharmacodynamic modelling of the in vitro antiinfective effect of piperacillin-tazobactam combinations. Dalla Costa, T; Derendorf, H; Nolting, A; Rand, K, 1997)	0.52
" Pharmacodynamic activity of the combinations can be prolonged by sufficiently high inhibitor concentrations."	( Pharmacokinetic-pharmacodynamic modelling of the in vitro antiinfective effect of piperacillin-tazobactam combinations. Dalla Costa, T; Derendorf, H; Nolting, A; Rand, K, 1997)	0.52
" peak concentration (30 minutes after the end of an infusion) was 20."	( Influence of piperacillin-tazobactam on pharmacokinetics of gentamicin given once daily. Hitt, CM; Nicolau, DP; Nightingale, CH; Patel, KB; Zhu, Z, 1997)	0.6
"Mathematical modeling methods were used to study pharmacokinetic and pharmacodynamic interactions of the antimicrobial combinations piperacillin plus ciprofloxacin and piperacillin plus tazobactam."	( Pharmacodynamic interactions of ciprofloxacin, piperacillin, and piperacillin/tazobactam in healthy volunteers. Forrest, A; Nix, DE; Schentag, JJ; Strenkoski-Nix, LC, 1998)	0.72
" The objective of this article is to evaluate the pharmacokinetic properties of three commercially available beta-lactamase inhibitors."	( Pharmacokinetic properties of beta-lactamase inhibitors. de la Pena, A; Derendorf, H, 1999)	0.3
"Based on published articles in the literature, the pharmacokinetic properties of the beta-lactamase inhibitors clavulanic acid, sulbactam and tazobactam are reviewed and compared."	( Pharmacokinetic properties of beta-lactamase inhibitors. de la Pena, A; Derendorf, H, 1999)	0.5
"When choosing combinations of a beta-lactam antibiotic with a beta-lactamase inhibitor, it is important to make sure that the pharmacokinetic properties of drug and inhibitor are similar and remain similar under changing pathophysiological conditions."	( Pharmacokinetic properties of beta-lactamase inhibitors. de la Pena, A; Derendorf, H, 1999)	0.3
"A population pharmacokinetic (PK) analysis was conducted to determine if piperacillin and tazobactam exhibited linear or nonlinear PKs and if incremental changes in the daily dosage of piperacillin affected tazobactam PKs."	( Piperacillin and tazobactam exhibit linear pharmacokinetics after multiple standard clinical doses. Auclair, B; Ducharme, MP, 1999)	0.86
" Based on pharmacodynamic data, cefepime is an appropriate empiric choice for treatment of nosocomial infections."	( Comparison of five beta-lactam antibiotics against common nosocomial pathogens using the time above MIC at different creatinine clearances. Kays, MB, 1999)	0.3
" No systematic changes in pharmacokinetic parameters were observed."	( Evaluating possible pharmacokinetic interactions between tobramycin, piperacillin, and a combination of piperacillin and tazobactam in patients with various degrees of renal impairment. Amorusi, P; Dowell, JA; Korth-Bradley, J; Milisci, M; Tantillo, K; Tse, S, 2001)	0.52
"To compare the pharmacokinetic and pharmacodynamic profiles of two dosing regimens for piperacillin-tazobactam against commonly encountered pathogens."	( Pharmacokinetic and pharmacodynamic evaluation of two dosing regimens for piperacillin-tazobactam. Capitano, B; Kim, MK; Mattoes, HM; Nicolau, DP; Nightingale, CH; Quintiliani, R; Xuan, D, 2002)	0.75
"Although statistically significant differences in the pharmacodynamic profile were noted for the regimens, both provide adequate T>MIC against commonly encountered pathogens considered susceptible to piperacillin-tazobactam."	( Pharmacokinetic and pharmacodynamic evaluation of two dosing regimens for piperacillin-tazobactam. Capitano, B; Kim, MK; Mattoes, HM; Nicolau, DP; Nightingale, CH; Quintiliani, R; Xuan, D, 2002)	0.72
" Maximizing the time above the minimum inhibitory concentration (MIC) for a pathogen is the best pharmacodynamic predictor of efficacy."	( Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam when administered by continuous infusion and intermittent dosing. Burgess, DS; Waldrep, T, 2002)	0.56
" Five clinical isolates each of P aeruginosa and K pneumoniae were used for pharmacodynamic analyses."	( Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam when administered by continuous infusion and intermittent dosing. Burgess, DS; Waldrep, T, 2002)	0.56
" Using a previously validated population pharmacokinetic equation, steady-state serum concentrations were estimated for 210 patients who received piperacillin/tazobactam via CI."	( Pharmacodynamic profiling of continuously infused piperacillin/tazobactam against Pseudomonas aeruginosa using Monte Carlo analysis. Kuti, JL; Nicolau, D; Nightingale, CH; Quintiliani, R, 2002)	0.75
"The pharmacokinetic profile of antibiotics at the site of antiinfective action is one of the most important determinants of drug response, since it correlates the antimicrobial effect."	( [Pharmacokinetics of antibiotics in inflamed and healthy lung tissue]. Maier, A; Smolle-Jüttner, FM; Tomaselli, F, 2003)	0.32
"The primary objectives of this analysis were to determine which pharmacokinetic model most accurately describes the elimination pathways for piperacillin in the presence of tazobactam through population pharmacokinetic modeling and to characterize its pharmacodynamic profile."	( Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Carlo simulation. Danziger, LH; Drusano, GL; Lodise, TP; Lomaestro, B; Rodvold, KA, 2004)	0.76
" NONMEM was used to perform population pharmacokinetic analysis in a subset of patients (n = 56) who had serum samples obtained at steady-state for drug concentration analyses."	( Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection. Dana, A; Kuti, JL; Li, C; Mansfield, DL; Nicolau, DP; Nightingale, CH, 2005)	0.57
" For patients (n = 30) receiving intermittent infusion in the pharmacokinetic study, mean Cmax and half-life were 122."	( Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection. Dana, A; Kuti, JL; Li, C; Mansfield, DL; Nicolau, DP; Nightingale, CH, 2005)	0.57
"An improved HPLC method was developed for the determination of piperacillin and tazobactam in human plasma and pharmacokinetic study in Chinese healthy volunteers."	( An improved high-performance liquid chromatographic method with a solid-phase extraction for the determination of piperacillin and tazobactam: application to pharmacokinetic study of different dosage in Chinese healthy volunteers. Wang, GJ; Xia, CH; Xiong, YQ, 2007)	0.77
"To report pharmacokinetic alterations and optimal dosing of piperacillin/tazobactam in an obese patient."	( Serum piperacillin/tazobactam pharmacokinetics in a morbidly obese individual. Adeyemi, OA; Montevecchi, M; Newman, D; Nicolau, DP; Noskin, GA; Postelnick, MJ; Scheetz, MH, 2007)	0.9
" Pharmacokinetic parameters such as maximal serum concentration, minimal serum concentration, average steady-state concentration, half-life, elimination rate constant, volume of distribution (V(d)), clearance, area under the curve at steadystate, and percent of time greater than the minimum inhibitory concentration (%t>MIC) were calculated and qualitatively compared between the sample and the population."	( Serum piperacillin/tazobactam pharmacokinetics in a morbidly obese individual. Adeyemi, OA; Montevecchi, M; Newman, D; Nicolau, DP; Noskin, GA; Postelnick, MJ; Scheetz, MH, 2007)	0.67
"Computer modeling was used to integrate national in vitro microbiologic data from 2002 with pharmacokinetic data from published studies in healthy volunteers."	( Pharmacokinetic/pharmacodynamic modeling to predict in vivo effectiveness of various dosing regimens of piperacillin/tazobactam and piperacillin monotherapy against gram-negative pulmonary isolates from patients managed in intensive care units in 2002. Burgess, DS; Frei, CR, 2008)	0.56
"With increasing antibiotic resistance in gram-negative pathogens, dosing strategies that optimize pharmacodynamic parameters of currently available antibiotics play an important role in treatment."	( Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulation and steady-state pharmacokinetic data from hospitalized patients. Rotschafer, JC; Ullman, M, 2009)	0.58
"To compare the pharmacodynamics of several dosing regimens of piperacillin/tazobactam administered by intermittent and prolonged infusion using pharmacokinetic data from hospitalized patients."	( Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulations and steady-state pharmacokinetic data from hospitalized patients. Cheatham, SC; Kays, MB; Shea, KM; Smith, DW; Sowinski, KM; Wack, MF, 2009)	0.81
" After a single dose of ceftolozane alone, the ranges of mean values for half-life (2."	( Pharmacokinetics and safety of intravenous ceftolozane-tazobactam in healthy adult subjects following single and multiple ascending doses. Benziger, D; Friedland, I; Hershberger, E; Miller, B; Trinh, M, 2012)	0.63
"Prospective, observational, multicenter, pharmacokinetic study."	( Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study. Bellomo, R; Cole, L; Lipman, J; Liu, X; Nair, P; Roberts, DM; Roberts, JA; Roberts, MS, 2012)	0.38
"This prospective pharmacokinetic study aimed to describe plasma and interstitial fluid (ISF) pharmacokinetics of piperacillin and tazobactam in critically ill patients on continuous venovenous haemodiafiltration (CVVHDF)."	( Pharmacokinetics of piperacillin and tazobactam in plasma and subcutaneous interstitial fluid in critically ill patients receiving continuous venovenous haemodiafiltration. Boots, RJ; Jarrett, P; Kirkpatrick, CM; Lipman, J; Roberts, JA; Varghese, JM, 2014)	0.88
" We used pharmacokinetic data to evaluate the diagnostic accuracy of a recently proposed ARC score."	( Modified Augmented Renal Clearance score predicts rapid piperacillin and tazobactam clearance in critically ill surgery and trauma patients. Akers, KS; Cannon, JW; Chung, KK; Cota, JM; Murray, CK; Niece, KL, 2014)	0.63
" We combined intermediate scores (4-6 points) into a single low score (≤6) group and compared pharmacokinetic parameters against the high (≥7) ARC score group."	( Modified Augmented Renal Clearance score predicts rapid piperacillin and tazobactam clearance in critically ill surgery and trauma patients. Akers, KS; Cannon, JW; Chung, KK; Cota, JM; Murray, CK; Niece, KL, 2014)	0.63
" Monte Carlo pharmacokinetic simulations demonstrated increased time at therapeutic drug levels with extended infusion dosing at a drug cost savings of up to 66."	( Modified Augmented Renal Clearance score predicts rapid piperacillin and tazobactam clearance in critically ill surgery and trauma patients. Akers, KS; Cannon, JW; Chung, KK; Cota, JM; Murray, CK; Niece, KL, 2014)	0.63
" Serum concentration data from 376 adults who received ceftolozane/tazobactam in doses ranging from 500 to 3000 mg were analyzed to identify factors contributing to the pharmacokinetic variability."	( Population pharmacokinetics of ceftolozane/tazobactam in healthy volunteers, subjects with varying degrees of renal function and patients with bacterial infections. Chandorkar, G; Hershberger, E; Krishna, G; Mouksassi, MS; Xiao, A, 2015)	0.92
" Population pharmacokinetic parameters were estimated using NONMEM, and Monte Carlo simulations were performed for three 4-hour dosing regimens to calculate probability of target attainment (PTA) at ≥50% fT>MIC."	( Population pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese and nonobese patients. Cheatham, SC; Chung, EK; Fleming, MR; Healy, DP; Kays, MB; Shea, KM, 2015)	0.65
" Surprisingly, although tazobactam has been available for over 20 years, few if any reliable data exist on the tazobactam pharmacokinetic (PK) properties in mice."	( Plasma and epithelial lining fluid pharmacokinetics of ceftolozane and tazobactam alone and in combination in mice. Lagarde, C; Mavridou, E; Melchers, MJ; Mouton, JW; Seyedmousavi, S; van Mil, AC, 2015)	0.96
"The study was to establish a population pharmacokinetic (PPK) model of piperacillin (PIP) and tazobactam (TAZ) that explain pharmacokinetic variability and to propose optimized dosage regimens in patients with nosocomial infections."	( Population Pharmacokinetics and Pharmacodynamics of Piperacillin/Tazobactam in Patients with Nosocomial Infections. Chen, R; Qian, CY; Qian, Q; Sun, MR; Wang, LY; Wang, ML; Zou, SL, 2016)	0.89
" A population pharmacokinetic (PK) model with the plasma-to-epithelial lining fluid (ELF) kinetics of ceftolozane/tazobactam was used to justify dosing regimens for patients with nosocomial pneumonia in phase 3 studies."	( Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia. Huntington, JA; Miller, BW; Nicolau, DP; Xiao, AJ, 2016)	1.02
"Antibiotic dosing in septic shock patients poses a challenge for clinicians due to the pharmacokinetic (PK) variability seen in this patient population."	( Population pharmacokinetics of piperacillin in the early phase of septic shock: does standard dosing result in therapeutic plasma concentrations? Brock, B; Gjedsted, J; Hardlei, TF; Juul, RV; Kreilgaard, M; Öbrink-Hansen, K; Storgaard, M; Thomsen, MK, 2015)	0.42
" In this study, we studied the pharmacodynamics of ceftolozane plus tazobactam against Escherichia coli and Pseudomonas aeruginosa using an in vitro pharmacokinetic model of infection."	( Pharmacodynamics of Ceftolozane plus Tazobactam Studied in an In Vitro Pharmacokinetic Model of Infection. Bowker, KE; MacGowan, AP; Nicholls, D; Noel, AR; Tomaselli, SG, 2016)	0.94
"63 μg/ml, time to Cmax (Tmax) of 4 h, area under the concentration-time curve from 0 to 8 h (AUC0-8) of 284."	( Ceftolozane-Tazobactam Pharmacokinetics in a Critically Ill Patient on Continuous Venovenous Hemofiltration. Gonzales, JP; Heil, EL; Mehrotra, S; Nicolau, DP; Oliver, WD; Robinett, K; Saleeb, P, 2015)	0.8
" Monte Carlo simulations (MCS) using pharmacokinetic parameters from published studies and CLTM from this study were used to generate ceftolozane/tazobactam dosing for patients receiving CRRT."	( Ex vivo Ceftolozane/Tazobactam Clearance during Continuous Renal Replacement Therapy. Chaijamorn, W; Lewis, SJ; Mueller, BA; Shaw, AR, 2017)	0.98
" MCS-derived ceftolozane/tazobactam doses of 750 (500/250)-1,500 (1,000/500) mg every 8 h met pharmacodynamic targets for virtual patients receiving CRRT at contemporary effluent rates."	( Ex vivo Ceftolozane/Tazobactam Clearance during Continuous Renal Replacement Therapy. Chaijamorn, W; Lewis, SJ; Mueller, BA; Shaw, AR, 2017)	1.08
" Clearance, half-life and area under the concentration-time curve during SLED-f obtained from this study were comparable with those reported in the post-dilution mode of continuous veno-venous haemodiafiltration studies."	( Pharmacokinetics of piperacillin in critically ill patients with acute kidney injury receiving sustained low-efficiency diafiltration. Lipman, J; Peake, SL; Roberts, JA; Roberts, MS; Sinnollareddy, MG, 2018)	0.48
"Critically ill children frequently display observed alterations of pharmacokinetic (PK) parameters, leading to a reduction in β-lactam concentrations."	( Piperacillin Population Pharmacokinetics and Dosing Regimen Optimization in Critically Ill Children with Normal and Augmented Renal Clearance. Benaboud, S; Béranger, A; Bille, E; Gana, I; Genuini, M; Hirt, D; Lesage, F; Moulin, F; Oualha, M; Renolleau, S; Tréluyer, JM; Urien, S; Zheng, Y, 2019)	0.51
"An in vitro pharmacokinetic model was used to assess changes in bacterial load and profiles after exposure to mean human serum concentrations over 168 h."	( Antibacterial effect of ceftolozane/tazobactam in combination with amikacin against aerobic Gram-negative bacilli studied in an in vitro pharmacokinetic model of infection. Attwood, M; Bowker, KE; MacGowan, AP; Noel, AR, 2018)	0.76
"Thirty-seven patients received study drug; 34 were included in the pharmacokinetic population."	( Pharmacokinetics and Safety of Single Intravenous Doses of Ceftolozane/Tazobactam in Children With Proven or Suspected Gram-Negative Infection. Ang, JY; Arrieta, AC; Bradley, JS; Caro, L; Johnson, MG; Larson, KB; Rhee, EG; Rizk, ML; Yang, S; Yu, B, 2018)	0.71
" Although well-defined reasons for these findings across trials are diverse or unknown, several potential pharmacokinetic and pharmacodynamic explanations for these discordant response rates exist."	( Suboptimal Clinical Response Rates with Newer Antibiotics Among Patients with Moderate Renal Impairment: Review of the Literature and Potential Pharmacokinetic and Pharmacodynamic Considerations for Observed Findings. Bidell, MR; Lodise, TP, 2018)	0.48
" However, pharmacokinetic variability among patient populations and across ages leads to uncertainty when selecting a dosing regimen to achieve an appropriate pharmacodynamic target."	( Population pharmacokinetics of piperacillin in febrile children receiving cancer chemotherapy: the impact of body weight and target on an optimal dosing regimen. Brock, B; Friberg, LE; Kristoffersson, AN; Maarbjerg, SF; Nielsen, EI; Schrøder, H; Thorsted, A; Wang, M, 2019)	0.51
"To guide dosing by establishing a population pharmacokinetic model for unbound piperacillin in febrile children receiving cancer chemotherapy, and to assess pharmacokinetic/pharmacodynamic target attainment (100% fT > 1×MIC and 50% fT > 4×MIC) and resultant exposure, across body weights."	( Population pharmacokinetics of piperacillin in febrile children receiving cancer chemotherapy: the impact of body weight and target on an optimal dosing regimen. Brock, B; Friberg, LE; Kristoffersson, AN; Maarbjerg, SF; Nielsen, EI; Schrøder, H; Thorsted, A; Wang, M, 2019)	0.51
"Forty-three children admitted for 89 febrile episodes contributed 482 samples to the pharmacokinetic analysis."	( Population pharmacokinetics of piperacillin in febrile children receiving cancer chemotherapy: the impact of body weight and target on an optimal dosing regimen. Brock, B; Friberg, LE; Kristoffersson, AN; Maarbjerg, SF; Nielsen, EI; Schrøder, H; Thorsted, A; Wang, M, 2019)	0.51
" Given the population pharmacokinetic profile, feasible dosing regimens with reasonable exposure are continuous infusion (100% fT > 1×MIC) or prolonged infusions (50% fT > 4×MIC)."	( Population pharmacokinetics of piperacillin in febrile children receiving cancer chemotherapy: the impact of body weight and target on an optimal dosing regimen. Brock, B; Friberg, LE; Kristoffersson, AN; Maarbjerg, SF; Nielsen, EI; Schrøder, H; Thorsted, A; Wang, M, 2019)	0.51
" Pharmacokinetic parameters were estimated by non-compartmental analysis and pharmacodynamic analyses were conducted to graphically evaluate achievement of target exposures (plasma and ELF ceftolozane concentrations >4 mg/L and tazobactam concentrations >1 mg/L; target in plasma: ≥30% and ≥20% of the dosing interval, respectively)."	( Lung penetration, bronchopulmonary pharmacokinetic/pharmacodynamic profile and safety of 3 g of ceftolozane/tazobactam administered to ventilated, critically ill patients with pneumonia. Adedoyin, A; Caro, L; De Waele, JJ; Gadzicki, E; Kuti, JL; Larson, KB; Nicolau, DP; Rhee, EG; Yu, B; Zeng, Z, 2020)	0.95
" Ceftolozane and tazobactam Tmax (6 and 2 h, respectively) were delayed in ELF compared with plasma (1 h)."	( Lung penetration, bronchopulmonary pharmacokinetic/pharmacodynamic profile and safety of 3 g of ceftolozane/tazobactam administered to ventilated, critically ill patients with pneumonia. Adedoyin, A; Caro, L; De Waele, JJ; Gadzicki, E; Kuti, JL; Larson, KB; Nicolau, DP; Rhee, EG; Yu, B; Zeng, Z, 2020)	1.11
" Pharmacokinetic analysis of in vivo data (non-compartmental analysis and non-linear mixed effects modelling) was performed to determine the influence of ECMO."	( Influence of extracorporeal membrane oxygenation on the pharmacokinetics of ceftolozane/tazobactam: an ex vivo and in vivo study. Concordet, D; Delmas, C; Gandia, P; Georges, B; Jourdan, G; Mané, C; Marcheix, B; Porterie, J; Ruiz, S; Verwaerde, P, 2020)	0.78
" In vivo pharmacokinetic exploration showed that ECMO induces a significant decrease of 37% for tazobactam clearance without significant modification in the pharmacokinetics of ceftolozane, probably due to a small cohort size."	( Influence of extracorporeal membrane oxygenation on the pharmacokinetics of ceftolozane/tazobactam: an ex vivo and in vivo study. Concordet, D; Delmas, C; Gandia, P; Georges, B; Jourdan, G; Mané, C; Marcheix, B; Porterie, J; Ruiz, S; Verwaerde, P, 2020)	1
"This methodology was successfully applied to one pilot pharmacokinetic study in infected critically ill patients, including patients receiving renal replacement therapy, and one case study of a patient with ventriculitis, where all patients received ceftolozane-tazobactam."	( A validated LC-MS/MS method for the simultaneous quantification of the novel combination antibiotic, ceftolozane-tazobactam, in plasma (total and unbound), CSF, urine and renal replacement therapy effluent: application to pilot pharmacokinetic studies. Lipman, J; Pandey, S; Parker, SL; Roberts, JA; Sime, FB; Stuart, J; Wallis, SC, 2021)	1.01
" This review summarizes the population pharmacokinetic models developed for piperacillin-tazobactam and provides comprehensive data on current dosing strategies while identifying significant covariates in critically ill patients."	( Piperacillin-Tazobactam in Intensive Care Units: A Review of Population Pharmacokinetic Analyses. Caissy, JA; El-Haffaf, I; Marsot, A, 2021)	1.21
" Steady state free ceftolozane plasma Cmax and Cmin concentrations were calculated to be 122."	( Ceftolozane/tazobactam for refractory P. aeruginosa endocarditis: A case report and pharmacokinetic analysis. Bremmer, DN; Kline, EG; Nicolau, DP; Shah, S; Shields, RK, 2022)	1.1
" Population pharmacokinetic models informed Monte Carlo simulations to assess probability of target attainment in plasma and pulmonary epithelial lining fluid."	( Ceftolozane/tazobactam probability of target attainment and outcomes in participants with augmented renal clearance from the randomized phase 3 ASPECT-NP trial. Basu, S; Bruno, CJ; De Anda, C; Feng, HP; Gao, W; Huntington, JA; Jensen, E; Kollef, MH; Rhee, EG; Shorr, AF; Yu, B; Zhang, Z, 2021)	1
" As critically ill patients often experience pharmacokinetic aberrations, and rates of antimicrobial resistance vary between hospital settings, reliance on tertiary sources or package labeling to guide empiric dosing often results in suboptimal β-lactam exposure."	( Time Above All Else: Pharmacodynamic Analysis of β-Lactams in Critically Ill Patients. Burgess, DS; Clark, JA; Landmesser, KB, 2022)	0.72
" We sought to aggregate previously published piperacillin and tazobactam (pip-tazo) pharmacokinetic data in critically ill patients undergoing CKRT to better understand pharmacokinetics of pip-tazo in this population and better inform dosing."	( Pharmacokinetics of piperacillin and tazobactam in critically Ill patients treated with continuous kidney replacement therapy: A mini-review and population pharmacokinetic analysis. Akers, KS; Chung, KK; DeLuca, JP; Livezey, JR; Nadeau, RJ; Por, ED; Pruskowski, KA; Selig, DJ, 2022)	1.23
" Of the 26 articles, 10 for piperacillin and 8 for tazobactam had complete information suitable for population pharmacokinetic modelling."	( Pharmacokinetics of piperacillin and tazobactam in critically Ill patients treated with continuous kidney replacement therapy: A mini-review and population pharmacokinetic analysis. Akers, KS; Chung, KK; DeLuca, JP; Livezey, JR; Nadeau, RJ; Por, ED; Pruskowski, KA; Selig, DJ, 2022)	1.25
" The proportion of patients meeting pre-defined pharmacodynamic (PD) targets (median 88."	( Pharmacokinetics of piperacillin and tazobactam in critically Ill patients treated with continuous kidney replacement therapy: A mini-review and population pharmacokinetic analysis. Akers, KS; Chung, KK; DeLuca, JP; Livezey, JR; Nadeau, RJ; Por, ED; Pruskowski, KA; Selig, DJ, 2022)	0.99
"Similar ratios of generic/originator (90% CI) Cmax were observed for Cefepime-MIP/Maxipime [93."	( Comparison of pharmacokinetics and stability of generics of cefepime, linezolid and piperacillin/tazobactam with their respective originator drugs: an intravenous bioequivalence study in healthy volunteers. Al Jalali, V; Ballarini, N; Bauer, M; Bergmann, F; Jorda, A; König, F; Lackner, E; Nussbaumer-Pröll, A; Oesterreicher, Z; Reiter, B; Stimpfl, T; Wölfl-Duchek, M; Wulkersdorfer, B; Zeitlinger, M, 2022)	0.94
"Very limited studies, so far, have been conducted to identify the pharmacodynamic targets of cefepime, a well-established fourth-generation cephalosporin."	( Cefepime pharmacodynamic targets against Enterobacterales employing neutropenic murine lung infection and in vitro pharmacokinetic models. Attwood, M; Chavan, R; MacGowan, A; Muller, AE; Noel, A; Periasamy, H; Van den Berg, S, 2022)	0.72
"We employed both a neutropenic murine lung infection model and an in vitro pharmacokinetic model (IVPM) to determine cefepime's pharmacodynamic target [percentage of the dosing interval during which unbound drug concentrations remain higher than the MIC (%fT>MIC)] for bacteriostatic and 1 log10 kill effects."	( Cefepime pharmacodynamic targets against Enterobacterales employing neutropenic murine lung infection and in vitro pharmacokinetic models. Attwood, M; Chavan, R; MacGowan, A; Muller, AE; Noel, A; Periasamy, H; Van den Berg, S, 2022)	0.72
" Through 24 h dose fractionation, both in lung infection and IVPM (in the latter case, tazobactam 8 mg/L continuous infusion was used to protect cefepime), varying cefepime exposures and corresponding pharmacodynamic effect scenarios were generated to identify the pharmacodynamic targets."	( Cefepime pharmacodynamic targets against Enterobacterales employing neutropenic murine lung infection and in vitro pharmacokinetic models. Attwood, M; Chavan, R; MacGowan, A; Muller, AE; Noel, A; Periasamy, H; Van den Berg, S, 2022)	0.94
"Both in vivo and in vitro studies showed that cefepime's pharmacodynamic requirements are lower than generally reported for cephalosporins (50%-70% fT>MIC)."	( Cefepime pharmacodynamic targets against Enterobacterales employing neutropenic murine lung infection and in vitro pharmacokinetic models. Attwood, M; Chavan, R; MacGowan, A; Muller, AE; Noel, A; Periasamy, H; Van den Berg, S, 2022)	0.72
" The population pharmacokinetic models that best characterized the observed plasma concentrations of piperacillin and tazobactam were one-compartment structural models with zero-order input and linear elimination."	( Population Pharmacokinetics of Piperacillin/Tazobactam Across the Adult Lifespan. An, G; Balevic, SJ; Chan, AW; Cohen-Wolkowiez, M; Conrad, T; Gu, K; Hemmersbach-Miller, M; Kirkpatrick, CMJ; Landersdorfer, CB; Schmader, KE; Swamy, GK; Walter, EB; Winokur, PL, 2023)	1.38
"To use a pre-clinical pharmacokinetic infection model to assess the antibacterial effect of ceftolozane/tazobactam alone or in combination with fosfomycin or tobramycin against Pseudomonas aeruginosa strains with MICs at or higher than the clinical breakpoint (MIC ≥ 4 mg/L)."	( Antibacterial effect of seven days exposure to ceftolozane-tazobactam as monotherapy and in combination with fosfomycin or tobramycin against Pseudomonas aeruginosa with ceftolozane-tazobactam MICs at or above 4 mg/l in an in vitro pharmacokinetic model. Albur, M; Attwood, M; Griffin, P; Macgowan, AP; Noel, AR, 2023)	1.37

Excerpt	Reference	Relevance
"The minimal inhibitory concentrations of piperacillin (PIP) or cefotaxime (CTX) alone or in combination with tazobactam (TAZ) were determined against 168 anaerobes."	( [Strict anaerobic bacteria: comparative study of various beta-lactam antibiotics in combination with tazobactam or sulbactam]. Dubreuil, L; Sedallian, A, 1991)	0.71
" The absence of the outer membrane proteins, OmpF and OmpC, did not significantly affect susceptibility to the combinations per se but when combined with the presence of beta-lactamase high MICs were observed."	( Factors determining resistance to beta-lactam combined with beta-lactamase inhibitors in Escherichia coli. Baquero, F; Martínez, JL; Pérez-Díaz, JC; Reguera, JA, 1991)	0.28
"Tazobactam (YTR 830), a new beta-lactamase inhibitor, was evaluated for its effect in combination with piperacillin, a broad spectrum, but beta-lactamase sensitive, penicillin, against 14 common bacteria."	( Antimicrobial activities of piperacillin alone and in combination with tazobactam against beta-lactamase-producing bacteria. Chang, SC; Hsieh, WC; Hsu, LY; Luh, KT, 1991)	1.96
"The in-vitro synergistic activity of tazobactam, a new beta-lactamase inhibitor, combined with piperacillin was tested against various beta-lactamase-producing strains."	( Inhibition of beta-lactamases by tazobactam and in-vitro antibacterial activity of tazobactam combined with piperacillin. Higashitani, F; Hyodo, A; Inoue, M; Ishida, N; Mitsuhashi, S, 1990)	0.83
"Cefpirome, a so-called fourth-generation cephalosporin, was tested alone and in combination with the sulfone beta-lactamase inhibitor, tazobactam, against 63 members of the Bacteroides fragilis group."	( Antimicrobial spectrum of cefpirome combined with tazobactam against the Bacteroides fragilis group. Barrett, MS; Croco, JL; Erwin, ME; Jones, RN; Novick, WJ, )	0.59
"We studied the efficacy of tazobactam (YTR 830), a new beta-lactamase inhibitor in combination with piperacillin (P) against 198 Enterobacteriaceae strains."	( [Efficiency of tazobactam as inhibitor of beta-lactamases, combined with piperacillin, against resistant strains to this penicillin]. Ràfols, M; Reig, R; Roy, C; Teruel, D; Tirado, M, 1989)	0.93
"YTR 830, a new beta-lactamase inhibitor, combined with amoxicillin or carbenicillin, showed a synergistic effect similar to that observed with clavulanic acid, and generally better than that with sulbactam, against strains harboring chromosome-encoded penicillinases and broad-spectrum beta-lactamases or plasmid-determined beta-lactamases."	( Comparative evaluation of a new beta-lactamase inhibitor, YTR 830, combined with different beta-lactam antibiotics against bacteria harboring known beta-lactamases. Acar, JF; Gutmann, L; Kitzis, MD; Yamabe, S, 1986)	0.27
"The in vitro synergistic activities of the beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam, combined with ampicillin, ticarcillin, mezlocillin, azlocillin, piperacillin, and apalcillin, were determined against 34 strains of members of the Enterobacteriaceae family, Pseudomonas aeruginosa, Aeromonas hydrophila, and Haemophilus influenzae with characterized plasmid or chromosomal beta-lactamases or both."	( Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with ampicillin and broad-spectrum penicillins against defined beta-lactamase-producing aerobic gram-negative bacilli. Aronoff, SC; Jacobs, MR; Johenning, S; Shlaes, DM; Yamabe, S, 1986)	0.27
"The in vitro activities of the beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with six beta-lactams against 88 beta-lactamase-producing anaerobes were determined."	( Comparative activity of beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with beta-lactams against beta-lactamase-producing anaerobes. Appelbaum, PC; Jacobs, MR; Spangler, SK; Yamabe, S, 1986)	0.27
" Combined with amoxicillin, YTR 830 is a potentially useful agent for therapy of many bacterial infections."	( Comparative activities of the beta-lactamase inhibitors YTR 830, sodium clavulanate, and sulbactam combined with amoxicillin or ampicillin. Aronoff, SC; Jacobs, MR; Johenning, S; Yamabe, S, 1984)	0.27
"The antibacterial in vitro activity of piperacillin and tazobactam (in a concentration ratio of 8/1) was studied in combination with netilmicin or amikacin by a microtiter checkerboard assay against 162 strains of Enterobacteriaceae."	( [In vitro antibacterial activity of piperacillin-tazobactam in combination with netilmicin or amikacin against Enterobacteriaceae resistant to amoxicillin]. Chamard-Neuwirth, C; Cordin, X; Duez, JM; Kazmierczak, A; Pechinot, A; Siebor, E, 1995)	0.79
"The pharmacodynamics of dosage regimens of piperacillin alone or in combination with tazobactam against piperacillin-resistant or -susceptible bacteria were studied in an in vitro model of infection."	( Pharmacodynamics of piperacillin alone and in combination with tazobactam against piperacillin-resistant and -susceptible organisms in an in vitro model of infection. Dudley, MN; Gilbert, DH; Medeiros, AA; Pivarnik, P; Strayer, AH; Zinner, SH, 1994)	0.75
" pneumophila activity was observed for ceftriaxone (32 micrograms/ml), piperacillin (32 micrograms/ml), tazobactam alone (16 micrograms/ml), clavulanate alone (2 micrograms/ml), or tazobactam in combination with ceftriaxone (ceftriaxone/tazobactam at 32/4 and 16/16 micrograms/ml) or piperacillin (32/4 micrograms/ml)."	( In vitro extracellular and intracellular activities of clavulanic acid and those of piperacillin and ceftriaxone alone and in combination with tazobactam against clinical isolates of Legionella species. Edelstein, MA; Edelstein, PH, 1994)	0.7
" However, strains expressing class A beta-lactamase were susceptible to cefodizime in combination with clavulanic acid."	( In vitro activity of cefodizime (HR-221) in combination with beta-lactamase inhibitors. Amicosante, G; Franceschini, N; Oratore, A; Perilli, M; Segatore, B; Setacci, D, 1993)	0.29
"The activity of piperacillin/tazobactam, ampicillin/sulbactam, imipenem and nafcillin alone and in combination with vancomycin was compared with vancomycin monotherapy against MRSA in test-tube time-kill studies and in infected fibrin clots."	( An evaluation of the bactericidal activity of ampicillin/sulbactam, piperacillin/tazobactam, imipenem or nafcillin alone and in combination with vancomycin against methicillin-resistant Staphylococcus aureus (MRSA) in time-kill curves with infected fibrin Palmer, SM; Rybak, MJ, 1997)	0.81
"In a randomized trial conducted in 35 centers, we compared the clinical efficacy and safety of piperacillin plus tazobactam (TAZ) alone (monotherapy [MT]) versus those of TAZ combined with amikacin (AMK) (combined therapy [CT]) for the treatment of severe generalized peritonitis (SGP)."	( Monotherapy with a broad-spectrum beta-lactam is as effective as its combination with an aminoglycoside in treatment of severe generalized peritonitis: a multicenter randomized controlled trial. The Severe Generalized Peritonitis Study Group. Carbon, C; Carlet, J; Dupont, H, 2000)	0.52
"The bactericidal activity of moxifloxacin alone and in combination with cefepime or piperacillin-tazobactam against clinical isolates of Klebsiella pneumoniae, Enterobacter cloacae, and Acinetobacter baumannii was evaluated by using time-kill methods and antimicrobial concentrations of one-half and one times the MIC."	( Synergistic activities of moxifloxacin combined with piperacillin-tazobactam or cefepime against Klebsiella pneumoniae, Enterobacter cloacae, and Acinetobacter baumannii clinical isolates. Choi, MK; Fish, DN; Husain, M; Jung, R, 2004)	0.78
"This randomized, double-blind, multicenter study compared the efficacy and safety of piperacillin/tazobactam (P/T) and imipenem/cilastatin (IMP), both in combination with an aminoglycoside, in hospitalized patients with acute nosocomial pneumonia (NP)."	( Comparison of piperacillin/tazobactam and imipenem/cilastatin, both in combination with tobramycin, administered every 6 h for treatment of nosocomial pneumonia. Cooper, A; Joshi, M; Kassira, W; McCarthy, M; Metzler, M; Olvey, S, 2006)	0.85
"To investigate the efficacy of piperacillin/tazobactam combined with indolicidin in the prevention of lethality in two rat models of polymicrobial peritonitis."	( Efficacy of the bovine antimicrobial peptide indolicidin combined with piperacillin/tazobactam in experimental rat models of polymicrobial peritonitis. Abbruzzetti, A; Cirioni, O; Di Matteo, F; Ghiselli, R; Giacometti, A; Mocchegiani, F; Orlando, F; Saba, V; Scalise, G; Silvestri, C, 2008)	0.83
" For each model, all animals were randomized to receive isotonic sodium chloride solution intraperitoneally, 1 mg/kg indolicidin, 120 mg/kg piperacillin/tazobactam, and 1 mg/kg indolicidin combined with 120 mg/kg piperacillin/tazobactam."	( Efficacy of the bovine antimicrobial peptide indolicidin combined with piperacillin/tazobactam in experimental rat models of polymicrobial peritonitis. Abbruzzetti, A; Cirioni, O; Di Matteo, F; Ghiselli, R; Giacometti, A; Mocchegiani, F; Orlando, F; Saba, V; Scalise, G; Silvestri, C, 2008)	0.77
"We investigated in vitro activities of piperacillin or cefoperazone alone and in combination with beta-lactamase inhibitors against Gram-negative bacilli."	( In vitro activities of piperacillin or cefoperazone alone and in combination with beta-lactamase inhibitors against gram-negative bacilli. Kuo, HY; Lin, ML; Liu, CY; Wang, FD; Yen, YF, 2009)	0.35
"CXA-101, a novel oxyimino-aminothiazolyl cephalosporin, CXA-201 (CXA-101 combined with tazobactam), and various comparators were susceptibility tested by broth microdilution methods against 1,301 well-characterized clinical strains collected worldwide, including ceftazidime-resistant members of the family Enterobacteriaceae and Klebsiella pneumoniae carbapenemase (KPC)- and extended-spectrum β-lactamase (ESBL)-producing strains of Pseudomonas aeruginosa and Bacteroides fragilis."	( Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes. Farrell, DJ; Jones, RN; Rhomberg, PR; Sader, HS, 2011)	0.82
" Herein, we describe dose fractionation studies designed to determine the exposure measure most predictive of tazobactam efficacy in combination with ceftolozane and the magnitude of this measure necessary for efficacy in a PK-PD in vitro infection model."	( Pharmacokinetics-pharmacodynamics of tazobactam in combination with ceftolozane in an in vitro infection model. Ambrose, PG; Bhavnani, SM; Bulik, CC; Castanheira, M; Forrest, A; Friedrich, LV; Jones, RN; Mendes, RE; Nicasio, AM; Okusanya, OO; Steenbergen, JN; VanScoy, B, 2013)	0.87
"We recently investigated the pharmacokinetics-pharmacodynamics (PK-PD) of tazobactam in combination with ceftolozane against an isogenic CTX-M-15-producing Escherichia coli triplet set, genetically engineered to transcribe different levels of blaCTX-M-15."	( Pharmacological basis of β-lactamase inhibitor therapeutics: tazobactam in combination with Ceftolozane. Ambrose, PG; Bhavnani, SM; Bulik, CC; Forrest, A; Friedrich, LV; Jones, RN; McCauley, J; Mendes, RE; Okusanya, OO; Steenbergen, JN; Vanscoy, B, 2013)	0.86
"The post-β-lactamase-inhibitor effect (PBLIE) of tazobactam combined with ceftolozane was evaluated by time-kill assays on two clinical Escherichia coli strains producing CTX-M-15 with or without TEM-1."	( Post-β-lactamase-inhibitor effect of tazobactam in combination with ceftolozane on extended-spectrum-β-lactamase-producing strains. Jones, RN; Rhomberg, PR; Sader, HS, 2014)	0.93
" When combined with a fixed amount of 4 mg/liter tazobactam (current CLSI concentration used for susceptibility testing), 90% of the isolates would have an MIC of ≤4 mg/liter."	( In Vitro Activity of Ceftolozane Alone and in Combination with Tazobactam against Extended-Spectrum-β-Lactamase-Harboring Enterobacteriaceae. Melchers, MJ; Mouton, JW; van Mil, AC, 2015)	0.91
" Ceftazidime, cefepime, and piperacillin-tazobactam in combination with amikacin showed greater activity than found in combination with ciprofloxacin."	( In vitro activities of 21 antimicrobial agents alone and in combination with aminoglycosides or fluoroquinolones against extended-spectrum-β-lactamase-producing Escherichia coli isolates causing bacteremia. Cha, MK; Cho, SY; Chung, DR; Ha, YE; Kang, CI; Kim, SH; Peck, KR; Song, JH; Wi, YM, 2015)	0.68
"The present study evaluates the synergistic effect of sulbactam/tazobactam in combination with meropenem or colistin against multidrug resistant (MDR) Acinetobacter baumannii isolated from hospitalized patients from a tertiary care hospital in Saudi Arabia."	( A prospective evaluation of synergistic effect of sulbactam and tazobactam combination with meropenem or colistin against multidrug resistant Acinetobacter baumannii. Alyousef, AA; Alzahrani, AJ; Krishnappa, LG; Marie, MA; Mubaraki, MA, 2015)	0.89
"We have previously demonstrated the pharmacokinetic-pharmacodynamic (PK-PD) index best associated with the efficacy of tazobactam when used in combination with ceftolozane to be the percentage of the dosing interval during which tazobactam concentrations remained above a threshold value (%time>threshold)."	( Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Piperacillin in an In Vitro Infection Model. Ambrose, PG; Bhavnani, SM; Bulik, CC; Castanheira, M; Forrest, A; Friedrich, LV; Jones, RN; Mendes, RE; Nicasio, AM; Okusanya, OO; Steenbergen, JN; VanScoy, BD, 2016)	0.92
" To assist the clinical decision-making process regarding the selection of combination antibiotics and dosages for this pathogen, we performed time-kill studies assessing clinical free peak and trough C/T concentrations alone and in combination with eight anti-pseudomonal agents against four clinical MDR PSA isolates."	( Antibacterial activity of ceftolozane/tazobactam alone and in combination with other antimicrobial agents against MDR Pseudomonas aeruginosa. Monogue, ML; Nicolau, DP, 2018)	0.75
"5 mg/L in combination with free peak and trough concentrations of clinical doses for cefepime, ciprofloxacin, colistin, aztreonam, meropenem, piperacillin/tazobactam, fosfomycin and amikacin was tested for all isolates."	( Antibacterial activity of ceftolozane/tazobactam alone and in combination with other antimicrobial agents against MDR Pseudomonas aeruginosa. Monogue, ML; Nicolau, DP, 2018)	0.95
"gov Identifier: NCT02739997) to investigate the efficacy and safety of tazobactam/ceftolozane used in combination with metronidazole in Japanese patients with cIAI was conducted."	( The efficacy and safety of tazobactam/ceftolozane in combination with metronidazole in Japanese patients with complicated intra-abdominal infections. Fujimoto, G; Fukuhara, T; Horiuchi, T; Mikamo, H; Miyasaka, Y; Monden, K; Rhee, EG; Shizuya, T; Yoshinari, T, 2019)	1.04
" aeruginosa strains, alone and in combination with colistin."	( Efficacy of ceftolozane/tazobactam, alone and in combination with colistin, against multidrug-resistant Pseudomonas aeruginosa in an in vitro biofilm pharmacodynamic model. Ariza, J; Benavent, E; El Haj, C; Gómez-Junyent, J; Murillo, O; Rigo-Bonnin, R; Sierra, Y; Soldevila, L; Torrejón, B; Tubau, F, 2019)	0.82
" This study evaluated in vitro antimicrobial synergy of ceftolozane/tazobactam in combination with aztreonam and fosfomycin against MDR PSA."	( In vitro synergy of ceftolozane/tazobactam in combination with fosfomycin or aztreonam against MDR Pseudomonas aeruginosa. Cayô, R; Cuba, GT; Gales, AC; Kiffer, CRV; Nicolau, DP; Nodari, CS; Pignatari, ACC; Rocha-Santos, G; Streling, AP, 2020)	1.08
"5 g q8h dose, respectively, in combination with 69 mg/L amikacin, corresponding to the free peak plasma concentration."	( In vitro activity of ceftolozane/tazobactam alone and in combination with amikacin against MDR/XDR Pseudomonas aeruginosa isolates from Greece. Adamou, P; Antoniadou, A; Damala, M; Deliolanis, I; Fountoulis, K; Galani, I; Galani, L; Giamarellou, H; Karaiskos, I; Karantani, I; Kirikou, H; Kodonaki, A; Maraki, S; Markopoulou, M; Papadogeorgaki, E; Papoutsaki, V; Petinaki, E; Prifti, E; Souli, M; Tsiplakou, S; Vagiakou, E, 2020)	0.84
" In combination with amikacin, a synergistic interaction at 24 h was observed against 85."	( In vitro activity of ceftolozane/tazobactam alone and in combination with amikacin against MDR/XDR Pseudomonas aeruginosa isolates from Greece. Adamou, P; Antoniadou, A; Damala, M; Deliolanis, I; Fountoulis, K; Galani, I; Galani, L; Giamarellou, H; Karaiskos, I; Karantani, I; Kirikou, H; Kodonaki, A; Maraki, S; Markopoulou, M; Papadogeorgaki, E; Papoutsaki, V; Petinaki, E; Prifti, E; Souli, M; Tsiplakou, S; Vagiakou, E, 2020)	0.84
"Vancomycin (VAN)-associated acute kidney injury (AKI) is increased when VAN is combined with certain beta-lactams (BLs) such as piperacillin-tazobactam (TZP) but has not been evaluated with ceftolozane-tazobactam (C/T)."	( Nephrotoxicity of Vancomycin in Combination With Beta-Lactam Agents: Ceftolozane-Tazobactam vs Piperacillin-Tazobactam. Alosaimy, S; Amaya, L; Biagi, M; Chandler, E; Cubillos, A; Davis, SL; Finch, N; Hobbs, ALV; Holger, D; Jorgensen, SCJ; Kufel, WD; Kunz Coyne, AJ; Lagnf, AM; Li, D; Molina, KC; Moore, WJ; Morrisette, T; Mubarez, M; Patch, M; Polisetty, RS; Rebold, N; Rico, M; Rybak, MJ; Sakoulas, G; Simon, SP; Smith, IMK; Tran, NN; Truong, J; Venugopalan, V; Veve, MP; Witucki, P; Wrin, J; Yost, C, 2023)	1.34
"This single-center study evaluated the efficacy and safety of tazobactam/ceftolozane (TAZ/CTLZ) in combination with metronidazole for intraabdominal infection in a hepato-biliary-pancreatic field in clinical practice."	( Efficacy and safety of tazobactam/ceftolozane in combination with metronidazole for intraabdominal infection in a hepato-biliary-pancreatic field in clinical practice. Ishizawa, T; Kimura, K; Kinoshita, M; Kubo, S; Nishio, K; Ohira, G; Okada, T; Shinkawa, H; Shirai, D; Tanaka, S; Tani, N; Tauchi, J, 2023)	1.46
"This observational study demonstrated that TAZ/CTLZ in combination with metronidazole has a favorable effect without major drug-related adverse events for intraabdominal infection in the hepato-biliary-pancreatic field in clinical practice although the efficacy of TAZ/CTLZ may decrease in compromised patients."	( Efficacy and safety of tazobactam/ceftolozane in combination with metronidazole for intraabdominal infection in a hepato-biliary-pancreatic field in clinical practice. Ishizawa, T; Kimura, K; Kinoshita, M; Kubo, S; Nishio, K; Ohira, G; Okada, T; Shinkawa, H; Shirai, D; Tanaka, S; Tani, N; Tauchi, J, 2023)	1.22
"To use a pre-clinical pharmacokinetic infection model to assess the antibacterial effect of ceftolozane/tazobactam alone or in combination with fosfomycin or tobramycin against Pseudomonas aeruginosa strains with MICs at or higher than the clinical breakpoint (MIC ≥ 4 mg/L)."	( Antibacterial effect of seven days exposure to ceftolozane-tazobactam as monotherapy and in combination with fosfomycin or tobramycin against Pseudomonas aeruginosa with ceftolozane-tazobactam MICs at or above 4 mg/l in an in vitro pharmacokinetic model. Albur, M; Attwood, M; Griffin, P; Macgowan, AP; Noel, AR, 2023)	1.37

Excerpt	Reference	Relevance
" Generic substitutions within hospital formularies should consider parameters of in vitro activity, in addition to applied chemical analyses and measures of bioavailability to avoid potential adverse clinical consequences."	( Expanded studies of piperacillin/tazobactam formulations: variations among branded product lots and assessment of 46 generic lots. Jones, RN; Moet, GJ; Sader, HS; Watters, AA, 2009)	0.63

Excerpt	Relevance	Reference
" Dosage alterations for creatinine clearance values less than 40 ml/min are recommended."	( Single-dose pharmacokinetics of piperacillin and tazobactam in patients with renal disease. Dutta, A; Faulkner, R; Greene, DS; Halstenson, CE; Haynes, J; Johnson, CA; Kelloway, JS; Shapiro, BE; Tonelli, A; Zimmerman, SW, 1992)	0.54
" The dosage regimen was 4 g piperacillin/500 mg tazobactam Q8H."	( Piperacillin/tazobactam in the treatment of serious acute soft tissue infection. Ansari, A; Douglas, JG; Gould, IM; Harvey, G; Reid, TM; Smith, CC, 1991)	0.91
" Different doses of piperacillin and tazobactam, as single agents and combined (8:1 ratio; dosage range, 40/5 to 200/25 mg/kg per h), and of ceftriaxone were given to experimentally infected rabbits by intravenous bolus injection followed by a 5-h constant infusion."	( Evaluation of piperacillin-tazobactam in experimental meningitis caused by a beta-lactamase-producing strain of K1-positive Escherichia coli. Gunderson, D; Kennedy, SL; Kern, W; Sachdeva, M; Sande, ER; Täuber, MG, 1990)	0.85
" With some antibiotic-inhibitor combinations, it may be possible to extend the dosage interval if an adequate amount of inhibitor is provided over the course of therapy."	( Combination beta-lactam and beta-lactamase-inhibitor therapy: pharmacokinetic and pharmacodynamic considerations. Dudley, MN, 1995)	0.29
" Blood samples and cumulative bile secretion were collected every 30 min, and liver fragments were isolated at the end of each experiment for dosage purposes."	( Biliary elimination and hepatic disposition of an association of piperacillin and tazobactam: experimental evaluation. Blickle, JF; Brogard, JM; Caro-Sampara, F; Jehl, F; Westphal, JF, 1994)	0.51
" In the TAZ/PIPC, maternal toxicity (decreased food consumption) was observed at 200 mg/kg and above dosage groups."	( [Reproductive and developmental toxicity studies of tazobactam/piperacillin or tazobactam(1)--Fertility and general reproduction study in rats with intraperitoneal administration]. Christian, MS; Hoberman, AM; Lochry, EA; Sato, T, 1994)	0.54
" In the TAZ, maternal toxicity (decreased food consumption) was observed at all dosage groups during perinatal period."	( [Reproductive and developmental toxicity studies of tazobactam/piperacillin or tazobactam (3)--Perinatal and postnatal study in rats with intraperitoneal administration]. Christian, MS; Hoberman, AM; Sato, T, 1994)	0.54
"The pharmacodynamics of dosage regimens of piperacillin alone or in combination with tazobactam against piperacillin-resistant or -susceptible bacteria were studied in an in vitro model of infection."	( Pharmacodynamics of piperacillin alone and in combination with tazobactam against piperacillin-resistant and -susceptible organisms in an in vitro model of infection. Dudley, MN; Gilbert, DH; Medeiros, AA; Pivarnik, P; Strayer, AH; Zinner, SH, 1994)	0.75
"Piperacillin/tazobactam, at a dosage of 4 g/500 mg every 8 h, was administered intravenously to 217 patients with complicated urinary tract infections."	( Piperacillin/tazobactam in complicated urinary tract infections. Nowé, P, 1994)	1.03
" An increase in the tazobactam dosage within the combination (80:25 mg/kg/h) was required in order to obtain a significantly faster elimination of viable organisms from the CSF (-0."	( Different ratios of the piperacillin-tazobactam combination for treatment of experimental meningitis due to Klebsiella pneumoniae producing the TEM-3 extended-spectrum beta-lactamase. Decazes, JM; Gutmann, L; Kitzis, MD; Leleu, G; Vallois, JM, 1994)	0.89
" At the dosage used piperacillin/tazobactam was as safe as, and statistically more effective than, imipenem/cilastatin in the treatment of intra-abdominal infections caused by sensitive organisms."	( A randomized multicenter trial of piperacillin/tazobactam versus imipenem/cilastatin in the treatment of severe intra-abdominal infections. Swedish Study Group. Eklund, AE; Nord, CE, 1993)	0.82
" Piperacillin and tazobactam concentrations can be adjusted by applying prolonged dosing intervals in renal patients."	( Pharmacokinetics of piperacillin, tazobactam and its metabolite in renal impairment. Dalla Costa, T; Derendorf, H, 1996)	0.91
" The drug was given to an underweight 18-year-old woman, at the usual dosage of 4/0."	( Reversible bone marrow depression by high-dose piperacillin/tazobactam. Aguirre, C; Barreiro, G; Ruiz-Irastorza, G, 1996)	0.54
" Serum bactericidal titers were determined and used to calculate the duration of measurable bactericidal activity over the dosing interval of each of the regimens against two clinical isolates of Bacillus fragilis, Escherichia coli, Enterococcus faecalis, and Pseudomonas aeruginosa."	( Comparison of the bactericidal activities of piperacillin-tazobactam, ticarcillin-clavulanate, and ampicillin-sulbactam against clinical isolates of Bacteroides fragilis, Enterococcus faecalis, Escherichia coli, and Pseudomonas aeruginosa. Klepser, ME; Marangos, MN; Nicolau, DP; Nightingale, CH; Quintiliani, R; Zhu, Z, 1997)	0.54
" pneumoniae may be highly dependent on dosing regimens, even for a specific organism and site of infection."	( Efficacies of piperacillin-tazobactam and cefepime in rats with experimental intra-abdominal abscesses due to an extended-spectrum beta-lactamase-producing strain of Klebsiella pneumoniae. Eliopoulos, GM; Moellering, RC; Thauvin-Eliopoulos, C; Tripodi, MF, 1997)	0.59
"In CVVH dependent patients, pip/taz fixed drug preparations can be used initially, but the pip dosage should be increased relative to that of taz (or interval-adjusted) to prevent cumulation of taz, as compared to the active antimicrobial agent pip."	( Pharmacokinetics of piperacillin and tazobactam in critically ill patients with renal failure, treated with continuous veno-venous hemofiltration (CVVH). Mulder, PO; Stegeman, CA; Uges, DR; van der Werf, TS; Zijlstra, JG, 1997)	0.57
" bolus multiple dose, using different dose ratio combinations (1:4, 1:8, 1:16) and dosing regimens, ranging from once-a-day to 4 times a day."	( Pharmacokinetic-pharmacodynamic modelling of the in vitro antiinfective effect of piperacillin-tazobactam combinations. Dalla Costa, T; Derendorf, H; Nolting, A; Rand, K, 1997)	0.52
"The PK-PD model allowed a detailed evaluation of the dosing regimens investigated."	( Pharmacokinetic-pharmacodynamic modelling of the in vitro antiinfective effect of piperacillin-tazobactam combinations. Dalla Costa, T; Derendorf, H; Nolting, A; Rand, K, 1997)	0.52
" The percentage of time that plasma concentrations remained above the MIC (T > MIC) for each organism and dosage regimen was calculated."	( Pharmacokinetics and pharmacodynamics of two multiple-dose piperacillin-tazobactam regimens. Danziger, LH; Occhipinti, DJ; Pendland, SL; Rodvold, KA; Rypins, EB; Schoonover, LL, 1997)	0.53
" Optimal dosage regimens of beta-lactamase inhibitors will provide mean concentrations of beta-lactamase inhibitor at or above those used in in-vitro testing."	( Beta-lactam/beta-lactamase inhibitor combinations: pharmacodynamic considerations and possible role in the management of bacterial infections in the neutropenic host. Dudley, MN; Okereke, C, 1998)	0.3
" Under base-case conditions, our pharmacoeconomic analysis showed that I/C was a cost-effective alternative to P/T at the dosage regimens studied."	( Cost-minimization analysis of piperacillin/tazobactam versus imipenem/cilastatin for the treatment of serious infections: a Canadian hospital perspective. Bryce, EA; Frighetto, LO; Jewesson, PJ; Marra, CA; Marra, FO; Reynolds, RP; Sleigh, KM; Stiver, HG, 1999)	0.57
"A population pharmacokinetic (PK) analysis was conducted to determine if piperacillin and tazobactam exhibited linear or nonlinear PKs and if incremental changes in the daily dosage of piperacillin affected tazobactam PKs."	( Piperacillin and tazobactam exhibit linear pharmacokinetics after multiple standard clinical doses. Auclair, B; Ducharme, MP, 1999)	0.86
" In patients with intra-abdominal infections, clinical and bacteriological response rates were significantly higher with piperacillin/tazobactam than with imipenem/cilastatin (administered at a dosage lower than is recommended in countries outside Scandinavia)."	( Piperacillin/tazobactam: an updated review of its use in the treatment of bacterial infections. Markham, A; Perry, CM, 1999)	0.88
" The T>MIC was calculated as percentage of the dosing interval in which free concentrations exceeded the weighted geometric mean MIC90."	( Comparison of five beta-lactam antibiotics against common nosocomial pathogens using the time above MIC at different creatinine clearances. Kays, MB, 1999)	0.3
"To compare the pharmacokinetic and pharmacodynamic profiles of two dosing regimens for piperacillin-tazobactam against commonly encountered pathogens."	( Pharmacokinetic and pharmacodynamic evaluation of two dosing regimens for piperacillin-tazobactam. Capitano, B; Kim, MK; Mattoes, HM; Nicolau, DP; Nightingale, CH; Quintiliani, R; Xuan, D, 2002)	0.75
"The two dosing regimens for piperacillin-tazobactam were administered intravenously in crossover design."	( Pharmacokinetic and pharmacodynamic evaluation of two dosing regimens for piperacillin-tazobactam. Capitano, B; Kim, MK; Mattoes, HM; Nicolau, DP; Nightingale, CH; Quintiliani, R; Xuan, D, 2002)	0.8
"Although intermittent bolus dosing is currently the standard of practice for many antimicrobial agents, beta-lactams exhibit time-dependent bacterial killing."	( Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam when administered by continuous infusion and intermittent dosing. Burgess, DS; Waldrep, T, 2002)	0.56
" aeruginosa infections due to the higher established breakpoint, these data suggest a high probability of achieving adequate drug exposure against susceptible isolates with this dosing regimen."	( Pharmacodynamic profiling of continuously infused piperacillin/tazobactam against Pseudomonas aeruginosa using Monte Carlo analysis. Kuti, JL; Nicolau, D; Nightingale, CH; Quintiliani, R, 2002)	0.55
" None of the patients dosed with piperacillin/tazobactam was adequately protected for the duration of their surgery and adequate prophylaxis was only evident in four of the nine patients administered cefalotin."	( Inadequate antimicrobial prophylaxis during surgery: a study of beta-lactam levels during burn debridement. Cross, SE; Dalley, AJ; Lipman, J; Roberts, MS; Rudd, M; Venkatesh, B, 2007)	0.6
"These results suggest a need to review antibiotic prophylaxis dosage regimens for burns surgery and the adoption of regimens that will minimize the risk of infection in this high-risk patient group."	( Inadequate antimicrobial prophylaxis during surgery: a study of beta-lactam levels during burn debridement. Cross, SE; Dalley, AJ; Lipman, J; Roberts, MS; Rudd, M; Venkatesh, B, 2007)	0.34
"To report pharmacokinetic alterations and optimal dosing of piperacillin/tazobactam in an obese patient."	( Serum piperacillin/tazobactam pharmacokinetics in a morbidly obese individual. Adeyemi, OA; Montevecchi, M; Newman, D; Nicolau, DP; Noskin, GA; Postelnick, MJ; Scheetz, MH, 2007)	0.9
"Pathogens with elevated MICs may require altered dosing schemes with piperacillin/tazobactam."	( Serum piperacillin/tazobactam pharmacokinetics in a morbidly obese individual. Adeyemi, OA; Montevecchi, M; Newman, D; Nicolau, DP; Noskin, GA; Postelnick, MJ; Scheetz, MH, 2007)	0.89
"With increasing antibiotic resistance in gram-negative pathogens, dosing strategies that optimize pharmacodynamic parameters of currently available antibiotics play an important role in treatment."	( Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulation and steady-state pharmacokinetic data from hospitalized patients. Rotschafer, JC; Ullman, M, 2009)	0.58
"To compare the pharmacodynamics of several dosing regimens of piperacillin/tazobactam administered by intermittent and prolonged infusion using pharmacokinetic data from hospitalized patients."	( Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulations and steady-state pharmacokinetic data from hospitalized patients. Cheatham, SC; Kays, MB; Shea, KM; Smith, DW; Sowinski, KM; Wack, MF, 2009)	0.81
"This study examined the effect of various levels of renal impairment on the probability of achieving free drug concentrations that exceed the MIC for 50% of the dosing interval (50% fT > MIC) for traditional and extended-infusion piperacillin-tazobactam (TZP) dosing strategies."	( Identification of optimal renal dosage adjustments for traditional and extended-infusion piperacillin-tazobactam dosing regimens in hospitalized patients. Drusano, GL; Lodise, TP; Patel, N; Scheetz, MH, 2010)	0.76
" With both longer PLIE and PASME, longer dosing interval should be recommended."	( [Post antibiotic, post beta-lactamase inhibitor and post antibiotic sub-MIC effect of ceftriaxone/tazobactam on beta-lactamase-producing Escherichia coli in vitro]. Chen, SW; Liu, XK; Wu, HY; Zhang, LL; Zhang, SC, 2009)	0.57
" The dosage was adjusted when the serum piperacillin concentration either fell below 4x the drug's minimum inhibitory concentration (MIC) for the causative agent or exceeded the toxic threshold of 150 mg/L."	( Daily serum piperacillin monitoring is advisable in critically ill patients. Blondiaux, N; Courcol, RJ; Durocher, A; Favory, R; Nseir, S; Onimus, T; Roussel-Delvallez, M; Wallet, F, 2010)	0.36
" Serum concentrations remained above 4 times the minimal inhibitory concentration (T > 4 × MIC), corresponding to the clinical breakpoint for Pseudomonas aeruginosa defined by the European Committee on Antimicrobial Susceptibility Testing (EUCAST), for 57% of the dosage interval for meropenem (target MIC = 8 μg/mL), 45% for ceftazidime (MIC = 32 μg/mL), 34% for cefepime (MIC = 32 μg/mL), and 33% for piperacillin-tazobactam (MIC = 64 μg/mL)."	( Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock. De Backer, D; Delattre, I; Dugernier, T; Jacobs, F; Laterre, PF; Layeux, B; Spapen, H; Taccone, FS; Vincent, JL; Wallemacq, P; Wittebole, X, 2010)	0.53
" Standard dosage regimens for piperacillin-tazobactam, ceftazidime and cefepime may, therefore, be insufficient to empirically cover less susceptible pathogens in the early phase of severe sepsis and septic shock."	( Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock. De Backer, D; Delattre, I; Dugernier, T; Jacobs, F; Laterre, PF; Layeux, B; Spapen, H; Taccone, FS; Vincent, JL; Wallemacq, P; Wittebole, X, 2010)	0.62
" Dialysis equipment and prescriptions have gradually changed over time, raising concern that current drug dosing recommendations in the literature may result in underdosing of antibiotics."	( Therapeutic drug monitoring of piperacillin-tazobactam using spent dialysate effluent in patients receiving continuous venovenous hemodialysis. Bauer, SR; Butler, R; Connor, MJ; Fissell, WH; Groszek, J; Hofmann, CL; Rehm, SJ; Salem, C, 2011)	0.63
" The pharmacokinetics of the dosing regimens evaluated were dose proportional and linear."	( Pharmacokinetics and safety of intravenous ceftolozane-tazobactam in healthy adult subjects following single and multiple ascending doses. Benziger, D; Friedland, I; Hershberger, E; Miller, B; Trinh, M, 2012)	0.63
"We obtained data from 40 dosing intervals and observed wide variability in trough concentrations (6."	( Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study. Bellomo, R; Cole, L; Lipman, J; Liu, X; Nair, P; Roberts, DM; Roberts, JA; Roberts, MS, 2012)	0.38
" Here, empirical dosing of antibiotics failed to achieve the target trough antibiotic concentration during 25% of the dosing intervals."	( Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study. Bellomo, R; Cole, L; Lipman, J; Liu, X; Nair, P; Roberts, DM; Roberts, JA; Roberts, MS, 2012)	0.38
" Mean maximum concentration and AUC from time 0 to the end of the dosing interval (AUC(0-τ)) for ceftolozane in ELF were 21."	( Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects. Chandorkar, G; Gotfried, MH; Huntington, JA; Rodvold, KA; Umeh, O, 2012)	0.64
" Therefore, the saturable elimination and its impact on the choice of optimal dosage regimens were quantified."	( Population pharmacokinetics of piperacillin at two dose levels: influence of nonlinear pharmacokinetics on the pharmacodynamic profile. Bulitta, JB; Drusano, GL; Holzgrabe, U; Kinzig, M; Kirkpatrick, CM; Landersdorfer, CB; Sörgel, F; Stephan, U, 2012)	0.38
" Formalized pharmacokinetic studies of piperacillin/tazobactam removal in patients on MARS therapy are necessary to make clear dosing recommendations."	( Molecular Adsorbent Recirculating System (MARS(®)) removal of piperacillin/tazobactam in a patient with acetaminophen-induced acute liver failure. Argento, AC; Heavner, MS; Ruggero, MA; Topal, JE, 2013)	0.87
" In these studies, the experimental duration (10 days), ceftolozane-tazobactam dose ratio (2:1), and dosing interval (every 8 h) were selected to approximate those expected to be used clinically."	( Relationship between ceftolozane-tazobactam exposure and drug resistance amplification in a hollow-fiber infection model. Ambrose, PG; Bhavnani, SM; Castanheira, M; Forrest, A; Friedrich, LV; Jones, RN; McCauley, J; Mendes, RE; Okusanya, OO; Steenbergen, J; Vanscoy, B, 2013)	0.91
" The percentage of the dosing interval that tazobactam concentrations remained above a threshold (%Time>threshold) was identified as the PK-PD exposure measure that was most closely associated with efficacy."	( Pharmacological basis of β-lactamase inhibitor therapeutics: tazobactam in combination with Ceftolozane. Ambrose, PG; Bhavnani, SM; Bulik, CC; Forrest, A; Friedrich, LV; Jones, RN; McCauley, J; Mendes, RE; Okusanya, OO; Steenbergen, JN; Vanscoy, B, 2013)	0.89
"5g piperacillin/tazobactam administered evry 8h resulted in piperacillin concentrations in plasma and ISF >32mg/L throughout most of the dosing interval."	( Pharmacokinetics of piperacillin and tazobactam in plasma and subcutaneous interstitial fluid in critically ill patients receiving continuous venovenous haemodiafiltration. Boots, RJ; Jarrett, P; Kirkpatrick, CM; Lipman, J; Roberts, JA; Varghese, JM, 2014)	1.02
"Recent evidence suggests that current antimicrobial dosing may be inadequate for some critically ill patients."	( Modified Augmented Renal Clearance score predicts rapid piperacillin and tazobactam clearance in critically ill surgery and trauma patients. Akers, KS; Cannon, JW; Chung, KK; Cota, JM; Murray, CK; Niece, KL, 2014)	0.63
" Alternative dosing strategies were explored in silico."	( Modified Augmented Renal Clearance score predicts rapid piperacillin and tazobactam clearance in critically ill surgery and trauma patients. Akers, KS; Cannon, JW; Chung, KK; Cota, JM; Murray, CK; Niece, KL, 2014)	0.63
" Monte Carlo pharmacokinetic simulations demonstrated increased time at therapeutic drug levels with extended infusion dosing at a drug cost savings of up to 66."	( Modified Augmented Renal Clearance score predicts rapid piperacillin and tazobactam clearance in critically ill surgery and trauma patients. Akers, KS; Cannon, JW; Chung, KK; Cota, JM; Murray, CK; Niece, KL, 2014)	0.63
" The experiment duration was 10 days, and the ceftolozane-tazobactam dose ratio (2:1) and dosing interval (every 8 h) were selected to approximate those expected to be used clinically."	( Relationship between ceftolozane-tazobactam exposure and selection for Pseudomonas aeruginosa resistance in a hollow-fiber infection model. Ambrose, PG; Bhavnani, SM; Castanheira, M; Friedrich, LV; Jones, RN; McCauley, J; Mendes, RE; Steenbergen, JN; VanScoy, BD, 2014)	0.93
"A better dosing strategy can improve clinical outcomes for patients."	( Clinical outcomes with alternative dosing strategies for piperacillin/tazobactam: a systematic review and meta-analysis. Chen, L; Wang, Y; Yang, H; Zhang, C; Zhou, Q, 2015)	0.65
"22) between the two dosing regimens."	( Clinical outcomes with alternative dosing strategies for piperacillin/tazobactam: a systematic review and meta-analysis. Chen, L; Wang, Y; Yang, H; Zhang, C; Zhou, Q, 2015)	0.65
" Therefore, this dosing strategy could be considered in clinical practice."	( Clinical outcomes with alternative dosing strategies for piperacillin/tazobactam: a systematic review and meta-analysis. Chen, L; Wang, Y; Yang, H; Zhang, C; Zhou, Q, 2015)	0.65
" Population pharmacokinetic parameters were estimated using NONMEM, and Monte Carlo simulations were performed for three 4-hour dosing regimens to calculate probability of target attainment (PTA) at ≥50% fT>MIC."	( Population pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese and nonobese patients. Cheatham, SC; Chung, EK; Fleming, MR; Healy, DP; Kays, MB; Shea, KM, 2015)	0.65
"The study was to establish a population pharmacokinetic (PPK) model of piperacillin (PIP) and tazobactam (TAZ) that explain pharmacokinetic variability and to propose optimized dosage regimens in patients with nosocomial infections."	( Population Pharmacokinetics and Pharmacodynamics of Piperacillin/Tazobactam in Patients with Nosocomial Infections. Chen, R; Qian, CY; Qian, Q; Sun, MR; Wang, LY; Wang, ML; Zou, SL, 2016)	0.89
"In total, 310 PIP and 280 TAZ concentration-time points were collected at steady state over multiple dosing intervals from 50 patients who received PIP/TAZ infused within 30 min or over 3 h."	( Population Pharmacokinetics and Pharmacodynamics of Piperacillin/Tazobactam in Patients with Nosocomial Infections. Chen, R; Qian, CY; Qian, Q; Sun, MR; Wang, LY; Wang, ML; Zou, SL, 2016)	0.67
" A population pharmacokinetic (PK) model with the plasma-to-epithelial lining fluid (ELF) kinetics of ceftolozane/tazobactam was used to justify dosing regimens for patients with nosocomial pneumonia in phase 3 studies."	( Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia. Huntington, JA; Miller, BW; Nicolau, DP; Xiao, AJ, 2016)	1.02
" Similar to other cephalosporins, the best pharmacodynamic property to predict efficacy for ceftolozane/tazobactam is a concentration that remains above the minimum inhibitory concentration (MIC) for 40-50% of the dosing interval."	( Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination. Cho, JC; Estrada, SJ; Fiorenza, MA, 2015)	1.01
"Antibiotic dosing in septic shock patients poses a challenge for clinicians due to the pharmacokinetic (PK) variability seen in this patient population."	( Population pharmacokinetics of piperacillin in the early phase of septic shock: does standard dosing result in therapeutic plasma concentrations? Brock, B; Gjedsted, J; Hardlei, TF; Juul, RV; Kreilgaard, M; Öbrink-Hansen, K; Storgaard, M; Thomsen, MK, 2015)	0.42
" Its dosing and chemistry provide expansive antimicrobial coverage of gram-negative organisms, including Pseudomonas aeruginosa, and stable activity against many β-lactamases, as well as coverage of most extended-spectrum β-lactamase-producing organisms and some anaerobes."	( Ceftolozane-tazobactam: A new-generation cephalosporin. Cluck, D; Lewis, P; Moorman, J; Spivey, J; Stayer, B, 2015)	0.8
"57 μg/ml, concentration at the end of the dosing interval (Cmin) of 31."	( Ceftolozane-Tazobactam Pharmacokinetics in a Critically Ill Patient on Continuous Venovenous Hemofiltration. Gonzales, JP; Heil, EL; Mehrotra, S; Nicolau, DP; Oliver, WD; Robinett, K; Saleeb, P, 2015)	0.8
"We have previously demonstrated the pharmacokinetic-pharmacodynamic (PK-PD) index best associated with the efficacy of tazobactam when used in combination with ceftolozane to be the percentage of the dosing interval during which tazobactam concentrations remained above a threshold value (%time>threshold)."	( Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Piperacillin in an In Vitro Infection Model. Ambrose, PG; Bhavnani, SM; Bulik, CC; Castanheira, M; Forrest, A; Friedrich, LV; Jones, RN; Mendes, RE; Nicasio, AM; Okusanya, OO; Steenbergen, JN; VanScoy, BD, 2016)	0.92
" After only 24 hours of treatment in the neutropenic murine thigh infection model, the generic amplified the resistant subpopulation up to 20-times compared with the innovator, following an inverted-U dose-response relationship."	( Impact on Bacterial Resistance of Therapeutically Nonequivalent Generics: The Case of Piperacillin-Tazobactam. Agudelo, M; Aguilar, YA; Rodriguez, CA; Vesga, O; Zuluaga, AF, 2016)	0.65
"A better dosing strategy can improve clinical outcomes for patients."	( Evaluation Outcomes Associated with Alternative Dosing Strategies for Piperacillin/Tazobactam: A Systematic Review and Meta-Analysis. Cui, X; Liu, L; Ma, Z; Yang, H, )	0.36
"To determine ceftolozane/tazobactam transmembrane clearances (CLTM) in continuous hemofiltration (CHF) and continuous hemodialysis (CHD) and to determine optimal ceftolozane/tazobactam dosing regimens for patients receiving continuous renal replacement therapy (CRRT)."	( Ex vivo Ceftolozane/Tazobactam Clearance during Continuous Renal Replacement Therapy. Chaijamorn, W; Lewis, SJ; Mueller, BA; Shaw, AR, 2017)	1.08
" Monte Carlo simulations (MCS) using pharmacokinetic parameters from published studies and CLTM from this study were used to generate ceftolozane/tazobactam dosing for patients receiving CRRT."	( Ex vivo Ceftolozane/Tazobactam Clearance during Continuous Renal Replacement Therapy. Chaijamorn, W; Lewis, SJ; Mueller, BA; Shaw, AR, 2017)	0.98
"To characterize the population pharmacokinetics of piperacillin and tazobactam in critically ill infants and children, in order to develop an evidence-based dosing regimen."	( Dose optimization of piperacillin/tazobactam in critically ill children. Carlier, M; De Cock, PAJG; de Jaeger, A; De Paepe, P; Delanghe, JR; Della Pasqua, OE; Robays, H; van Dijkman, SC; Vande Walle, J; Verstraete, AG; Willems, J, 2017)	0.97
"Standard intermittent dosing regimens do not ensure optimal piperacillin/tazobactam exposure in critically ill patients, thereby risking treatment failure."	( Dose optimization of piperacillin/tazobactam in critically ill children. Carlier, M; De Cock, PAJG; de Jaeger, A; De Paepe, P; Delanghe, JR; Della Pasqua, OE; Robays, H; van Dijkman, SC; Vande Walle, J; Verstraete, AG; Willems, J, 2017)	0.97
"Appropriate antibiotic dosing is critical to improve outcomes in critically ill patients with sepsis."	( Antibiotic Dosing in Continuous Renal Replacement Therapy. Mueller, BA; Shaw, AR, 2017)	0.46
" Dosing of piperacillin-tazobactam requires an understanding of this patient group to maximise the effectiveness of this antibiotic and limit a further emergence of resistant pathogens."	( A UHPLC-MS/MS method for the simultaneous determination of piperacillin and tazobactam in plasma (total and unbound), urine and renal replacement therapy effluent. Guerra Valero, YC; Lipman, J; Naicker, S; Ordenez Meija, JL; Parker, SL; Roberts, JA; Wallis, SC, 2018)	1.02
"We sought to identify ceftolozane/tazobactam dosing schemes that optimized the probability of target attainment (PTA) against infections due to MDR-PA with ceftolozane/tazobactam MICs between 4 and 32 mg/L across different categories of renal function."	( Determination of alternative ceftolozane/tazobactam dosing regimens for patients with infections due to Pseudomonas aeruginosa with MIC values between 4 and 32 mg/L. Lodise, TP; Natesan, S; Pai, MP, 2017)	1
"Extended infusion ceftolozane/tazobactam regimens should be investigated as a potential dosing solution to improve the PTA against infections due to MDR-PA with higher ceftolozane/tazobactam MICs."	( Determination of alternative ceftolozane/tazobactam dosing regimens for patients with infections due to Pseudomonas aeruginosa with MIC values between 4 and 32 mg/L. Lodise, TP; Natesan, S; Pai, MP, 2017)	1.01
" However, knowledge regarding the effect of sustained low-efficiency diafiltration (SLED-f), a technique increasingly being used in ICUs, on piperacillin pharmacokinetics (PK) and dosing in critically ill patients is lacking."	( Pharmacokinetics of piperacillin in critically ill patients with acute kidney injury receiving sustained low-efficiency diafiltration. Lipman, J; Peake, SL; Roberts, JA; Roberts, MS; Sinnollareddy, MG, 2018)	0.48
"As it can be challenging to accurately predict when SLED-f will be initiated in the critically ill, a maintenance dose of at least 4 g every 12 h with at least a 2 g replacement dose post-SLED-f would be a practical approach to piperacillin dosing in ICU patients with anuria receiving SLED-f with a duration similar to the current study."	( Pharmacokinetics of piperacillin in critically ill patients with acute kidney injury receiving sustained low-efficiency diafiltration. Lipman, J; Peake, SL; Roberts, JA; Roberts, MS; Sinnollareddy, MG, 2018)	0.48
"The aim of this study was to evaluate the effectiveness of ceftolozane/tazobactam (C/T) for treating extensively drug-resistant Pseudomonas aeruginosa (XDR-PA) infections, and to analyze whether high C/T dosing (2 g ceftolozane and 1 g tazobactam every 8 h) and infection source control have an impact on outcome."	( Ceftolozane/tazobactam for the treatment of XDR Pseudomonas aeruginosa infections. Almirante, B; Arévalo, Á; Campany, D; Escolà-Vergé, L; Ferrer, R; Larrosa, N; Len, O; Los-Arcos, I; Nuvials, X; Pigrau, C; Viñado, B, 2018)	1.09
"Sustained low-efficiency dialysis (SLED), is increasingly being used in intensive care units (ICUs) but studies informing drug dosing for such patients is lacking."	( Piperacillin Population Pharmacokinetics in Critically Ill Adults During Sustained Low-Efficiency Dialysis. Alobaid, A; Hiremath, S; Kanji, S; Patel, R; Porteous, R; Roberts, JA; Watpool, I; Xie, J; Zelenitsky, S; Zhang, G, 2018)	0.48
"To describe the population pharmacokinetics (PKs) of piperacillin/tazobactam in critically ill adults receiving SLED and to provide dosing recommendations."	( Piperacillin Population Pharmacokinetics in Critically Ill Adults During Sustained Low-Efficiency Dialysis. Alobaid, A; Hiremath, S; Kanji, S; Patel, R; Porteous, R; Roberts, JA; Watpool, I; Xie, J; Zelenitsky, S; Zhang, G, 2018)	0.72
" This study aimed to develop a PK population model for piperacillin in order to optimize individual dosing regimens."	( Piperacillin Population Pharmacokinetics and Dosing Regimen Optimization in Critically Ill Children with Normal and Augmented Renal Clearance. Benaboud, S; Béranger, A; Bille, E; Gana, I; Genuini, M; Hirt, D; Lesage, F; Moulin, F; Oualha, M; Renolleau, S; Tréluyer, JM; Urien, S; Zheng, Y, 2019)	0.51
"Unlike standard intermittent piperacillin dosing regimens, extended and continuous infusion allows the PK targets to be reached, for children with normal or augmented renal clearance."	( Piperacillin Population Pharmacokinetics and Dosing Regimen Optimization in Critically Ill Children with Normal and Augmented Renal Clearance. Benaboud, S; Béranger, A; Bille, E; Gana, I; Genuini, M; Hirt, D; Lesage, F; Moulin, F; Oualha, M; Renolleau, S; Tréluyer, JM; Urien, S; Zheng, Y, 2019)	0.51
"To use a pre-clinical infection model to assess the antibacterial effect of human simulations of dosing with ceftolozane/tazobactam (with or without amikacin) or meropenem against Enterobacteriaceae and Pseudomonas aeruginosa."	( Antibacterial effect of ceftolozane/tazobactam in combination with amikacin against aerobic Gram-negative bacilli studied in an in vitro pharmacokinetic model of infection. Attwood, M; Bowker, KE; MacGowan, AP; Noel, AR, 2018)	0.96
" In this review, we summarize the phase III studies that observed lower response rates with ceftazidime-avibactam, ceftolozane-tazobactam, daptomycin, and telavancin relative to their comparators among patients with moderate renal impairment, discuss potential explanations for the observed findings, provide considerations for future antibiotic development, and offer strategies for optimizing antibiotic dosage selection among patients with moderate renal impairment in clinical settings."	( Suboptimal Clinical Response Rates with Newer Antibiotics Among Patients with Moderate Renal Impairment: Review of the Literature and Potential Pharmacokinetic and Pharmacodynamic Considerations for Observed Findings. Bidell, MR; Lodise, TP, 2018)	0.69
"Prolonged intermittent renal replacement therapy (PIRRT) eliminates many drugs, and without dosing data, for new antibiotics like ceftolozane/tazobactam, suboptimal concentrations and treatment failure are likely."	( Pharmacokinetics of Ceftolozane-Tazobactam during Prolonged Intermittent Renal Replacement Therapy. Cheng, V; Dyer, J; Ingram, P; McWhinney, BC; Raby, E; Rawlins, M; Regli, A; Roberts, JA; Ungerer, JPJ, 2018)	0.97
"A ceftolozane/tazobactam dose of 500 mg/250 mg appears to be sufficient to attain pharmacokinetic/pharmacodynamic targets during PIRRT while the manufacturer's recommended dosing of 100 mg/50 mg every 8 h was sufficient during non-PIRRT periods."	( Pharmacokinetics of Ceftolozane-Tazobactam during Prolonged Intermittent Renal Replacement Therapy. Cheng, V; Dyer, J; Ingram, P; McWhinney, BC; Raby, E; Rawlins, M; Regli, A; Roberts, JA; Ungerer, JPJ, 2018)	1.13
" However, pharmacokinetic variability among patient populations and across ages leads to uncertainty when selecting a dosing regimen to achieve an appropriate pharmacodynamic target."	( Population pharmacokinetics of piperacillin in febrile children receiving cancer chemotherapy: the impact of body weight and target on an optimal dosing regimen. Brock, B; Friberg, LE; Kristoffersson, AN; Maarbjerg, SF; Nielsen, EI; Schrøder, H; Thorsted, A; Wang, M, 2019)	0.51
"To guide dosing by establishing a population pharmacokinetic model for unbound piperacillin in febrile children receiving cancer chemotherapy, and to assess pharmacokinetic/pharmacodynamic target attainment (100% fT > 1×MIC and 50% fT > 4×MIC) and resultant exposure, across body weights."	( Population pharmacokinetics of piperacillin in febrile children receiving cancer chemotherapy: the impact of body weight and target on an optimal dosing regimen. Brock, B; Friberg, LE; Kristoffersson, AN; Maarbjerg, SF; Nielsen, EI; Schrøder, H; Thorsted, A; Wang, M, 2019)	0.51
" The typical doses required for target attainment were compared for various dosing regimens, in particular prolonged infusions, across MICs and body weights."	( Population pharmacokinetics of piperacillin in febrile children receiving cancer chemotherapy: the impact of body weight and target on an optimal dosing regimen. Brock, B; Friberg, LE; Kristoffersson, AN; Maarbjerg, SF; Nielsen, EI; Schrøder, H; Thorsted, A; Wang, M, 2019)	0.51
" Given the population pharmacokinetic profile, feasible dosing regimens with reasonable exposure are continuous infusion (100% fT > 1×MIC) or prolonged infusions (50% fT > 4×MIC)."	( Population pharmacokinetics of piperacillin in febrile children receiving cancer chemotherapy: the impact of body weight and target on an optimal dosing regimen. Brock, B; Friberg, LE; Kristoffersson, AN; Maarbjerg, SF; Nielsen, EI; Schrøder, H; Thorsted, A; Wang, M, 2019)	0.51
"Therapeutic drug monitoring (TDM) is increasingly used to optimize the dosing of beta-lactam antibiotics in critically ill patients."	( Preanalytical Stability of Piperacillin, Tazobactam, Meropenem, and Ceftazidime in Plasma and Whole Blood Using Liquid Chromatography-Tandem Mass Spectrometry. Doogue, M; Jensen, BP; Mortensen, JS; Zhang, M, 2019)	0.78
" Further evaluations with multiple dose in vitro and in vivo investigations are needed before specific drug dosing recommendations can be made for clinical application with extracorporeal membrane oxygenation."	( Oxygenator Impact on Ceftolozane and Tazobactam in Extracorporeal Membrane Oxygenation Circuits. Chopra, A; Cies, JJ; Enache, A; Giliam, N; Low, T; Moore, WS, 2020)	0.83
" High-dose vitamin C was defined as a dosage in excess of 10 g or 24 g within 2 days of admission."	( Effect of high-dose vitamin C therapy on severe burn patients: a nationwide cohort study. Aso, S; Fushimi, K; Goto, H; Kaita, Y; Kojiro, M; Matsui, H; Nakajima, M; Yamaguchi, Y; Yasunaga, H, 2019)	0.51
" In a second stage, a pilot experimental study was performed with the random comparison of patients for evaluation and adaptation of the software in the real environment of an intensive care unit, where it was compared between patients who used the standardized dose of piperacillin/tazobactam, and those who used an individualized dose adjusted through the software Individually Designed and Optimized Dosing Strategies."	( Linguistic and cultural adaptation to the Portuguese language of antimicrobial dose adjustment software. Alves, GCDS; Chequer, FMD; Daróczi, G; Farkas, A; Roberts, JA; Sanches, C; Silva, SDD, 2020)	0.74
" Pharmacokinetic parameters were estimated by non-compartmental analysis and pharmacodynamic analyses were conducted to graphically evaluate achievement of target exposures (plasma and ELF ceftolozane concentrations >4 mg/L and tazobactam concentrations >1 mg/L; target in plasma: ≥30% and ≥20% of the dosing interval, respectively)."	( Lung penetration, bronchopulmonary pharmacokinetic/pharmacodynamic profile and safety of 3 g of ceftolozane/tazobactam administered to ventilated, critically ill patients with pneumonia. Adedoyin, A; Caro, L; De Waele, JJ; Gadzicki, E; Kuti, JL; Larson, KB; Nicolau, DP; Rhee, EG; Yu, B; Zeng, Z, 2020)	0.95
" Mean ceftolozane and tazobactam ELF concentrations remained >4 mg/L and >1 mg/L, respectively, for 100% of the dosing interval."	( Lung penetration, bronchopulmonary pharmacokinetic/pharmacodynamic profile and safety of 3 g of ceftolozane/tazobactam administered to ventilated, critically ill patients with pneumonia. Adedoyin, A; Caro, L; De Waele, JJ; Gadzicki, E; Kuti, JL; Larson, KB; Nicolau, DP; Rhee, EG; Yu, B; Zeng, Z, 2020)	1.09
" Individual attainment of PK/pharmacodynamic (PD) targets of ceftolozane and tazobactam (free ceftolozane concentration >4 µg/mL for >30% and free tazobactam concentration >1 µg/mL for 20% of the dosing interval) in patients with and without CF were evaluated."	( Plasma pharmacokinetics of ceftolozane/tazobactam in pediatric patients with cystic fibrosis. Ang, JY; Arrieta, AC; Feng, EH; Johnson, MG; Larson, KB; Rhee, EG; Rizk, ML; Yu, B; Zhang, Z, 2020)	1.06
"Considering that the influence of ECMO on the pharmacokinetics of ceftolozane/tazobactam is not clinically significant, normal ceftolozane and tazobactam dosing in critically ill patients should be effective for patients undergoing ECMO."	( Influence of extracorporeal membrane oxygenation on the pharmacokinetics of ceftolozane/tazobactam: an ex vivo and in vivo study. Concordet, D; Delmas, C; Gandia, P; Georges, B; Jourdan, G; Mané, C; Marcheix, B; Porterie, J; Ruiz, S; Verwaerde, P, 2020)	1.01
" Higher dosing regimens coupled with continuous/extended infusion may be required in the case of higher CRRT intensity, deep-seated infections or poorly susceptible isolates."	( Ceftolozane/tazobactam exposure in critically ill patients undergoing continuous renal replacement therapy: a PK/PD approach to tailor dosing. De Ponti, F; Gatti, M; Giannella, M; Raschi, E; Viale, P, 2021)	1
" Forty-six episodes were treated with high-dose C/T (3 g every 8 hours) and 38 episodes were treated with standard dosage (1."	( Multicenter study of ceftolozane/tazobactam for treatment of Pseudomonas aeruginosa infections in critically ill patients. Asensio-Martín, MJ; Balandin, B; Ballesteros, D; Chicot, M; Fernández-Simón, I; Iranzo, R; López-Vergara, L; Martínez-Sagasti, F; Pérez-Pedrero, MJ; Pintado, V; Rodríguez-Serrano, D; Royuela, A; Ruiz de Luna, R; Sancho-González, M; Silva, A; Soriano-Cuesta, C, 2021)	0.9
" Cefepime and tazobactam dosing regimens produced plasma profiles of fAUC, fT>MIC and fCmax similar to human exposure after WCK 4282 2/2 g every 8 h (1."	( In vivo activity of WCK 4282 (high-dose cefepime/tazobactam) against serine β-lactamase-producing Enterobacterales and Pseudomonas aeruginosa in the neutropenic murine thigh infection model. Abdelraouf, K; Gill, CM; Nicolau, DP, 2021)	1.24
" The median dosage of TA and VAN were 10."	( Comparison of risk of acute kidney injury between patients receiving the combination of teicoplanin and piperacillin/tazobactam versus vancomycin and piperacillin/tazobactam. Lin, FJ; Shao, CH; Tai, CH; Wang, CC; Wang, JT; Wu, CC, 2022)	0.93
"The studies identified in this review demonstrate that C/T is effective in clinical practice, despite the diverse group of seriously ill patients, different levels of resistance of the pathogens treated, and varying dosing regimens used."	( Real-world use of ceftolozane/tazobactam: a systematic literature review. Collings, H; Dillon, R; Enstone, A; Palmer, T; Puzniak, L, 2021)	0.91
" This review summarizes the population pharmacokinetic models developed for piperacillin-tazobactam and provides comprehensive data on current dosing strategies while identifying significant covariates in critically ill patients."	( Piperacillin-Tazobactam in Intensive Care Units: A Review of Population Pharmacokinetic Analyses. Caissy, JA; El-Haffaf, I; Marsot, A, 2021)	1.21
" The dosage regimen was customised in all patients based on creatinine clearance."	( Real-life experience with ceftolozane/tazobactam in Canada: results from the CLEAR (Canadian LEadership on Antimicrobial Real-life usage) registry. Ariano, R; Bassetti, M; Baxter, M; Borgia, S; Cervera, C; Dhami, R; Dow, G; Dube, M; Irfan, N; Karlowsky, JA; Kosar, J; Savoie, M; Tessier, JF; Walkty, A; Zhanel, GG; Zvonar, R, 2021)	0.89
" With well-characterized stability, this assay can be used with residual specimens for pharmacokinetic modeling, which may lead to individualized dosing and improved patient care."	( Stability and Validation of a High-Throughput LC-MS/MS Method for the Quantification of Cefepime, Meropenem, and Piperacillin and Tazobactam in Serum. Barreto, EF; Bjergum, MW; Jannetto, PJ; Rule, AD; Scheetz, MH, 2021)	0.83
" As critically ill patients often experience pharmacokinetic aberrations, and rates of antimicrobial resistance vary between hospital settings, reliance on tertiary sources or package labeling to guide empiric dosing often results in suboptimal β-lactam exposure."	( Time Above All Else: Pharmacodynamic Analysis of β-Lactams in Critically Ill Patients. Burgess, DS; Clark, JA; Landmesser, KB, 2022)	0.72
" The higher dosing regimen (80 mg/L) showed a slight advantage in effectiveness."	( Impact of ceftolozane/tazobactam concentrations in continuous infusion against extensively drug-resistant Pseudomonas aeruginosa isolates in a hollow-fiber infection model. Angulo-Brunet, A; Campillo, N; Domene-Ochoa, S; Ferrer-Alapont, L; Grau, S; Horcajada, JP; López-Causapé, C; Luque, S; Montero, MM; Oliver, A; Padilla, E; Prim, N; Sorlí, L, 2021)	0.94
" The increased use of RDD and the lack of standardization among available protocols in terms of formulation, starting dose, number of steps and dosing frequency make it essential to determine the safety and appropriate management of these protocols, especially regarding reconstitution, diluents, stability and drug administration in order to guarantee reproducibility."	( Evaluation of desensitization protocols to betalactam antibiotics. Albanell-Fernández, M; Aranda, L; Bartra, J; Gelis, S; González-García, R; López-Cabezas, C; Soy Muner, D, 2022)	0.72
" Application of recommended dosages in patients with renal impairment requires the use of fractions of the full dose, as only one dosage is available for both antibiotics."	( Pharmacokinetic/Pharmacodynamic Simulations of Cost-Effective Dosage Regimens of Ceftolozane-Tazobactam and Ceftazidime-Avibactam in Patients with Renal Impairment. Bourguignon, L; Dheyriat, L; Ferry, T; Goutelle, S; Perpoint, T, 2022)	0.94
"High-dose cefepime-tazobactam (WCK 4282) is currently under clinical development at a dosage of 2 grams/2 grams every 8 hours with prolonged infusion (90 minutes)."	( Antimicrobial activity of high-dose cefepime-tazobactam (WCK 4282) against a large collection of gram-negative organisms collected worldwide in 2018 and 2019. Carvalhaes, CG; Castanheira, M; Mendes, RE; Sader, HS, 2022)	1.31
"To explore extracorporeal membrane oxygenation (ECMO)-related alterations of the pharmacokinetics (PK) of piperacillin/tazobactam and determine an optimal dosage regimen for critically ill adult patients."	( Population pharmacokinetics of piperacillin/tazobactam in critically ill Korean patients and the effects of extracorporeal membrane oxygenation. Kim, HI; Kim, HS; Kim, YK; Lee, DH; Lee, SH; Park, S, 2022)	1.19
" The percentage of time within 24 h for which the free concentration exceeded the MIC at a steady-state (50%fT>MIC, 100%fT>MIC, and 100%fT>4×MIC) for various combinations of dosage regimens and renal function were explored using Monte-Carlo simulation."	( Population pharmacokinetics of piperacillin/tazobactam in critically ill Korean patients and the effects of extracorporeal membrane oxygenation. Kim, HI; Kim, HS; Kim, YK; Lee, DH; Lee, SH; Park, S, 2022)	0.98
" Patients with Escherichia coli or Klebsiella pneumoniae infection, but not those with Pseudomonas aeruginosa infection, exhibited a PK/pharmacodynamic target attainment >90% when the target is 50%fT>MIC, as a result of applying the currently recommended dosage regimen."	( Population pharmacokinetics of piperacillin/tazobactam in critically ill Korean patients and the effects of extracorporeal membrane oxygenation. Kim, HI; Kim, HS; Kim, YK; Lee, DH; Lee, SH; Park, S, 2022)	0.98
"Timely and appropriate dosing of antibiotics is essential for the treatment of bacterial sepsis."	( Pharmacokinetics of piperacillin and tazobactam in critically Ill patients treated with continuous kidney replacement therapy: A mini-review and population pharmacokinetic analysis. Akers, KS; Chung, KK; DeLuca, JP; Livezey, JR; Nadeau, RJ; Por, ED; Pruskowski, KA; Selig, DJ, 2022)	0.99
" However, some critically ill CKRT populations may need higher or lower doses and dosing strategies should be tailored to individuals based on all available clinical data including the specific critical care setting."	( Pharmacokinetics of piperacillin and tazobactam in critically Ill patients treated with continuous kidney replacement therapy: A mini-review and population pharmacokinetic analysis. Akers, KS; Chung, KK; DeLuca, JP; Livezey, JR; Nadeau, RJ; Por, ED; Pruskowski, KA; Selig, DJ, 2022)	0.99
" The molecule is time-dependent and stable when reconstituted at room temperature, facilitating safe and effective dosage optimization in frail and critically ill patients."	( Ceftolozane-tazobactam in nosocomial pneumonia. Candel, FJ; González Del Castillo, J; Julián Jiménez, A; Matesanz, M, 2022)	1.1
" The pharmacokinetic/pharmacodynamic therapeutic target of C/T was defined as 100% of the duration of the dosing interval that free concentrations are above the minimum inhibitory concentration (MIC) (100 %ƒT ≥ MIC) of the causative pathogen."	( Therapeutic Drug Monitoring and Prolonged Infusions of Ceftolozane/Tazobactam for MDR/XDR Pseudomonas aeruginosa Infections: An Observational Study. Benítez-Cano, A; Grau, S; Luque, S; Navarrete-Rouco, ME; Roberts, JA; Sorlí, L, 2022)	0.96
"The administration of C/T by prolonged infusion with TDM-guided dosing allowed the achievement of a pharmacokinetic/pharmacodynamic target even at lower doses."	( Therapeutic Drug Monitoring and Prolonged Infusions of Ceftolozane/Tazobactam for MDR/XDR Pseudomonas aeruginosa Infections: An Observational Study. Benítez-Cano, A; Grau, S; Luque, S; Navarrete-Rouco, ME; Roberts, JA; Sorlí, L, 2022)	0.96
" Dosing regimens were independently selected by intensivists."	( Clearance of Piperacillin-Tazobactam and Vancomycin During Continuous Renal Replacement With Regional Citrate Anticoagulation. Ankravs, MJ; Bellomo, R; Deane, AM; Rechnitzer, T; Roberts, JA; Sharrock, L; Wallis, SC, 2023)	1.21
" A modeling/simulation approach was undertaken to inform optimal dosing in this population, using previously developed ceftolozane and tazobactam population pharmacokinetic models informed by data from 16 clinical studies."	( Probability of Target Attainment Analyses to Inform Ceftolozane/Tazobactam Dosing Regimens for Patients With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia and End-Stage Renal Disease Receiving Intermittent Hemodialysis. Bruno, CJ; De Anda, C; Feng, HP; Fiedler-Kelly, J; Gao, W; Patel, YT; Rhee, EG; Zhang, Z, 2023)	1.35
"Probability of target attainment (PTA) analyses were conducted to support the recommended ceftolozane/tazobactam dosing regimens, adjusted for renal function, in patients with hospital-acquired/ventilator-associated bacterial pneumonia (HABP/VABP)."	( Ceftolozane/Tazobactam Probability of Target Attainment in Patients With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia. Anda, C; Bruno, CJ; Feng, HP; Fiedler-Kelly, J; Gao, W; Johnson, MG; Patel, YT; Rhee, EG; Zhang, Z, 2023)	1.5
"We employed both a neutropenic murine lung infection model and an in vitro pharmacokinetic model (IVPM) to determine cefepime's pharmacodynamic target [percentage of the dosing interval during which unbound drug concentrations remain higher than the MIC (%fT>MIC)] for bacteriostatic and 1 log10 kill effects."	( Cefepime pharmacodynamic targets against Enterobacterales employing neutropenic murine lung infection and in vitro pharmacokinetic models. Attwood, M; Chavan, R; MacGowan, A; Muller, AE; Noel, A; Periasamy, H; Van den Berg, S, 2022)	0.72
" Optimization of pharmacokinetic/pharmacodynamic parameters, such as prolonged infusion (for time-dependent antibiotics), increased dosage (for concentration-dependent antibiotics), and therapeutic drug monitoring, also influences the outcome."	( How to Manage Pseudomonas aeruginosa Infections. Guery, B; Jacot, D; Papadimitriou-Olivgeris, M, 2022)	0.72
" These data could serve as the foundation for implementation of model-informed precision dosing to reduce AKI incidence in patients given piperacillin/tazobactam."	( Relationship between piperacillin concentrations, clinical factors and piperacillin/tazobactam-associated acute kidney injury. Caldwell, JT; Dong, S; Fei, L; Goldstein, SL; Hasson, D; Kaplan, J; Slagle, C; Tang Girdwood, S; Tang, P; Vinks, AA, 2023)	1.33
" A 5000-patient Monte Carlo simulation was performed using various piperacillin/tazobactam dosing regimens to determine the probability of target attainment (PTA) for 50% free time above the MIC."	( Piperacillin/Tazobactam Dose Optimization in the Setting of Piperacillin/Tazobactam-susceptible, Carbapenem-resistant Pseudomonas aeruginosa: Time to Reconsider Susceptible Dose Dependent. Gill, CM; Nicolau, DP, 2023)	1.51
" Using an opportunistic study design, we evaluated the pharmacokinetics of piperacillin/tazobactam as a probe drug to evaluate changes in antibacterial drug exposure and dosing requirements, including in older adults."	( Population Pharmacokinetics of Piperacillin/Tazobactam Across the Adult Lifespan. An, G; Balevic, SJ; Chan, AW; Cohen-Wolkowiez, M; Conrad, T; Gu, K; Hemmersbach-Miller, M; Kirkpatrick, CMJ; Landersdorfer, CB; Schmader, KE; Swamy, GK; Walter, EB; Winokur, PL, 2023)	1.39
" However, for a target of 50% fT + minimum inhibitory concentration, dosing based on renal function is generally preferable to dosing by age, and simulations suggested that patients with creatinine clearance ≥ 120 mL/min may benefit from infusions of 4 g every 8 hours for organisms with higher minimum inhibitory concentrations."	( Population Pharmacokinetics of Piperacillin/Tazobactam Across the Adult Lifespan. An, G; Balevic, SJ; Chan, AW; Cohen-Wolkowiez, M; Conrad, T; Gu, K; Hemmersbach-Miller, M; Kirkpatrick, CMJ; Landersdorfer, CB; Schmader, KE; Swamy, GK; Walter, EB; Winokur, PL, 2023)	1.17
" The primary outcome was major delay, defined as an administration delay >25% of the recommended dosing interval, which was evaluated with multivariable logistic regression and interrupted time series analysis."	( Association between emergency department sepsis order set design and delay to second dose piperacillin-tazobactam administration. Bauer, SR; Campbell, MJ; Dettmer, MR; Erickson, RM; Fertel, BS; Sacha, GL; Wesolek, JL, 2023)	1.13
"Ceftolozane-tazobactam (C/T) recommended dosing in patients undergoing renal replacement therapies (RRT) is lacking evidence."	( Clinical outcomes of ceftolozane-tazobactam dosing in patients with sepsis undergoing renal replacement therapies. Abidi, E; Al Ali, M; Attallah, N; El Lababidi, R; El Nekidy, WS; Ghazi, IM; Hijazi, F; Mallat, J, 2023)	1.57
" Larger outcomes and pharmacokinetics studies are needed to establish effective dosing and therapy duration."	( Clinical outcomes of ceftolozane-tazobactam dosing in patients with sepsis undergoing renal replacement therapies. Abidi, E; Al Ali, M; Attallah, N; El Lababidi, R; El Nekidy, WS; Ghazi, IM; Hijazi, F; Mallat, J, 2023)	1.19

Role	Description
antimicrobial agent	A substance that kills or slows the growth of microorganisms, including bacteria, viruses, fungi and protozoans.
antiinfective agent	A substance used in the prophylaxis or therapy of infectious diseases.
EC 3.5.2.6 (beta-lactamase) inhibitor	An EC 3.5.2.* (non-peptide cyclic amide C-N hydrolase) inhibitor that interferes with the action of beta-lactamase (EC 3.5.2.6).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
penicillanic acids
triazoles	An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Beta-lactamase	Klebsiella pneumoniae	IC50 (µMol)	0.0800	0.0800	0.9000	1.7200	AID519751
Beta-lactamase	Escherichia coli	IC50 (µMol)	0.0100	0.0100	2.0933	6.2000	AID326273
Beta-lactamase	Citrobacter freundii	IC50 (µMol)	0.0960	0.0960	0.0960	0.0960	AID405083
Beta-lactamase	Citrobacter gillenii	IC50 (µMol)	0.0400	0.0090	0.0245	0.0400	AID285444
Beta-lactamase	Escherichia coli	IC50 (µMol)	171.0000	0.0260	0.0290	0.0320	AID394491
Beta-lactamase	Shouchella clausii	IC50 (µMol)	0.0040	0.0040	0.0547	0.0850	AID373218
Beta-lactamase	Burkholderia cenocepacia	IC50 (µMol)	0.5000	0.5000	0.5000	0.5000	AID541026
Beta-lactamase	Pseudomonas aeruginosa	IC50 (µMol)	0.0600	0.0600	0.1700	0.3700	AID511293
Beta-lactamase	Pseudomonas aeruginosa	IC50 (µMol)	2.0000	0.1000	1.7000	3.0000	AID495659
B2 bradykinin receptor	Cavia porcellus (domestic guinea pig)	IC50 (µMol)	4.8000	0.0011	2.5864	8.0000	AID43112
Beta-lactamase	Staphylococcus aureus	IC50 (µMol)	0.5000	0.0800	1.9509	6.5000	AID43908
Beta-lactamase	Bacillus licheniformis	IC50 (µMol)	0.5100	0.5100	0.5100	0.5100	AID43110
Beta-lactamase	Escherichia coli K-12	IC50 (µMol)	49.6500	0.0150	2.4657	8.0000	AID209008; AID38400; AID43114; AID43428; AID44067
Beta-lactamase	Citrobacter freundii	IC50 (µMol)	0.9300	0.9300	1.8150	2.7000	AID43118
Beta-lactamase	Enterobacter cloacae	IC50 (µMol)	20.9436	0.1000	1.8745	7.7000	AID266529; AID297200; AID43275; AID43276; AID43281; AID44072; AID44073; AID44074; AID44075; AID44076; AID44077; AID44078; AID44079; AID44080; AID50708; AID584977
Beta-lactamase	Enterobacter cloacae	Ki	170.0000	7.3000	7.5000	7.7000	AID584988
Beta-lactamase SHV-1	Escherichia coli	IC50 (µMol)	0.2220	0.0280	0.1250	0.2220	AID297199
Beta-lactamase SHV-1	Klebsiella pneumoniae	IC50 (µMol)	0.1100	0.1100	0.1500	0.1700	AID519750
Beta-lactamase SHV-1	Klebsiella pneumoniae	Ki	0.2200	0.2200	1.2400	2.0000	AID1801066
Beta-lactamase OXA-1	Escherichia coli	IC50 (µMol)	4.8000	3.2000	4.0000	4.8000	AID43112
5-hydroxytryptamine receptor 1A	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.8300	0.0003	1.3833	8.4000	AID44078
Cytochrome P450 2B6	Homo sapiens (human)	IC50 (µMol)	0.1100	0.0011	3.4186	10.0000	AID519750
Beta-lactamase	Pseudomonas aeruginosa PAO1	IC50 (µMol)	10.8825	0.1280	1.6916	4.6000	AID43879; AID43880; AID43881; AID584978
Angiotensin-converting enzyme	Rattus norvegicus (Norway rat)	IC50 (µMol)	48.0000	0.0009	0.3322	3.0300	AID38400
Metallo-beta-lactamase L1 type 3	Stenotrophomonas maltophilia	IC50 (µMol)	4,000.0000	7.8000	7.8000	7.8000	AID44051
Beta-lactamase TEM	Escherichia coli	IC50 (µMol)	0.0828	0.0019	1.7618	10.0000	AID209020; AID266526; AID297198; AID326275; AID372630; AID44065
Beta-lactamase TEM	Escherichia coli	Ki	0.1900	0.0270	1.8234	7.3000	AID1576703
Beta-lactamase	Morganella morganii	IC50 (µMol)	0.1900	0.1900	0.1900	0.1900	AID43744
Beta-lactamase	Salmonella enterica subsp. enterica serovar Westhampton	IC50 (µMol)	0.0022	0.0022	0.0061	0.0100	AID556339
Beta-lactamase	Pseudomonas aeruginosa	IC50 (µMol)	2.0000	0.1000	1.7000	3.0000	AID495660
Beta-lactamase	Enterobacter cloacae	IC50 (µMol)	0.0300	0.0300	0.0300	0.0300	AID374028; AID44064
Class D beta-lactamase	Brachyspira pilosicoli	IC50 (µMol)	0.1600	0.1600	1.0800	2.0000	AID519637
Beta-lactamase	Pseudomonas luteola	IC50 (µMol)	0.0400	0.0360	0.0380	0.0400	AID495653
Beta-lactamase	Escherichia coli	IC50 (µMol)	0.2400	0.2400	4.4200	8.6000	AID372627
Beta-lactamase	Serratia fonticola	IC50 (µMol)	6.9000	6.9000	6.9000	6.9000	AID374027
Beta-lactamase	Enterobacter cloacae	IC50 (µMol)	0.0600	0.0600	0.1900	0.3200	AID44222
Beta-lactamase	Escherichia coli	IC50 (µMol)	0.0020	0.0020	0.0055	0.0090	AID368519
Carbapenem-hydrolyzing beta-lactamase KPC	Klebsiella pneumoniae	IC50 (µMol)	0.3720	0.3700	0.3720	0.3740	AID374029; AID495801
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Beta-lactamase	Enterobacter cloacae	Km	300.0000	2.9000	6.4364	9.8000	AID584992
Beta-lactamase class B VIM-2	Pseudomonas aeruginosa	Km	875.0000	2.0000	6.6500	9.4000	AID531315
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
antibiotic catabolic process	Beta-lactamase	Escherichia coli K-12
response to antibiotic	Beta-lactamase	Escherichia coli K-12
xenobiotic metabolic process	Cytochrome P450 2B6	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 2B6	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 2B6	Homo sapiens (human)
cellular ketone metabolic process	Cytochrome P450 2B6	Homo sapiens (human)
epoxygenase P450 pathway	Cytochrome P450 2B6	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
beta-lactamase activity	Beta-lactamase	Escherichia coli K-12
hydrolase activity	Beta-lactamase	Escherichia coli K-12
monooxygenase activity	Cytochrome P450 2B6	Homo sapiens (human)
iron ion binding	Cytochrome P450 2B6	Homo sapiens (human)
testosterone 16-alpha-hydroxylase activity	Cytochrome P450 2B6	Homo sapiens (human)
heme binding	Cytochrome P450 2B6	Homo sapiens (human)
testosterone 16-beta-hydroxylase activity	Cytochrome P450 2B6	Homo sapiens (human)
anandamide 8,9 epoxidase activity	Cytochrome P450 2B6	Homo sapiens (human)
anandamide 11,12 epoxidase activity	Cytochrome P450 2B6	Homo sapiens (human)
anandamide 14,15 epoxidase activity	Cytochrome P450 2B6	Homo sapiens (human)
estrogen 2-hydroxylase activity	Cytochrome P450 2B6	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2B6	Homo sapiens (human)
arachidonic acid epoxygenase activity	Cytochrome P450 2B6	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
outer membrane-bounded periplasmic space	Beta-lactamase	Escherichia coli K-12
periplasmic space	Beta-lactamase	Escherichia coli K-12
endoplasmic reticulum membrane	Cytochrome P450 2B6	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2B6	Homo sapiens (human)
cytoplasm	Cytochrome P450 2B6	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (335)

Assay ID	Title	Year	Journal	Article
AID1559347	Inhibition of TEM/CTX-M/SHV/Cephalosporinase in Escherichia coli CH1 assessed as cefepime antibacterial activity at 4 ug/ml after 16 to 20 hrs by CLSI-based microbroth dilution method (Rvb > 128 ug/ml)	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID324363	Inhibition of Acinetobacter johnsonii SCO1	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Identification of the novel narrow-spectrum beta-lactamase SCO-1 in Acinetobacter spp. from Argentina.
AID525579	Inhibition of Beta-lactamase OXA-10 expressed in Escherichia coli BL21 (DE3) by nitrocefin hydrolysis assay	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Penicillin sulfone inhibitors of class D beta-lactamases.
AID209008	Inhibitory activity against class A TEM-1 beta-lactamase	2002	Bioorganic & medicinal chemistry letters, Jun-17, Volume: 12, Issue:12	Cephalosporin-derived inhibitors of beta-lactamase. Part 4: The C3 substituent.
AID727641	Binding affinity to wild type Beta-lactamase SHV-1 in Escherichia coli DH10B assessed as change in secondary structure at 50 uM by circular dichroism analysis	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Design and exploration of novel boronic acid inhibitors reveals important interactions with a clavulanic acid-resistant sulfhydryl-variable (SHV) β-lactamase.
AID531315	Activity of Pseudomonas aeruginosa beta-lactamase VIM-2 by spectrophotometry	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family.
AID1604445	Inhibition of OXA-24/40 in Acinetobacter baumannii assessed as potentiation of imipenem-induced antibacterial activity by CLSI based broth microdilution method	2020	Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5	β-Lactamase Inhibitors To Restore the Efficacy of Antibiotics against Superbugs.
AID1559326	Inhibition of KPC-2/PDC-42 in Pseudomonas aeruginosa CDC-0356 assessed as piperacillin antibacterial activity at 16 ug/ml after 16 to 20 hrs by CLSI-based microbroth dilution method (Rvb > 128 ug/ml)	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID542048	Antibacterial activity against rifampicin resistant Escherichia coli J53-2 by Etest method in presence of Tazobactam	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Nationwide survey of CTX-M-type extended-spectrum beta-lactamases among Klebsiella pneumoniae isolates in Slovenian hospitals.
AID1576700	Inhibition of bacterial N-terminal His-tagged TEV protease site linked SFH1 (3 to 234 amino acids) expressed in Escherichia coli Transetta (DE3) preincubated for 10 mins followed by FC5 fluorescent substrate addition by fluorescence assay
AID1471290	Inhibition of Klebsiella pneumoniae NP6 KPC-2 expressed in Escherichia coli DH5alpha	2017	Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20	Pharmaceutical Approaches to Target Antibiotic Resistance Mechanisms.
AID1559340	Inhibition of NDM-1/CMY-6/OXA-1 in Escherichia coli CDC-0055 assessed as meropenem antibacterial activity at 4 ug/ml after 16 to 20 hrs by CLSI-based microbroth dilution method (Rvb = 32 ug/ml)	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID558577	Antibacterial activity against bla gene-positive and nitrocefin reaction-positive beta-lactamase harboring Campylobacter jejuni isolate P1618 by NCCLS agar doubling dilution method in presence of Tazobactam	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID577229	Antibacterial activity against intI1-positive tigecycline-susceptible Acinetobacter baumannii AB095 with PFGE subgroup E containing carbapenemase OXA-23 and OXA-51 by Etest	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS.
AID44064	In vitro inhibitory activity against Class A (Imi-1) beta-Lactamases	2004	Journal of medicinal chemistry, Jul-01, Volume: 47, Issue:14	Mechanism of inactivation of beta-lactamases by novel 6-methylidene penems elucidated using electrospray ionization mass spectrometry.
AID1559345	Inhibition of KPC-2/PDC-42 in Pseudomonas aeruginosa CDC-0457 assessed as meropenem antibacterial activity at 4 ug/ml after 16 to 20 hrs by CLSI-based microbroth dilution method (Rvb = 128 ug/ml)	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID1559348	Inhibition of TEM/CTX-M/SHV/Cephalosporinase in Enterobacter cloacae CH23 assessed as cefepime antibacterial activity at 4 ug/ml after 16 to 20 hrs by CLSI-based microbroth dilution method (Rvb > 128 ug/ml)	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID572898	Inhibition of Enterobacter cloacae Beta-lactamase AmpC	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	In vitro activity of LK-157, a novel tricyclic carbapenem as broad-spectrum {beta}-lactamase inhibitor.
AID1225761	Inhibition of Escherichia coli recombinant SHV-12 assessed as substrate nitrocefin degradation preincubated for 10 mins followed by substrate addition measured every 10 secs for 10 mins by spectrophotometric analysis	2015	Journal of medicinal chemistry, May-14, Volume: 58, Issue:9	Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases.
AID577236	Antibacterial activity against intI1-positive tigecycline-resistant Acinetobacter baumannii AB113 with PFGE subgroup B1 containing carbapenemase OXA-23 and OXA-51 by Etest	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS.
AID558321	Antibacterial activity against Campylobacter coli by NCCLS agar doubling dilution method in presence of Tazobactam	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID358400	Inhibition of Escherichia coli beta lactamase OXA-1	2007	The Journal of biological chemistry, Jul-27, Volume: 282, Issue:30	Efficient inhibition of class A and class D beta-lactamases by Michaelis complexes.
AID1559323	Inhibition of VIM-27/CTX-M-15/SHV-11/OXA-1 in Klebsiella pneumoniae CDC-0040 assessed as piperacillin antibacterial activity at 16 ug/ml after 16 to 20 hrs by CLSI-based microbroth dilution method (Rvb > 128 ug/ml)	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID524593	Antimicrobial activity against multidrug-resistant Klebsiella pneumoniae isolate Kpn-DK2 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	KPC-producing extreme drug-resistant Klebsiella pneumoniae isolate from a patient with diabetes mellitus and chronic renal failure on hemodialysis in South Korea.
AID1209732	Drug uptake by mouse OAT3 expressed in CHO cells at 100 uM after 25 mins by HPLC/UV detection method in presence of probenecid	2013	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4	Organic anion transporter 3 interacts selectively with lipophilic β-lactam antibiotics.
AID727648	Antimicrobial activity against Escherichia coli DH10B expressing Beta-lactamase SHV K234R mutant by CLSI agar dilution method in presence of ampicillin	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Design and exploration of novel boronic acid inhibitors reveals important interactions with a clavulanic acid-resistant sulfhydryl-variable (SHV) β-lactamase.
AID18730	Compound was tested for the values for the rate of formation of the acyl-enzyme complex in Escherichia coli TEM-3.	1996	Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19	Design, synthesis, and evaluation of 2 beta-alkenyl penam sulfone acids as inhibitors of beta-lactamases.
AID1529360	Inhibition of beta lactamase in Prevotella sp. clinical isolate assessed as potentiation of ceftolozane-induced antibacterial activity by measuring ceftolozane MIC90	2018	MedChemComm, Sep-01, Volume: 9, Issue:9	β-lactam/β-lactamase inhibitor combinations: an update.
AID1576712	Inhibition of beta lactamase KPC-2 in Escherichia coli 11119 assessed as potentiation of meropenem-induced antibacterial activity by measuring meropenem MIC at 50 uM after 16 to 20 hrs by broth microdilution assay (Rvb = 16 ug/ml)
AID1559355	Inhibition of VIM-1/VIM-2/VIM-4/NDM-1 in Klebsiella pneumoniae assessed as cefepime antibacterial activity at 4 ug/ml after 16 to 20 hrs by CLSI-based microbroth dilution method (Rvb = 32 to 512 ug/ml)	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID1559356	Inhibition of VIM-1/VIM-2/VIM-4/NDM-1 in Pseudomonas aeruginosa assessed as cefepime antibacterial activity at 4 ug/ml after 16 to 20 hrs by CLSI-based microbroth dilution method (Rvb = 32 to 512 ug/ml)	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID44222	Inhibitory activity against class A Beta-lactamase TEM isolated from Enterobacter coli	2000	Bioorganic & medicinal chemistry letters, Oct-02, Volume: 10, Issue:19	The synthesis and SAR of rhodanines as novel class C beta-lactamase inhibitors.
AID1559354	Inhibition of VIM-1/VIM-2/VIM-4/NDM-1 in Enterobacter cloacae assessed as cefepime antibacterial activity at 4 ug/ml after 16 to 20 hrs by CLSI-based microbroth dilution method (Rvb = 32 to 512 ug/ml)	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID727650	Antimicrobial activity against Escherichia coli DH10B by CLSI agar dilution method in presence of ampicillin	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Design and exploration of novel boronic acid inhibitors reveals important interactions with a clavulanic acid-resistant sulfhydryl-variable (SHV) β-lactamase.
AID558771	Antibacterial activity against bla-positive and beta-lactamase-weakly positive Campylobacter coli isolate P1627 by NCCLS agar doubling dilution method in presence of Tazobactam	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID1476623	Antibacterial activity against clinical isolates of Acinetobacter baumannii ARC 5079 after 18 hrs by broth microdilution method	2017	Journal of medicinal chemistry, 11-09, Volume: 60, Issue:21	Methodology for Monobactam Diversification: Syntheses and Studies of 4-Thiomethyl Substituted β-Lactams with Activity against Gram-Negative Bacteria, Including Carbapenemase Producing Acinetobacter baumannii.
AID531317	Activity of Escherichia coli beta-lactamase VIM-1 by spectrophotometry	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family.
AID266526	Inhibition of Escherichia coli TEM1	2006	Journal of medicinal chemistry, Jul-27, Volume: 49, Issue:15	Structure-activity relationship of 6-methylidene penems bearing 6,5 bicyclic heterocycles as broad-spectrum beta-lactamase inhibitors: evidence for 1,4-thiazepine intermediates with C7 R stereochemistry by computational methods.
AID1576710	Inhibition of beta lactamase NDM1 in Klebsiella pneumoniae 13249 assessed as potentiation of meropenem-induced antibacterial activity by measuring meropenem MIC at 50 uM after 16 to 20 hrs by broth microdilution assay (Rvb = 64 ug/ml)
AID558770	Antibacterial activity against bla gene-positive and nitrocefin reaction-positive beta-lactamase harboring Campylobacter coli isolate P321 by NCCLS agar doubling dilution method in presence of Tazobactam	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID50708	Inhibitory activity against Class C beta-lactamase	2002	Bioorganic & medicinal chemistry letters, Jun-17, Volume: 12, Issue:12	Cephalosporin-derived inhibitors of beta-lactamase. Part 4: The C3 substituent.
AID1169072	Inhibition of Klebsiella pneumoniae OXA-48 pre-incubated with enzyme for 5 mins before nitrocefin substrate addition by colorimetric assay	2014	ACS medicinal chemistry letters, Oct-09, Volume: 5, Issue:10	Enantioselective Synthesis and Profiling of Two Novel Diazabicyclooctanone β-Lactamase Inhibitors.
AID326273	Inhibition of Escherichia coli beta-lactamase SCO1	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	SCO-1, a novel plasmid-mediated class A beta-lactamase with carbenicillinase characteristics from Escherichia coli.
AID285160	Antimicrobial activity against non replicating persistence Mycobacterium tuberculosis H37Rv in aerobic condition assessed as bacterial density after 7 days	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis.
AID1559336	Inhibition of NDM in Escherichia coli CDC-0452 assessed as cefepime antibacterial activity after 16 to 20 hrs by CLSI-based microbroth dilution method (Rvb = 64 ug/ml)	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID1559331	Inhibition of VIM-27/CTX-M-15/SHV-11/OXA-1 in Klebsiella pneumoniae CDC-0040 assessed as cefepime antibacterial activity at 8 ug/ml after 16 to 20 hrs by CLSI-based microbroth dilution method (Rvb > 128 ug/ml)	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID525580	Inhibition of Beta-lactamase OXA-1 expressed in Escherichia coli BL21 (DE3) by nitrocefin hydrolysis assay	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Penicillin sulfone inhibitors of class D beta-lactamases.
AID1476625	Antibacterial activity against cephalosporinase producing Acinetobacter baumannii ATCC 17978-PNT-320 after 18 hrs by broth microdilution method	2017	Journal of medicinal chemistry, 11-09, Volume: 60, Issue:21	Methodology for Monobactam Diversification: Syntheses and Studies of 4-Thiomethyl Substituted β-Lactams with Activity against Gram-Negative Bacteria, Including Carbapenemase Producing Acinetobacter baumannii.
AID1476628	Antibacterial activity against Acinetobacter baumannii ATCC BAA 1800 at 10 ug/ml after 18 hrs by broth microdilution method	2017	Journal of medicinal chemistry, 11-09, Volume: 60, Issue:21	Methodology for Monobactam Diversification: Syntheses and Studies of 4-Thiomethyl Substituted β-Lactams with Activity against Gram-Negative Bacteria, Including Carbapenemase Producing Acinetobacter baumannii.
AID584983	Inhibition of beta-lactamase TEM-1 assessed as inactivation rate constant for longer incubation time yield of enzyme by spectrophotometry	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-beta-lactam beta-lactamase inhibitor.
AID44066	In vitro inhibitory activity against Class B (CCRA) beta-Lactamases	2004	Journal of medicinal chemistry, Jul-01, Volume: 47, Issue:14	Mechanism of inactivation of beta-lactamases by novel 6-methylidene penems elucidated using electrospray ionization mass spectrometry.
AID18756	Compound was tested for the half saturation constant derived from concentration dependence studies in Escherichia coli SHV-2.	1996	Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19	Design, synthesis, and evaluation of 2 beta-alkenyl penam sulfone acids as inhibitors of beta-lactamases.
AID266528	Inhibition of Bacteroides fragilis CcrA	2006	Journal of medicinal chemistry, Jul-27, Volume: 49, Issue:15	Structure-activity relationship of 6-methylidene penems bearing 6,5 bicyclic heterocycles as broad-spectrum beta-lactamase inhibitors: evidence for 1,4-thiazepine intermediates with C7 R stereochemistry by computational methods.
AID1808873	Inhibition beta lactamase PDC-1 in Pseudomonas aeruginosa PAO1 using nitrocefin as substrate measured by 96 well microtitre plate
AID584976	Inhibition of beta-lactamase TEM- 1 assessed as nitrocefin hydrolysis after 5 mins enzyme-compound preincubation	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-beta-lactam beta-lactamase inhibitor.
AID1529354	Inhibition of beta lactamase in Pseudomonas aeruginosa assessed as potentiation of ceftolozane-induced antibacterial activity by measuring ceftolozane MIC90	2018	MedChemComm, Sep-01, Volume: 9, Issue:9	β-lactam/β-lactamase inhibitor combinations: an update.
AID541026	Inhibition of Burkholderia cenocepacia 07-34 beta-lactamase PenB1	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Naturally occurring Class A ss-lactamases from the Burkholderia cepacia complex.
AID548267	Inhibition of Klebsiella pneumoniae 1534 beta-lactamase KPC-2 T237S mutant by competitive assay	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID44079	In vitro inhibitory activity against Beta-lactamase AmpC of class C enzyme	2003	Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13	Spirocyclopropyl beta-lactams as mechanism-based inhibitors of serine beta-lactamases. Synthesis by rhodium-catalyzed cyclopropanation of 6-diazopenicillanate sulfone.
AID1559328	Inhibition of NDM in Escherichia coli CDC-0452 assessed as piperacillin antibacterial activity at 16 ug/ml after 16 to 20 hrs by CLSI-based microbroth dilution method (Rvb > 128 ug/ml)	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID727646	Antimicrobial activity against Escherichia coli DH10B expressing Beta-lactamase SHV K234X mutant by CLSI agar dilution method in presence of ampicillin	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Design and exploration of novel boronic acid inhibitors reveals important interactions with a clavulanic acid-resistant sulfhydryl-variable (SHV) β-lactamase.
AID1559357	Inhibition of VIM-1/VIM-2/VIM-4/NDM-1 in Acinetobacter baumannii assessed as cefepime antibacterial activity at 4 ug/ml after 16 to 20 hrs by CLSI-based microbroth dilution method (Rvb = 32 to 512 ug/ml)	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID18551	Compound was tested for the rate of the acyl-enzyme complex in Citrobacter freundii	1996	Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19	Design, synthesis, and evaluation of 2 beta-alkenyl penam sulfone acids as inhibitors of beta-lactamases.
AID577238	Antibacterial activity against intI1-positive tigecycline-resistant Acinetobacter baumannii AB125 with PFGE subgroup A1 containing carbapenemase OXA-23 and OXA-51 by Etest	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS.
AID43118	Compound was tested for inhibition of Beta-lactamase from Citrobacter freundii 1982	1996	Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19	Design, synthesis, and evaluation of 2 beta-alkenyl penam sulfone acids as inhibitors of beta-lactamases.
AID560706	Inhibition of Escherichia coli MC4100 Beta-Lactamase CMY-2 using cephalothin as reporter substrate	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Extended-spectrum properties of CMY-30, a Val211Gly mutant of CMY-2 cephalosporinase.
AID1559327	Inhibition of KPC-2/SHV12/TEM-1 in Klebsiella pneumoniae CDC-0361 assessed as piperacillin antibacterial activity at 16 ug/ml after 16 to 20 hrs by CLSI-based microbroth dilution method (Rvb > 128 ug/ml)	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID1559341	Inhibition of OXA-232/OXA-9/TEM-1A/CTX-M-15/OXA-1 in Klebsiella pneumoniae CDC-0066 assessed as meropenem antibacterial activity at 4 ug/ml after 16 to 20 hrs by CLSI-based microbroth dilution method (Rvb = 32 ug/ml)	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID285444	Inhibition of Citrobacter gillenii CIP 106783 Beta-lactamase GIL1 expressed in Escherichia coli DH10B	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Chromosome-encoded narrow-spectrum Ambler class A beta-lactamase GIL-1 from Citrobacter gillenii.
AID70143	The ratio of compound to that of piperacillin was evaluated for antimicrobial activity against Escherichia coli OC 4075 by inhibiting enzyme TEM-1 at 4 ug/mL	2000	Bioorganic & medicinal chemistry letters, Oct-02, Volume: 10, Issue:19	The synthesis and SAR of rhodanines as novel class C beta-lactamase inhibitors.
AID1559333	Inhibition of OXA-232/OXA-9/TEM-1A/CTX-M-15/OXA-1 in Klebsiella pneumoniae CDC-0066 assessed as cefepime antibacterial activity at 8 ug/ml after 16 to 20 hrs by CLSI-based microbroth dilution method (Rvb > 128 ug/ml)	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID584986	Ratio of Inactivation rate constant for longer incubation time yield to Km for Enterobacter cloacae beta-lactamase P99 by spectrophotometry	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-beta-lactam beta-lactamase inhibitor.
AID571686	Antimicrobial activity against ESBL producing Escherichia coli isolated from patient bloodstream assessed as resistant isolate by Etest method in presence of Tazobactam	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Bloodstream infections caused by extended-spectrum-beta-lactamase- producing Escherichia coli: risk factors for inadequate initial antimicrobial therapy.
AID43879	Compound was tested for inhibition of Beta-lactamase from Pseudomonas aeruginosa GN10362	1996	Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19	Design, synthesis, and evaluation of 2 beta-alkenyl penam sulfone acids as inhibitors of beta-lactamases.
AID43281	Inhibitory activity against class C Beta-lactamase isolated from Enterobacter cloacae	2000	Bioorganic & medicinal chemistry letters, Oct-02, Volume: 10, Issue:19	The synthesis and SAR of rhodanines as novel class C beta-lactamase inhibitors.
AID163442	The ratio of compound to that of piperacillin was evaluated for antimicrobial activity against Pseudomonas aeruginosa OC 4290 by inhibiting enzyme AmpC(const) at 4 ug/mL	2000	Bioorganic & medicinal chemistry letters, Oct-02, Volume: 10, Issue:19	The synthesis and SAR of rhodanines as novel class C beta-lactamase inhibitors.
AID577230	Antibacterial activity against intI1-positive tigecycline-susceptible Acinetobacter baumannii AB110 with PFGE subgroup C containing carbapenemase OXA-51 by Etest	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS.
AID43110	Compound was tested for inhibition of Beta-lactamase from Bacillus licheniformis 749/C	1996	Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19	Design, synthesis, and evaluation of 2 beta-alkenyl penam sulfone acids as inhibitors of beta-lactamases.
AID1559353	Inhibition of VIM-1/VIM-2/VIM-4/NDM-1 in Escherichia coli assessed as cefepime antibacterial activity at 4 ug/ml after 16 to 20 hrs by CLSI-based microbroth dilution method (Rvb = 32 to 512 ug/ml)	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID531318	Ratio of Kcat to Km for Escherichia coli beta-lactamase VIM-1 by spectrophotometry	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family.
AID572899	Inhibition of Beta-lactamase TEM-1	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	In vitro activity of LK-157, a novel tricyclic carbapenem as broad-spectrum {beta}-lactamase inhibitor.
AID577234	Antibacterial activity against intI1-positive tigecycline-intermediate Acinetobacter baumannii AB099 with PFGE subgroup H containing carbapenemase OXA-23 and OXA-51 by Etest	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS.
AID584975	Inhibition of beta-lactamase CTX-M-15 assessed as nitrocefin hydrolysis after 5 mins enzyme-compound preincubation	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-beta-lactam beta-lactamase inhibitor.
AID1529357	Inhibition of beta lactamase in Pseudomonas aeruginosa assessed as potentiation of colistin-induced antibacterial activity by measuring colistin MIC90	2018	MedChemComm, Sep-01, Volume: 9, Issue:9	β-lactam/β-lactamase inhibitor combinations: an update.
AID560594	Antimicrobial activity against Pseudomonas aeruginosa isolate IMCJ798 by microdilution method in presence of beta-lactamase inhibitor Tazobactam	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	AAC(6')-Iaf, a novel aminoglycoside 6'-N-acetyltransferase from multidrug-resistant Pseudomonas aeruginosa clinical isolates.
AID1476622	Antibacterial activity against clinical isolates of Acinetobacter baumannii ISR14-005 after 18 hrs by broth microdilution method	2017	Journal of medicinal chemistry, 11-09, Volume: 60, Issue:21	Methodology for Monobactam Diversification: Syntheses and Studies of 4-Thiomethyl Substituted β-Lactams with Activity against Gram-Negative Bacteria, Including Carbapenemase Producing Acinetobacter baumannii.
AID548266	Inhibition of Klebsiella pneumoniae 1534 beta-lactamase KPC-2 by competitive assay	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID548270	Ratio of Ki for Klebsiella pneumoniae 1534 beta-lactamase KPC-2 T237A mutant to Ki for Klebsiella pneumoniae beta-lactamase KPC-2 T237S mutant by competitive assay	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID1604446	Inhibition of OXA-24/40 in Acinetobacter baumannii assessed as potentiation of meropenem-induced antibacterial activity by CLSI based broth microdilution method	2020	Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5	β-Lactamase Inhibitors To Restore the Efficacy of Antibiotics against Superbugs.
AID558765	Antibacterial activity against bla gene-positive and nitrocefin reaction-positive beta-lactamase harboring Campylobacter jejuni isolate P1730 by NCCLS agar doubling dilution method in presence of Tazobactam	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID1559329	Inhibition of KPC-2/PDC-42 in Pseudomonas aeruginosa CDC-0457 assessed as piperacillin antibacterial activity at 16 ug/ml after 16 to 20 hrs by CLSI-based microbroth dilution method (Rvb = 64 ug/ml)	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID1476609	Antibacterial activity against Pseudomonas aeruginosa ARC 3502 after 18 hrs by broth microdilution method	2017	Journal of medicinal chemistry, 11-09, Volume: 60, Issue:21	Methodology for Monobactam Diversification: Syntheses and Studies of 4-Thiomethyl Substituted β-Lactams with Activity against Gram-Negative Bacteria, Including Carbapenemase Producing Acinetobacter baumannii.
AID577237	Antibacterial activity against intI1-positive tigecycline-resistant Acinetobacter baumannii AB118 with PFGE subgroup B2 containing carbapenemase OXA-23 and OXA-51 by Etest	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS.
AID558319	Antibacterial activity against Campylobacter coli by NCCLS agar doubling dilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID558768	Antibacterial activity against bla gene-negative and nitrocefin reaction-positive beta-lactamase harboring Campylobacter jejuni isolate P843 by NCCLS agar doubling dilution method in presence of Tazobactam	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID531314	Ratio of Kcat to Km for Pseudomonas aeruginosa beta-lactamase VIM-7 by spectrophotometry	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family.
AID374028	Inhibition of Enterobacter cloacae IMI1 beta lactamase expressed in Escherichia coli DH5alpha by SDS-PAGE	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Biochemical Characterization of SFC-1, a class A carbapenem-hydrolyzing beta-lactamase.
AID44075	Compound was tested for inhibition of Beta-lactamase from RTEM-2	1996	Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19	Design, synthesis, and evaluation of 2 beta-alkenyl penam sulfone acids as inhibitors of beta-lactamases.
AID558567	Antibacterial activity against bla gene-negative and nitrocefin reaction-negative beta-lactamase harboring Campylobacter jejuni isolate P850 by NCCLS agar doubling dilution method in presence of Tazobactam	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID1576704	Inhibition of bacterial N-terminal His-tagged TEV protease site linked AmpC (20 to 377 amino acids) expressed in Escherichia coli Transetta (DE3) preincubated for 10 mins followed by FC5 fluorescent substrate addition by fluorescence assay
AID558565	Antibacterial activity against Campylobacter jejuni isolate P270 harboring blaOXA-61::cat gene by NCCLS agar doubling dilution method in presence of Tazobactam	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID1559325	Inhibition of OXA-232/OXA-9/TEM-1A/CTX-M-15/OXA-1 in Klebsiella pneumoniae CDC-0066 assessed as piperacillin antibacterial activity at 16 ug/ml after 16 to 20 hrs by CLSI-based microbroth dilution method (Rvb > 128 ug/ml)	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID297200	Inhibition of Enterobacter cloacae AmpC	2007	Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17	4-Substituted trinems as broad spectrum beta-lactamase inhibitors: structure-based design, synthesis, and biological activity.
AID577243	Antibacterial activity against intI1-positive tigecycline-resistant Acinetobacter baumannii AB096 with PFGE subgroup B1 containing carbapenemase OXA-23 and OXA-51 by Etest	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS.
AID372630	Inhibition of Escherichia coli DH5alpha beta-lactamase TEM-1	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases.
AID266532	Antibacterial activity against Pseudomonas aeruginosa expressing AmpC	2006	Journal of medicinal chemistry, Jul-27, Volume: 49, Issue:15	Structure-activity relationship of 6-methylidene penems bearing 6,5 bicyclic heterocycles as broad-spectrum beta-lactamase inhibitors: evidence for 1,4-thiazepine intermediates with C7 R stereochemistry by computational methods.
AID1576702	Inhibition of bacterial N-terminal His-tagged TEV protease site linked KPC-2 (29 to 289 amino acids) expressed in Escherichia coli Transetta (DE3) preincubated for 10 mins followed by FC5 fluorescent substrate addition by fluorescence assay
AID496596	Ratio of Kcat to Kinact for Escherichia coli DH10B beta-lactamase KPC-2	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Inhibitor resistance in the KPC-2 beta-lactamase, a preeminent property of this class A beta-lactamase.
AID1169069	Inhibition of Klebsiella pneumoniae CTX-M-15 pre-incubated with enzyme for 5 mins before nitrocefin substrate addition by colorimetric assay	2014	ACS medicinal chemistry letters, Oct-09, Volume: 5, Issue:10	Enantioselective Synthesis and Profiling of Two Novel Diazabicyclooctanone β-Lactamase Inhibitors.
AID43881	Compound was tested for inhibition of Beta-lactamase from Pseudomonas aeruginosa 18SH	1996	Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19	Design, synthesis, and evaluation of 2 beta-alkenyl penam sulfone acids as inhibitors of beta-lactamases.
AID1559338	Inhibition of KPC-2 in Klebsiella pneumoniae ATCC BAA 1705 assessed as meropenem antibacterial activity at 4 ug/ml after 16 to 20 hrs by CLSI-based microbroth dilution method (Rvb = 16 ug/ml)	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID585192	Inhibition of Beta-lactamase GES-13 K104, N170 mutant preincubated for 5 mins before substrate addition using cephalothin substrate by spectrophotometry	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases.
AID374364	Antimicrobial activity against Aeromonas caviae A324R expressing metallo-beta-lactamase IMP-19 by broth dilution method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	First occurrence of an IMP metallo-beta-lactamase in Aeromonas caviae: IMP-19 in an isolate from France.
AID1529352	Inhibition of ESBL in Escherichia coli clinical isolate assessed as potentiation of ceftolozane-induced antibacterial activity by measuring ceftolozane MIC by broth microdilution method	2018	MedChemComm, Sep-01, Volume: 9, Issue:9	β-lactam/β-lactamase inhibitor combinations: an update.
AID285162	Antimicrobial activity against non replicating persistence Mycobacterium tuberculosis H37Rv in anaerobic condition assessed as bacterial density after 10 days	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis.
AID285276	Inhibition of Escherichia coli BL21(DE3) beta-lactamase TEM36	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient.
AID577233	Antibacterial activity against intI1-negative tigecycline-intermediate Acinetobacter baumannii AB098 with PFGE subgroup F containing carbapenemase OXA-23 and OXA-51 by Etest	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS.
AID1225759	Inhibition of Escherichia coli recombinant KPC-2 assessed as substrate nitrocefin degradation preincubated for 10 mins followed by substrate addition measured every 10 secs for 10 mins by spectrophotometric analysis	2015	Journal of medicinal chemistry, May-14, Volume: 58, Issue:9	Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases.
AID511293	Inhibition of Pseudomonas aeruginosa GES-13 beta lactamase	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	GES-13, a beta-lactamase variant possessing Lys-104 and Asn-170 in Pseudomonas aeruginosa.
AID44067	In vitro inhibitory activity against Class C (Amp-C) beta-Lactamases	2004	Journal of medicinal chemistry, Jul-01, Volume: 47, Issue:14	Mechanism of inactivation of beta-lactamases by novel 6-methylidene penems elucidated using electrospray ionization mass spectrometry.
AID44051	Compound was tested for inhibition of Beta-lactamase from Xanthomonas maltophila 328	1996	Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19	Design, synthesis, and evaluation of 2 beta-alkenyl penam sulfone acids as inhibitors of beta-lactamases.
AID727649	Antimicrobial activity against Escherichia coli DH10B expressing wild type Beta-lactamase SHV1 gene by CLSI agar dilution method in presence of ampicillin	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Design and exploration of novel boronic acid inhibitors reveals important interactions with a clavulanic acid-resistant sulfhydryl-variable (SHV) β-lactamase.
AID525578	Inhibition of Beta-lactamase OXA-14 expressed in Escherichia coli BL21 (DE3) by nitrocefin hydrolysis assay	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Penicillin sulfone inhibitors of class D beta-lactamases.
AID558576	Antibacterial activity against Campylobacter jejuni isolate P1093 harboring blaOXA-61::cat gene by NCCLS agar doubling dilution method in presence of Tazobactam	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID558564	Antibacterial activity against bla gene-positive and nitrocefin reaction-negative beta-lactamase harboring Campylobacter jejuni isolate NCTC 11168 by NCCLS agar doubling dilution method in presence of Tazobactam	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID1559352	Inhibition of TEM/CTX-M/SHV/Oxacillinases in Klebsiella pneumoniae 971 assessed as cefepime antibacterial activity at 4 ug/ml after 16 to 20 hrs by CLSI-based microbroth dilution method (Rvb > 128 ug/ml)	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID558566	Antibacterial activity against bla gene-negative and nitrocefin reaction-negative beta-lactamase harboring Campylobacter jejuni isolate P835 by NCCLS agar doubling dilution method in presence of Tazobactam	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID1576703	Inhibition of bacterial N-terminal His-tagged TEV protease site linked TEM-1 (24 to 286 amino acids) expressed in Escherichia coli Transetta (DE3) preincubated for 10 mins followed by FC5 fluorescent substrate addition by fluorescence assay
AID18728	Compound was tested for the rate of formation of the acyl-enzyme complex in Escherichia coli SNO3.	1996	Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19	Design, synthesis, and evaluation of 2 beta-alkenyl penam sulfone acids as inhibitors of beta-lactamases.
AID558774	Antibacterial activity against Campylobacter jejuni by NCCLS agar doubling dilution method in presence of Tazobactam	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID1559330	Inhibition of KPC-2 in Klebsiella pneumoniae ATCC BAA 1705 assessed as cefepime antibacterial activity at 8 ug/ml after 16 to 20 hrs by CLSI-based microbroth dilution method (Rvb = 16 ug/ml)	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID727652	Inhibition of wild type Beta-lactamase SHV-1 in Escherichia coli DH10B by Henri-Michaelis-Menten steady state equation analysis	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Design and exploration of novel boronic acid inhibitors reveals important interactions with a clavulanic acid-resistant sulfhydryl-variable (SHV) β-lactamase.
AID374366	Antimicrobial activity against Escherichia coli DH5alpha by broth dilution method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	First occurrence of an IMP metallo-beta-lactamase in Aeromonas caviae: IMP-19 in an isolate from France.
AID1559321	Inhibition of bacterial IMP-1 using nitrocefin as substrate preincubated for 15 mins followed by susbtrate addition and measured after 10 mins by spectrophotometric method	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID1559308	Inhibition of bacterial KPC-2 using imipenem as substrate preincubated for 15 mins followed by susbtrate addition and measured after 10 mins by spectrophotometric method	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID1476626	Antibacterial activity against Burkholderia dolosa AU0018 after 18 hrs by broth microdilution method	2017	Journal of medicinal chemistry, 11-09, Volume: 60, Issue:21	Methodology for Monobactam Diversification: Syntheses and Studies of 4-Thiomethyl Substituted β-Lactams with Activity against Gram-Negative Bacteria, Including Carbapenemase Producing Acinetobacter baumannii.
AID1559343	Inhibition of KPC-2/SHV12/TEM-1 in Klebsiella pneumoniae CDC-0361 assessed as meropenem antibacterial activity at 4 ug/ml after 16 to 20 hrs by CLSI-based microbroth dilution method (Rvb = 16 ug/ml)	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID584984	Inhibition of Enterobacter cloacae beta-lactamase P99 assessed as inactivation rate constant for longer incubation time yield of enzyme by spectrophotometry	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-beta-lactam beta-lactamase inhibitor.
AID584988	Inhibition of Enterobacter cloacae beta-lactamase P99 after 5 seconds incubation with nitrocefin substrate by spectrophotometry	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-beta-lactam beta-lactamase inhibitor.
AID1559310	Inhibition of bacterial OXA-48 using nitrocefin as substrate preincubated for 15 mins followed by susbtrate addition and measured after 10 mins by spectrophotometric method	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID584991	Activity of beta-lactamase TEM-1 by spectrophotometry	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-beta-lactam beta-lactamase inhibitor.
AID374029	Inhibition of Klebsiella pneumoniae KPC-1 beta lactamase expressed in Escherichia coli DH5alpha by SDS-PAGE	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Biochemical Characterization of SFC-1, a class A carbapenem-hydrolyzing beta-lactamase.
AID1476611	Antibacterial activity against clinical isolates of Pseudomonas aeruginosa ISR-14-003 after 18 hrs by broth microdilution method	2017	Journal of medicinal chemistry, 11-09, Volume: 60, Issue:21	Methodology for Monobactam Diversification: Syntheses and Studies of 4-Thiomethyl Substituted β-Lactams with Activity against Gram-Negative Bacteria, Including Carbapenemase Producing Acinetobacter baumannii.
AID1529355	Inhibition of beta lactamase in Pseudomonas aeruginosa assessed as potentiation of ceftazidime-induced antibacterial activity by measuring ceftazidime MIC by broth microdilution method	2018	MedChemComm, Sep-01, Volume: 9, Issue:9	β-lactam/β-lactamase inhibitor combinations: an update.
AID1529361	Inhibition of beta lactamase in Fusobacterium sp. clinical isolate assessed as potentiation of ceftolozane-induced antibacterial activity by measuring ceftolozane MIC90	2018	MedChemComm, Sep-01, Volume: 9, Issue:9	β-lactam/β-lactamase inhibitor combinations: an update.
AID495659	Inhibition of Pseudomonas aeruginosa 531 beta-lactamase BEL-2	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	BEL-2, an extended-spectrum beta-lactamase with increased activity toward expanded-spectrum cephalosporins in Pseudomonas aeruginosa.
AID38400	In vitro inhibitory concentration against AmpC enzyme	2001	Bioorganic & medicinal chemistry letters, Apr-23, Volume: 11, Issue:8	Allyl and propargyl substituted penam sulfones as versatile intermediates toward the syntheses of new beta-lactamase inhibitors.
AID495653	Inhibition of Pseudomonas luteola LAM Beta-lactamase LUT-1	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Molecular and biochemical characterization of the natural chromosome-encoded class A beta-lactamase from Pseudomonas luteola.
AID43276	Compound was tested for inhibition of Beta-lactamase from Enterobacter cloacae 908R	1996	Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19	Design, synthesis, and evaluation of 2 beta-alkenyl penam sulfone acids as inhibitors of beta-lactamases.
AID558318	Antibacterial activity against Campylobacter jejuni by NCCLS agar doubling dilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID727651	Inhibition of Beta-lactamase SHV-1 K234R protein mutant in Escherichia coli DH10B by Henri-Michaelis-Menten steady state equation analysis	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Design and exploration of novel boronic acid inhibitors reveals important interactions with a clavulanic acid-resistant sulfhydryl-variable (SHV) β-lactamase.
AID1559349	Inhibition of TEM/CTX-M/SHV in Klebsiella pneumoniae 9032 assessed as cefepime antibacterial activity at 4 ug/ml after 16 to 20 hrs by CLSI-based microbroth dilution method (Rvb = 64 ug/ml)	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID1225763	Inhibition of Escherichia coli recombinant P99 assessed as substrate nitrocefin degradation preincubated for 10 mins followed by substrate addition measured every 10 secs for 10 mins by spectrophotometric analysis	2015	Journal of medicinal chemistry, May-14, Volume: 58, Issue:9	Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases.
AID585187	Inhibition of Beta-lactamase GES-1 E104, G170 mutant preincubated for 5 mins before substrate addition using cephalothin substrate by spectrophotometry	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases.
AID18720	Compound was tested for the rate of the acyl-enzyme complex in Escherichia coli SHV-2.	1996	Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19	Design, synthesis, and evaluation of 2 beta-alkenyl penam sulfone acids as inhibitors of beta-lactamases.
AID542055	Antibacterial activity against Klebsiella pneumoniae A expressing CTX-M group 1 beta-lactamase by Etest method in presence of Tazobactam	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Nationwide survey of CTX-M-type extended-spectrum beta-lactamases among Klebsiella pneumoniae isolates in Slovenian hospitals.
AID727643	Binding affinity to wild type Beta-lactamase SHV-1 in Escherichia coli DH10B assessed as melting temperature at 50 uM by circular dichroism analysis (Rvb = 54.2 degC)	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Design and exploration of novel boronic acid inhibitors reveals important interactions with a clavulanic acid-resistant sulfhydryl-variable (SHV) β-lactamase.
AID1559309	Inhibition of bacterial AmpC using nitrocefin as substrate preincubated for 15 mins followed by susbtrate addition and measured after 10 mins by spectrophotometric method	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID542067	Antibacterial activity against Escherichia coli TrC C expressing Klebsiella pneumoniae C blaCTX-M beta-lactamase by Etest method in presence of Tazobactam	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Nationwide survey of CTX-M-type extended-spectrum beta-lactamases among Klebsiella pneumoniae isolates in Slovenian hospitals.
AID1559318	Inhibition of bacterial CMY-2 using nitrocefin as substrate preincubated for 15 mins followed by susbtrate addition and measured after 10 mins by spectrophotometric method	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID560705	Inhibition of Escherichia coli MC4100 Beta-Lactamase CMY-30 using cephalothin as reporter substrate	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Extended-spectrum properties of CMY-30, a Val211Gly mutant of CMY-2 cephalosporinase.
AID44078	Compound was tested for inhibition of Beta-lactamase fromOXA-2	1996	Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19	Design, synthesis, and evaluation of 2 beta-alkenyl penam sulfone acids as inhibitors of beta-lactamases.
AID1559320	Inhibition of bacterial NDM-1 using cefepime as substrate preincubated for 15 mins followed by susbtrate addition and measured after 10 mins by spectrophotometric method	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID1576711	Inhibition of beta lactamase KPC-2 in Escherichia coli BAA-2340 assessed as potentiation of meropenem-induced antibacterial activity by measuring meropenem MIC at 50 uM after 16 to 20 hrs by broth microdilution assay (Rvb = 4 ug/ml)
AID558573	Antibacterial activity against Campylobacter jejuni isolate P338 harboring blaOXA-61::cat gene by NCCLS agar doubling dilution method in presence of Tazobactam	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID577231	Antibacterial activity against intI1-positive tigecycline-intermediate Acinetobacter baumannii AB127 with PFGE subgroup I containing carbapenemase OXA-23 and OXA-51 by Etest	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS.
AID51552	In vitro inhibitory concentration against CCRA enzyme	2001	Bioorganic & medicinal chemistry letters, Apr-23, Volume: 11, Issue:8	Allyl and propargyl substituted penam sulfones as versatile intermediates toward the syntheses of new beta-lactamase inhibitors.
AID542045	Antibacterial activity against Escherichia coli TrC A expressing Klebsiella pneumoniae A blaCTX-M beta-lactamase by Etest method in presence of Tazobactam	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Nationwide survey of CTX-M-type extended-spectrum beta-lactamases among Klebsiella pneumoniae isolates in Slovenian hospitals.
AID43112	Compound was tested for inhibition of Beta-lactamase from Bacteroides fragilis 36	1996	Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19	Design, synthesis, and evaluation of 2 beta-alkenyl penam sulfone acids as inhibitors of beta-lactamases.
AID1559322	Inhibition of KPC-2 in Klebsiella pneumoniae ATCC BAA 1705 assessed as piperacillin antibacterial activity at 16 ug/ml after 16 to 20 hrs by CLSI-based microbroth dilution method (Rvb > 128 ug/ml)	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID584977	Inhibition of Enterobacter cloacae beta-lactamase P99 assessed as nitrocefin hydrolysis after 5 mins enzyme-compound preincubation	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-beta-lactam beta-lactamase inhibitor.
AID18758	Compound was tested for the half saturation constant derived from concentration dependence studies in Escherichia coli TEM-3.	1996	Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19	Design, synthesis, and evaluation of 2 beta-alkenyl penam sulfone acids as inhibitors of beta-lactamases.
AID18729	Compound was tested for the values for the rate of formation of the acyl-enzyme complex in Escherichia coli SHV-2.	1996	Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19	Design, synthesis, and evaluation of 2 beta-alkenyl penam sulfone acids as inhibitors of beta-lactamases.
AID1529356	Inhibition of beta lactamase in Pseudomonas aeruginosa assessed as potentiation of piperacillin-induced antibacterial activity by measuring piperacillin MIC by broth microdilution method	2018	MedChemComm, Sep-01, Volume: 9, Issue:9	β-lactam/β-lactamase inhibitor combinations: an update.
AID531313	Activity of Pseudomonas aeruginosa beta-lactamase VIM-7 by spectrophotometry	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family.
AID1576715	Inhibition of beta lactamase AmpC in Klebsiella pneumoniae C660 assessed as potentiation of meropenem-induced antibacterial activity by measuring meropenem MIC at 50 uM after 16 to 20 hrs by broth microdilution assay (Rvb = 32 ug/ml)
AID1576701	Inhibition of bacterial N-terminal His-tagged TEV protease site linked GOB-18 (1 to 290 amino acids) expressed in Escherichia coli Transetta (DE3) preincubated for 10 mins followed by FC5 fluorescent substrate addition by fluorescence assay
AID372627	Inhibition of Escherichia coli DH5alpha beta-lactamase TEM-158	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases.
AID66077	The ratio of compound to that of piperacillin was evaluated for antimicrobial activity against Enterobacter cloacae OC 4080 by inhibiting enzyme P99 at 4 ug/mL	2000	Bioorganic & medicinal chemistry letters, Oct-02, Volume: 10, Issue:19	The synthesis and SAR of rhodanines as novel class C beta-lactamase inhibitors.
AID372629	Inhibition of Escherichia coli CF0042 beta-lactamase TEM-35	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases.
AID1476627	Antibacterial activity against Acinetobacter baumannii ATCC BAA 1793 at 10 ug/ml after 18 hrs by broth microdilution method	2017	Journal of medicinal chemistry, 11-09, Volume: 60, Issue:21	Methodology for Monobactam Diversification: Syntheses and Studies of 4-Thiomethyl Substituted β-Lactams with Activity against Gram-Negative Bacteria, Including Carbapenemase Producing Acinetobacter baumannii.
AID203173	The ratio of compound to that of piperacillin was evaluated for antimicrobial activity against Serratia marcescens OC 4294 by inhibiting enzyme AmpC(const) at 4 ug/mL	2000	Bioorganic & medicinal chemistry letters, Oct-02, Volume: 10, Issue:19	The synthesis and SAR of rhodanines as novel class C beta-lactamase inhibitors.
AID558569	Antibacterial activity against bla gene-positive and nitrocefin reaction-positive beta-lactamase harboring Campylobacter jejuni isolate P285 by NCCLS agar doubling dilution method in presence of Tazobactam	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID18721	Compound was tested for the rate of the acyl-enzyme complex in Escherichia coli SNO3.	1996	Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19	Design, synthesis, and evaluation of 2 beta-alkenyl penam sulfone acids as inhibitors of beta-lactamases.
AID727642	Binding affinity to Beta-lactamase SHV-1 K234R protein mutant in Escherichia coli DH10B assessed as melting temperature at 50 uM by circular dichroism analysis (Rvb = 48.2 degC)	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Design and exploration of novel boronic acid inhibitors reveals important interactions with a clavulanic acid-resistant sulfhydryl-variable (SHV) β-lactamase.
AID373218	Inhibition of Bacillus clausii NR beta-lactamase BCL1 expressed in Escherichia coli BL21 (DE3)	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii.
AID558767	Antibacterial activity against bla gene-positive and nitrocefin reaction-negative beta-lactamase harboring Campylobacter jejuni isolate P1699 by NCCLS agar doubling dilution method in presence of Tazobactam	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID1576705	Inhibition of bacterial N-terminal His-tagged TEV protease site linked OXA-48 (1 to 265 amino acids) expressed in Escherichia coli Transetta (DE3) preincubated for 10 mins followed by FC5 fluorescent substrate addition by fluorescence assay
AID1169068	Hydrolytic solution stability in pH 7.4 aqueous phosphate buffer at 70 degC by HPLC-UV method	2014	ACS medicinal chemistry letters, Oct-09, Volume: 5, Issue:10	Enantioselective Synthesis and Profiling of Two Novel Diazabicyclooctanone β-Lactamase Inhibitors.
AID285273	Inhibition of Escherichia coli BL21(DE3) beta-lactamase TEM152	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient.
AID727644	Ratio of Kcat to Kinact for Beta-lactamase SHV-1 K234R protein mutant in Escherichia coli DH10B	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Design and exploration of novel boronic acid inhibitors reveals important interactions with a clavulanic acid-resistant sulfhydryl-variable (SHV) β-lactamase.
AID519751	Inhibition of Klebsiella pneumoniae Beta-Lactamase SHV-72	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	The Lys234Arg substitution in the enzyme SHV-72 is a determinant for resistance to clavulanic acid inhibition.
AID1559311	Inhibition of bacterial VIM-2 using nitrocefin as substrate preincubated for 15 mins followed by susbtrate addition and measured after 10 mins by spectrophotometric method	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID44080	In vitro inhibitory activity against Beta-lactamase TEM-1 of class A enzyme	2003	Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13	Spirocyclopropyl beta-lactams as mechanism-based inhibitors of serine beta-lactamases. Synthesis by rhodium-catalyzed cyclopropanation of 6-diazopenicillanate sulfone.
AID266531	Antibacterial activity against Enterobacter cloacae expressing P99	2006	Journal of medicinal chemistry, Jul-27, Volume: 49, Issue:15	Structure-activity relationship of 6-methylidene penems bearing 6,5 bicyclic heterocycles as broad-spectrum beta-lactamase inhibitors: evidence for 1,4-thiazepine intermediates with C7 R stereochemistry by computational methods.
AID560135	Inhibition of recombinant beta-lactamase RTG4 expressed in Escherichia coli TOP10 by nitrocefin hydrolysis assay	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Genetic and biochemical characterization of the first extended-spectrum CARB-type beta-lactamase, RTG-4, from Acinetobacter baumannii.
AID374027	Inhibition of Serratia fonticola UTAD54 SFC1 beta lactamase expressed in Escherichia coli BL21(DE3) by SDS-PAGE	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Biochemical Characterization of SFC-1, a class A carbapenem-hydrolyzing beta-lactamase.
AID44065	In vitro inhibitory activity against Class A (TEM-1) beta-Lactamases	2004	Journal of medicinal chemistry, Jul-01, Volume: 47, Issue:14	Mechanism of inactivation of beta-lactamases by novel 6-methylidene penems elucidated using electrospray ionization mass spectrometry.
AID44073	Compound was tested for inhibition of Beta-lactamase from PSE-1	1996	Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19	Design, synthesis, and evaluation of 2 beta-alkenyl penam sulfone acids as inhibitors of beta-lactamases.
AID584974	Inhibition of beta-lactamase KPC-2 assessed as nitrocefin hydrolysis after 5 mins enzyme-compound preincubation	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-beta-lactam beta-lactamase inhibitor.
AID1169070	Inhibition of Enterobacter cloacae KPC-2 pre-incubated with enzyme for 5 mins before nitrocefin substrate addition by colorimetric assay	2014	ACS medicinal chemistry letters, Oct-09, Volume: 5, Issue:10	Enantioselective Synthesis and Profiling of Two Novel Diazabicyclooctanone β-Lactamase Inhibitors.
AID542053	Antibacterial activity against Klebsiella pneumoniae C expressing CTX-M group 1 beta-lactamase by Etest method in presence of Tazobactam	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Nationwide survey of CTX-M-type extended-spectrum beta-lactamases among Klebsiella pneumoniae isolates in Slovenian hospitals.
AID558568	Antibacterial activity against bla gene-negative and nitrocefin reaction-negative beta-lactamase harboring Campylobacter jejuni isolate P1962 by NCCLS agar doubling dilution method in presence of Tazobactam	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID1476612	Antibacterial activity against clinical isolates of Pseudomonas aeruginosa ISR-14-004 after 18 hrs by broth microdilution method	2017	Journal of medicinal chemistry, 11-09, Volume: 60, Issue:21	Methodology for Monobactam Diversification: Syntheses and Studies of 4-Thiomethyl Substituted β-Lactams with Activity against Gram-Negative Bacteria, Including Carbapenemase Producing Acinetobacter baumannii.
AID203172	The ratio of compound to that of piperacillin was evaluated for antimicrobial activity against Serratia marcescens OC 4101 by inhibiting enzyme AmpC(ind) at 4 ug/mL	2000	Bioorganic & medicinal chemistry letters, Oct-02, Volume: 10, Issue:19	The synthesis and SAR of rhodanines as novel class C beta-lactamase inhibitors.
AID585191	Inhibition of Beta-lactamase GES-6 K104, S170 mutant preincubated for 5 mins before substrate addition using cephalothin substrate by spectrophotometry	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases.
AID556339	Inhibition of Salmonella enterica serotype Westhampton beta-lactamase CTX-M-53	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Novel plasmid-encoded ceftazidime-hydrolyzing CTX-M-53 extended-spectrum beta-lactamase from Salmonella enterica serotypes Westhampton and Senftenberg.
AID44072	Compound was tested for inhibition of Beta-lactamase from OXA-1	1996	Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19	Design, synthesis, and evaluation of 2 beta-alkenyl penam sulfone acids as inhibitors of beta-lactamases.
AID1529358	Inhibition of beta lactamase in Pseudomonas aeruginosa assessed as potentiation of meropenem-induced antibacterial activity by measuring meropenem MIC90	2018	MedChemComm, Sep-01, Volume: 9, Issue:9	β-lactam/β-lactamase inhibitor combinations: an update.
AID340738	Ratio of Kcat to Km of Chryseobacterium indologenes metallo-beta-lactamase IND-5 expressed in Escherichia coli BL21(DE3) assessed as substrate hydrolysis relative to control	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Identification and characterization of a new metallo-beta-lactamase, IND-5, from a clinical isolate of Chryseobacterium indologenes.
AID43114	Compound was tested for inhibition of Beta-lactamase from Bacteroides fragilis 98	1996	Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19	Design, synthesis, and evaluation of 2 beta-alkenyl penam sulfone acids as inhibitors of beta-lactamases.
AID1559342	Inhibition of KPC-2/PDC-42 in Pseudomonas aeruginosa CDC-0356 assessed as meropenem antibacterial activity at 4 ug/ml after 16 to 20 hrs by CLSI-based microbroth dilution method (Rvb = 32 ug/ml)	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID558769	Antibacterial activity against bla gene-negative and nitrocefin reaction-positive beta-lactamase harboring Campylobacter jejuni isolate P854 by NCCLS agar doubling dilution method in presence of Tazobactam	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID368519	Inhibition of Escherichia coli CTX-M-15	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID43275	Compound was tested for inhibition of Beta-lactamase from Ent. cloacae 6300	1996	Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19	Design, synthesis, and evaluation of 2 beta-alkenyl penam sulfone acids as inhibitors of beta-lactamases.
AID285161	Antimicrobial activity against non replicating persistence Mycobacterium tuberculosis H37Rv in anaerobic condition assessed as relative light unit after 11 days by LORA assay	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis.
AID495660	Inhibition of Pseudomonas aeruginosa 51170 beta-lactamase BEL-1	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	BEL-2, an extended-spectrum beta-lactamase with increased activity toward expanded-spectrum cephalosporins in Pseudomonas aeruginosa.
AID584987	Inhibition of beta-lactamase TEM-1 after 5 seconds incubation with nitrocefin substrate by spectrophotometry	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-beta-lactam beta-lactamase inhibitor.
AID577228	Antibacterial activity against intI1-positive tigecycline-susceptible Acinetobacter baumannii AB039 with PFGE subgroup B1 containing carbapenemase OXA-23 and OXA-51 by Etest	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS.
AID1529344	Inhibition of beta lactamase in Pseudomonas aeruginosa assessed as potentiation of ceftazidime-induced antibacterial activity by measuring fold reduction in ceftazidime MIC90 at 4 ug/ml relative to ceftazidime alone	2018	MedChemComm, Sep-01, Volume: 9, Issue:9	β-lactam/β-lactamase inhibitor combinations: an update.
AID496597	Ratio of Kinact to Km for Escherichia coli DH10B beta-lactamase KPC-2	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Inhibitor resistance in the KPC-2 beta-lactamase, a preeminent property of this class A beta-lactamase.
AID1559335	Inhibition of KPC-2/SHV12/TEM-1 in Klebsiella pneumoniae CDC-0361 assessed as cefepime antibacterial activity at 8 ug/ml after 16 to 20 hrs by CLSI-based microbroth dilution method (Rvb = 32 ug/ml)	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID542054	Antibacterial activity against Klebsiella pneumoniae B expressing CTX-M group 1 beta-lactamase by Etest method in presence of Tazobactam	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Nationwide survey of CTX-M-type extended-spectrum beta-lactamases among Klebsiella pneumoniae isolates in Slovenian hospitals.
AID525575	Antibacterial activity against Escherichia coli DH10B harboring RGN238 plasmid containing Beta-lactamase OXA-1 at 4 ug/ml in presence of increasing concentrations of piperacillin by broth agar dilution assay	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Penicillin sulfone inhibitors of class D beta-lactamases.
AID297198	Inhibition of Escherichia coli TEM1	2007	Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17	4-Substituted trinems as broad spectrum beta-lactamase inhibitors: structure-based design, synthesis, and biological activity.
AID372628	Inhibition of Escherichia coli DH5alpha beta-lactamase TEM-12	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases.
AID525577	Inhibition of Beta-lactamase OXA-24/40 expressed in Escherichia coli BL21 (DE3) by nitrocefin hydrolysis assay	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Penicillin sulfone inhibitors of class D beta-lactamases.
AID18757	Compound was tested for the half saturation constant derived from concentration dependence studies in Escherichia coli SNO3.	1996	Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19	Design, synthesis, and evaluation of 2 beta-alkenyl penam sulfone acids as inhibitors of beta-lactamases.
AID18727	Compound was tested for the rate of formation of the acyl-enzyme complex in Citrobacter freundii	1996	Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19	Design, synthesis, and evaluation of 2 beta-alkenyl penam sulfone acids as inhibitors of beta-lactamases.
AID18722	Compound was tested for the rate of the acyl-enzyme complex in Escherichia coli TEM-3.	1996	Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19	Design, synthesis, and evaluation of 2 beta-alkenyl penam sulfone acids as inhibitors of beta-lactamases.
AID577240	Antibacterial activity against intI1-positive tigecycline-resistant Acinetobacter baumannii AB168 with PFGE subgroup A1 containing carbapenemase OXA-23 and OXA-51 by Etest	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS.
AID340736	Activity of Chryseobacterium indologenes metallo-beta-lactamase IND-5 expressed in Escherichia coli BL21(DE3) assessed as substrate hydrolysis	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Identification and characterization of a new metallo-beta-lactamase, IND-5, from a clinical isolate of Chryseobacterium indologenes.
AID584978	Inhibition of Pseudomonas aeruginosa beta-lactamase AmpC assessed as nitrocefin hydrolysis after 5 mins enzyme-compound preincubation	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-beta-lactam beta-lactamase inhibitor.
AID1529359	Inhibition of beta lactamase in Bacteroides fragilis assessed as potentiation of ceftolozane-induced antibacterial activity by measuring ceftolozane MIC90	2018	MedChemComm, Sep-01, Volume: 9, Issue:9	β-lactam/β-lactamase inhibitor combinations: an update.
AID285277	Inhibition of Escherichia coli BL21(DE3) beta-lactamase TEM1	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient.
AID1559351	Inhibition of TEM/CTX-M/SHV/KPC in Klebsiella pneumoniae 964-2 assessed as cefepime antibacterial activity at 4 ug/ml after 16 to 20 hrs by CLSI-based microbroth dilution method (Rvb > 128 ug/ml)	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID285275	Inhibition of Escherichia coli BL21(DE3) beta-lactamase TEM29	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient.
AID1225764	Inhibition of Escherichia coli recombinant CMY-2 assessed as substrate nitrocefin degradation preincubated for 10 mins followed by substrate addition measured every 10 secs for 10 mins by spectrophotometric analysis	2015	Journal of medicinal chemistry, May-14, Volume: 58, Issue:9	Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases.
AID266533	Antibacterial activity against Serratia marcescens expressing AmpC and Smel	2006	Journal of medicinal chemistry, Jul-27, Volume: 49, Issue:15	Structure-activity relationship of 6-methylidene penems bearing 6,5 bicyclic heterocycles as broad-spectrum beta-lactamase inhibitors: evidence for 1,4-thiazepine intermediates with C7 R stereochemistry by computational methods.
AID1529351	Inhibition of beta lactamase in Enterobacteriaceae clinical isolate assessed as potentiation of ceftolozane-induced antibacterial activity by measuring ceftolozane MIC by broth microdilution method	2018	MedChemComm, Sep-01, Volume: 9, Issue:9	β-lactam/β-lactamase inhibitor combinations: an update.
AID558575	Antibacterial activity against bla gene-positive and nitrocefin reaction-positive beta-lactamase harboring Campylobacter jejuni isolate P1093 by NCCLS agar doubling dilution method in presence of Tazobactam	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID1559316	Inhibition of bacterial SHV-5 using cefotaxime as substrate preincubated for 15 mins followed by susbtrate addition and measured after 10 mins by spectrophotometric method	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID1559337	Inhibition of KPC-2/PDC-42 in Pseudomonas aeruginosa CDC-0457 assessed as cefepime antibacterial activity at 8 ug/ml after 16 to 20 hrs by CLSI-based microbroth dilution method (Rvb = 16 ug/ml)	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID577242	Antibacterial activity against intI1-positive tigecycline-resistant Acinetobacter baumannii AB097 with PFGE subgroup B1 containing carbapenemase OXA-23 and OXA-51 by Etest	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS.
AID727640	Binding affinity to Beta-lactamase SHV-1 K234R protein mutant in Escherichia coli DH10B assessed as change in secondary structure at 50 uM by circular dichroism analysis	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Design and exploration of novel boronic acid inhibitors reveals important interactions with a clavulanic acid-resistant sulfhydryl-variable (SHV) β-lactamase.
AID44077	Compound was tested for inhibition of Beta-lactamase from SHV-2	1996	Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19	Design, synthesis, and evaluation of 2 beta-alkenyl penam sulfone acids as inhibitors of beta-lactamases.
AID1576698	Inhibition of bacterial N-terminal His-tagged TEV protease site linked VIM-2 (27 to 266 amino acids) expressed in Escherichia coli Transetta (DE3) preincubated for 10 mins followed by FC5 fluorescent substrate addition by fluorescence assay
AID266529	Inhibition of Enterobacter cloacae AmpC	2006	Journal of medicinal chemistry, Jul-27, Volume: 49, Issue:15	Structure-activity relationship of 6-methylidene penems bearing 6,5 bicyclic heterocycles as broad-spectrum beta-lactamase inhibitors: evidence for 1,4-thiazepine intermediates with C7 R stereochemistry by computational methods.
AID558772	Antibacterial activity against bla gene-positive and nitrocefin reaction-positive beta-lactamase harboring Campylobacter coli isolate P1826 by NCCLS agar doubling dilution method in presence of Tazobactam	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID1225760	Inhibition of Escherichia coli recombinant CTX-M-15 assessed as substrate nitrocefin degradation preincubated for 10 mins followed by substrate addition measured every 10 secs for 10 mins by spectrophotometric analysis	2015	Journal of medicinal chemistry, May-14, Volume: 58, Issue:9	Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases.
AID43744	Compound was tested for inhibition of beta-Lactamases from Morganell morgani U1627	1996	Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19	Design, synthesis, and evaluation of 2 beta-alkenyl penam sulfone acids as inhibitors of beta-lactamases.
AID1476610	Antibacterial activity against Pseudomonas aeruginosa ARC 3506 after 18 hrs by broth microdilution method	2017	Journal of medicinal chemistry, 11-09, Volume: 60, Issue:21	Methodology for Monobactam Diversification: Syntheses and Studies of 4-Thiomethyl Substituted β-Lactams with Activity against Gram-Negative Bacteria, Including Carbapenemase Producing Acinetobacter baumannii.
AID266530	Antibacterial activity against Escherichia coli expressing TEM1	2006	Journal of medicinal chemistry, Jul-27, Volume: 49, Issue:15	Structure-activity relationship of 6-methylidene penems bearing 6,5 bicyclic heterocycles as broad-spectrum beta-lactamase inhibitors: evidence for 1,4-thiazepine intermediates with C7 R stereochemistry by computational methods.
AID519637	Inhibition of Brachyspira pilosicoli beta-lactamase OXA-63 expressed in Escherichia coli BL21 (DE3) assessed as reduction in nitrocefin hydrolysis by spectrophotometry relative to oxacillin	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Genetic and biochemical characterization of OXA-63, a new class D beta-lactamase from Brachyspira pilosicoli BM4442.
AID574203	Ratio of Kinact to Ki for beta-lactamase OXA-1 expressed in Escherichia coli BL21 (DE3) using nitrocefin substrate by spectrophotometry	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Inhibition of OXA-1 beta-lactamase by penems.
AID70946	In vitro antibacterial activity against TEM-1 producing Escherichia coli (GC2206)	2001	Bioorganic & medicinal chemistry letters, Apr-23, Volume: 11, Issue:8	Allyl and propargyl substituted penam sulfones as versatile intermediates toward the syntheses of new beta-lactamase inhibitors.
AID1576719	Inhibition of bacterial KPC-2 (29 to 289 amino acids) expressed in Escherichia coli Transetta (DE3) preincubated for 10 mins followed by FC5 fluorescent substrate addition by jump-dilution recovery method
AID1559324	Inhibition of NDM-1/CMY-6/OXA-1 in Escherichia coli CDC-0055 assessed as piperacillin antibacterial activity at 16 ug/ml after 16 to 20 hrs by CLSI-based microbroth dilution method (Rvb > 128 ug/ml)	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID560596	Antimicrobial activity against multidrug resistant Pseudomonas aeruginosa isolate IMCJ2S1 by microdilution method in presence of beta-lactamase inhibitor Tazobactam	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	AAC(6')-Iaf, a novel aminoglycoside 6'-N-acetyltransferase from multidrug-resistant Pseudomonas aeruginosa clinical isolates.
AID577235	Antibacterial activity against intI1-positive tigecycline-resistant Acinetobacter baumannii AB106 with PFGE subgroup B1 containing carbapenemase OXA-23 and OXA-51 by Etest	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS.
AID1559344	Inhibition of NDM in Escherichia coli CDC-0452 assessed as meropenem antibacterial activity at 4 ug/ml after 16 to 20 hrs by CLSI-based microbroth dilution method (Rvb = 32 ug/ml)	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID43908	Compound was tested for inhibition of Beta-lactamase from Staphylococcus aureus PCI	1996	Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19	Design, synthesis, and evaluation of 2 beta-alkenyl penam sulfone acids as inhibitors of beta-lactamases.
AID572897	Inhibition of Klebsiella pneumoniae Beta-lactamase SHV-1	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	In vitro activity of LK-157, a novel tricyclic carbapenem as broad-spectrum {beta}-lactamase inhibitor.
AID560597	Antimicrobial activity against rifampin-resistant Pseudomonas aeruginosa ATCC 27853 by microdilution method in presence of beta-lactamase inhibitor Tazobactam	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	AAC(6')-Iaf, a novel aminoglycoside 6'-N-acetyltransferase from multidrug-resistant Pseudomonas aeruginosa clinical isolates.
AID374361	Antimicrobial activity against Escherichia coli DH5alpha expressing pJDB2 containing Aeromonas caviae A324R metallo-beta-lactamase gene by broth dilution method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	First occurrence of an IMP metallo-beta-lactamase in Aeromonas caviae: IMP-19 in an isolate from France.
AID43880	Compound was tested for inhibition of Beta-lactamase from Pseudomonas aeruginosa MK-1184	1996	Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19	Design, synthesis, and evaluation of 2 beta-alkenyl penam sulfone acids as inhibitors of beta-lactamases.
AID43113	Compound was tested for inhibition of Beta-lactamase from Bacteroides fragilis BF 101	1996	Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19	Design, synthesis, and evaluation of 2 beta-alkenyl penam sulfone acids as inhibitors of beta-lactamases.
AID297199	Inhibition of Escherichia coli SHV1	2007	Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17	4-Substituted trinems as broad spectrum beta-lactamase inhibitors: structure-based design, synthesis, and biological activity.
AID560595	Antimicrobial activity against Pseudomonas aeruginosa isolate IMCJ799 by microdilution method in presence of beta-lactamase inhibitor Tazobactam	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	AAC(6')-Iaf, a novel aminoglycoside 6'-N-acetyltransferase from multidrug-resistant Pseudomonas aeruginosa clinical isolates.
AID1529353	Inhibition of beta lactamase in Pseudomonas aeruginosa assessed as potentiation of ceftolozane-induced antibacterial activity by measuring ceftolozane MIC by broth microdilution method	2018	MedChemComm, Sep-01, Volume: 9, Issue:9	β-lactam/β-lactamase inhibitor combinations: an update.
AID519750	Inhibition of Klebsiella pneumoniae Beta-Lactamase SHV-1	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	The Lys234Arg substitution in the enzyme SHV-72 is a determinant for resistance to clavulanic acid inhibition.
AID44076	Compound was tested for inhibition of Beta-lactamase from RTEM-3	1996	Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19	Design, synthesis, and evaluation of 2 beta-alkenyl penam sulfone acids as inhibitors of beta-lactamases.
AID542042	Antibacterial activity against Escherichia coli TrC B expressing Klebsiella pneumoniae B blaCTX-M beta-lactamase by Etest method in presence of Tazobactam	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Nationwide survey of CTX-M-type extended-spectrum beta-lactamases among Klebsiella pneumoniae isolates in Slovenian hospitals.
AID584992	Activity of Enterobacter cloacae beta-lactamase P99 by spectrophotometry	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-beta-lactam beta-lactamase inhibitor.
AID525576	Inhibition of Beta-lactamase OXA-17 expressed in Escherichia coli BL21 (DE3) by nitrocefin hydrolysis assay	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Penicillin sulfone inhibitors of class D beta-lactamases.
AID558574	Antibacterial activity against bla gene-positive and nitrocefin reaction-positive beta-lactamase harboring Campylobacter jejuni isolate P790 by NCCLS agar doubling dilution method in presence of Tazobactam	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID1559334	Inhibition of KPC-2/PDC-42 in Pseudomonas aeruginosa CDC-0356 assessed as cefepime antibacterial activity at 8 ug/ml after 16 to 20 hrs by CLSI-based microbroth dilution method (Rvb > 128 ug/ml)	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID266527	Inhibition of Enterobacter cloacae Imi1	2006	Journal of medicinal chemistry, Jul-27, Volume: 49, Issue:15	Structure-activity relationship of 6-methylidene penems bearing 6,5 bicyclic heterocycles as broad-spectrum beta-lactamase inhibitors: evidence for 1,4-thiazepine intermediates with C7 R stereochemistry by computational methods.
AID577239	Antibacterial activity against intI1-positive tigecycline-resistant Acinetobacter baumannii AB134 with PFGE subgroup A2 containing carbapenemase OXA-23 and OXA-51 by Etest	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS.
AID585189	Inhibition of Beta-lactamase GES-2 E104, N170 mutant preincubated for 5 mins before substrate addition using cephalothin substrate by spectrophotometry	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases.
AID1576699	Inhibition of bacterial N-terminal His-tagged TEV protease site linked NDM-1 (1 to 270 amino acids) expressed in Escherichia coli Transetta (DE3) preincubated for 10 mins followed by FC5 fluorescent substrate addition by fluorescence assay
AID326275	Inhibition of Escherichia coli K12 TEM1	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	SCO-1, a novel plasmid-mediated class A beta-lactamase with carbenicillinase characteristics from Escherichia coli.
AID548269	Ratio of Ki for Klebsiella pneumoniae 1534 beta-lactamase KPC-2 T237S mutant to Ki for Klebsiella pneumoniae wild type beta-lactamase KPC-2 by competitive assay	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID584985	Ratio of Inactivation rate constant for longer incubation time yield to Km for beta-lactamase TEM-1 by spectrophotometry	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-beta-lactam beta-lactamase inhibitor.
AID18755	Compound was tested for the half saturation constant derived from concentration dependence studies in Citrobacter freundii	1996	Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19	Design, synthesis, and evaluation of 2 beta-alkenyl penam sulfone acids as inhibitors of beta-lactamases.
AID70901	In vitro antibacterial activity against AmpC producing Escherichia coli (GC2894)	2001	Bioorganic & medicinal chemistry letters, Apr-23, Volume: 11, Issue:8	Allyl and propargyl substituted penam sulfones as versatile intermediates toward the syntheses of new beta-lactamase inhibitors.
AID558578	Antibacterial activity against bla gene-positive and nitrocefin reaction-positive beta-lactamase harboring Campylobacter jejuni isolate P1650 by NCCLS agar doubling dilution method in presence of Tazobactam	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID1559319	Inhibition of bacterial OXA-1 using nitrocefin as substrate preincubated for 15 mins followed by susbtrate addition and measured after 10 mins by spectrophotometric method	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID577232	Antibacterial activity against intI1-positive tigecycline-intermediate Acinetobacter baumannii AB166 with PFGE subgroup A3 containing carbapenemase OXA-51 by Etest	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS.
AID422500	Inhibition of Carnobacterium divergens BM4489 penicillinase Cad-1	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Genetic and biochemical characterization of CAD-1, a chromosomally encoded new class A penicillinase from Carnobacterium divergens.
AID558572	Antibacterial activity against bla gene-positive and nitrocefin reaction-positive beta-lactamase harboring Campylobacter jejuni isolate P338 by NCCLS agar doubling dilution method in presence of Tazobactam	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID405083	Inhibition of Citrobacter freundii PER2 beta lactamase	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Biochemical characterization of PER-2 and genetic environment of blaPER-2.
AID588220	Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset	2008	Toxicology mechanisms and methods, , Volume: 18, Issue:2-3	Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID1169071	Inhibition of Pseudomonas aeruginosa AmpC pre-incubated with enzyme for 5 mins before nitrocefin substrate addition by colorimetric assay	2014	ACS medicinal chemistry letters, Oct-09, Volume: 5, Issue:10	Enantioselective Synthesis and Profiling of Two Novel Diazabicyclooctanone β-Lactamase Inhibitors.
AID585190	Inhibition of Beta-lactamase GES-5 E104, S170 mutant preincubated for 5 mins before substrate addition using cephalothin substrate by spectrophotometry	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases.
AID577227	Antibacterial activity against intI1-positive tigecycline-susceptible Acinetobacter baumannii AB018 with PFGE subgroup G containing carbapenemase OXA-58 and OXA-51 by Etest	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS.
AID1559332	Inhibition of NDM-1/CMY-6/OXA-1 in Escherichia coli CDC-0055 assessed as cefepime antibacterial activity at 8 ug/ml after 16 to 20 hrs by CLSI-based microbroth dilution method (Rvb = 128 ug/ml)	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID285274	Inhibition of Escherichia coli BL21(DE3) beta-lactamase TEM28	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient.
AID574202	Inhibition of beta-lactamase OXA-1 expressed in Escherichia coli BL21 (DE3) using nitrocefin substrate by spectrophotometry	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Inhibition of OXA-1 beta-lactamase by penems.
AID1225762	Inhibition of Escherichia coli recombinant TEM-10 assessed as substrate nitrocefin degradation preincubated for 10 mins followed by substrate addition measured every 10 secs for 10 mins by spectrophotometric analysis	2015	Journal of medicinal chemistry, May-14, Volume: 58, Issue:9	Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases.
AID531316	Ratio of Kcat to Km for Pseudomonas aeruginosa beta-lactamase VIM-2 by spectrophotometry	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family.
AID558571	Antibacterial activity against bla gene-positive and nitrocefin reaction-positive beta-lactamase harboring Campylobacter jejuni isolate P316 by NCCLS agar doubling dilution method in presence of Tazobactam	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID374365	Antimicrobial activity against Escherichia coli DH5alpha expressing pIP19 containing Aeromonas caviae A324R metallo-beta-lactamase blaIMP-19 gene by broth dilution method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	First occurrence of an IMP metallo-beta-lactamase in Aeromonas caviae: IMP-19 in an isolate from France.
AID394491	Inhibition of Escherichia coli beta-lactamase ACC4	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Plasmid-encoded ACC-4, an extended-spectrum cephalosporinase variant from Escherichia coli.
AID577241	Antibacterial activity against intI1-positive tigecycline-resistant Acinetobacter baumannii AB173 with PFGE subgroup B1 containing carbapenemase OXA-23 and OXA-51 by Etest	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS.
AID495801	Inhibition of carbapenem-resistant Klebsiella pneumoniae carbepenem-hydrolyzing beta-lactamase KPC-1	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel ambler class A carbapenem-hydrolyzing beta-lactamase from a Pseudomonas fluorescens isolate from the Seine River, Paris, France.
AID585188	Inhibition of Beta-lactamase GES-7 K104, G170 mutant preincubated for 5 mins before substrate addition using cephalothin substrate by spectrophotometry	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases.
AID1559339	Inhibition of VIM-27/CTX-M-15/SHV-11/OXA-1 in Klebsiella pneumoniae CDC-0040 assessed as meropenem antibacterial activity at 4 ug/ml after 16 to 20 hrs by CLSI-based microbroth dilution method (Rvb > 128 ug/ml)	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID496594	Ratio of Kcat to Km for Escherichia coli DH10B beta-lactamase KPC-2	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Inhibitor resistance in the KPC-2 beta-lactamase, a preeminent property of this class A beta-lactamase.
AID209020	In vitro inhibitory concentration against TEM-1 enzyme	2001	Bioorganic & medicinal chemistry letters, Apr-23, Volume: 11, Issue:8	Allyl and propargyl substituted penam sulfones as versatile intermediates toward the syntheses of new beta-lactamase inhibitors.
AID495800	Inhibition of Pseudomonas fluorescens PF-1 beta-lactamase BIC-1 expressed in Escherichia coli DH10B carrying pSau1	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel ambler class A carbapenem-hydrolyzing beta-lactamase from a Pseudomonas fluorescens isolate from the Seine River, Paris, France.
AID1559346	Inhibition of TEM/CTX-M/SHV/Cephalosporinase in Escherichia coli EC1552 assessed as cefepime antibacterial activity at 4 ug/ml after 16 to 20 hrs by CLSI-based microbroth dilution method (Rvb = 16 ug/ml)	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID584973	Inhibition of beta-lactamase SHV-4 assessed as nitrocefin hydrolysis after 5 mins enzyme-compound preincubation	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-beta-lactam beta-lactamase inhibitor.
AID358399	Inhibition of beta lactamase SHV1	2007	The Journal of biological chemistry, Jul-27, Volume: 282, Issue:30	Efficient inhibition of class A and class D beta-lactamases by Michaelis complexes.
AID44074	Compound was tested for inhibition of Beta-lactamase from RTEM-1	1996	Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19	Design, synthesis, and evaluation of 2 beta-alkenyl penam sulfone acids as inhibitors of beta-lactamases.
AID1559350	Inhibition of KPC/Cephalosporinase in Klebsiella pneumoniae 664-1 assessed as cefepime antibacterial activity at 4 ug/ml after 16 to 20 hrs by CLSI-based microbroth dilution method (Rvb > 128 ug/ml)	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID560136	Inhibition of recombinant beta-lactamase RTG3 expressed in Escherichia coli TOP10 by nitrocefin hydrolysis assay	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Genetic and biochemical characterization of the first extended-spectrum CARB-type beta-lactamase, RTG-4, from Acinetobacter baumannii.
AID1209731	Drug uptake by mouse OAT3 expressed in CHO cells at 100 uM after 25 mins by HPLC/UV detection method	2013	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4	Organic anion transporter 3 interacts selectively with lipophilic β-lactam antibiotics.
AID496600	Inhibition of Escherichia coli DH10B beta-lactamase KPC-2 assessed as residual activity at 25 to 200 uM after 15 mins by diode array spectrophotometry	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Inhibitor resistance in the KPC-2 beta-lactamase, a preeminent property of this class A beta-lactamase.
AID285159	Antimicrobial activity against non replicating persistence Mycobacterium tuberculosis H37Rv in aerobic condition assessed by relative light units after 7 days	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis.
AID574204	Ratio of Kcat to Kinact for beta-lactamase OXA-1 expressed in Escherichia coli BL21 (DE3) using nitrocefin substrate by spectrophotometry	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Inhibition of OXA-1 beta-lactamase by penems.
AID727647	Antimicrobial activity against Escherichia coli DH10B expressing Beta-lactamase SHV K234A mutant by CLSI agar dilution method in presence of ampicillin	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Design and exploration of novel boronic acid inhibitors reveals important interactions with a clavulanic acid-resistant sulfhydryl-variable (SHV) β-lactamase.
AID326274	Inhibition of Escherichia coli K12 CARB1	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	SCO-1, a novel plasmid-mediated class A beta-lactamase with carbenicillinase characteristics from Escherichia coli.
AID43428	Compound was tested for inhibition of Beta-lactamase from Escherichia coli SN03	1996	Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19	Design, synthesis, and evaluation of 2 beta-alkenyl penam sulfone acids as inhibitors of beta-lactamases.
AID285272	Inhibition of Escherichia coli BL21(DE3) beta-lactamase TEM151	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient.
AID1559317	Inhibition of bacterial CTX-M-15 using cefotaxime as substrate preincubated for 15 mins followed by susbtrate addition and measured after 10 mins by spectrophotometric method	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID558570	Antibacterial activity against bla gene-positive and nitrocefin reaction-positive beta-lactamase harboring Campylobacter jejuni isolate P286 by NCCLS agar doubling dilution method in presence of Tazobactam	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID163441	The ratio of compound to that of piperacillin was evaluated for antimicrobial activity against Pseudomonas aeruginosa OC 4270 by inhibiting enzyme AmpC(ind) at 4 ug/mL	2000	Bioorganic & medicinal chemistry letters, Oct-02, Volume: 10, Issue:19	The synthesis and SAR of rhodanines as novel class C beta-lactamase inhibitors.
AID1576709	Inhibition of beta lactamase NDM1 in Escherichia coli BAA-2452 assessed as potentiation of meropenem-induced antibacterial activity by measuring meropenem MIC at 50 uM after 16 to 20 hrs by broth microdilution assay (Rvb = 32 ug/ml)
AID1576714	Inhibition of beta lactamase KPC-2 in Klebsiella pneumoniae 5846 assessed as potentiation of meropenem-induced antibacterial activity by measuring meropenem MIC at 50 uM after 16 to 20 hrs by broth microdilution assay (Rvb = 16 ug/ml)
AID1576713	Inhibition of beta lactamase KPC-2 in Klebsiella pneumoniae BAA-1705 assessed as potentiation of meropenem-induced antibacterial activity by measuring meropenem MIC at 50 uM after 16 to 20 hrs by broth microdilution assay (Rvb = 16 ug/ml)
AID548268	Inhibition of Klebsiella pneumoniae 1534 beta-lactamase KPC-2 T237A mutant by competitive assay	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID727645	Ratio of Kcat to Kinact for wild type Beta-lactamase SHV-1 in Escherichia coli DH10B	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Design and exploration of novel boronic acid inhibitors reveals important interactions with a clavulanic acid-resistant sulfhydryl-variable (SHV) β-lactamase.
AID558766	Antibacterial activity against bla gene-positive and nitrocefin reaction-negative beta-lactamase harboring Campylobacter jejuni isolate P1698 by NCCLS agar doubling dilution method in presence of Tazobactam	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID1801066	Steady-State Kinetics Assay from Article 10.1021/bi501197t: \\Detecting a quasi-stable imine species on the reaction pathway of SHV-1 u00DF-lactamase and 6u00DF-(hydroxymethyl)penicillanic acid sulfone.\\	2015	Biochemistry, Jan-27, Volume: 54, Issue:3	Detecting a quasi-stable imine species on the reaction pathway of SHV-1 β-lactamase and 6β-(hydroxymethyl)penicillanic acid sulfone.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	29 (2.28)	18.7374
1990's	259 (20.33)	18.2507
2000's	262 (20.57)	29.6817
2010's	445 (34.93)	24.3611
2020's	279 (21.90)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	153 (11.53%)	5.53%
Reviews	111 (8.36%)	6.00%
Case Studies	146 (11.00%)	4.05%
Observational	17 (1.28%)	0.25%
Other	900 (67.82%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (139)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Phase 2, Randomized, Active Comparator-Controlled, Multicenter, Double-Blind Clinical Trial to Study the Safety and Efficacy of Ceftolozane/Tazobactam (MK-7625A) Versus Meropenem in Pediatric Subjects With Complicated Urinary Tract Infection, Including [NCT03230838]	Phase 2	134 participants (Actual)	Interventional	2018-04-26	Completed
A Phase 2, Randomized, Active Comparator-Controlled, Multicenter, Double-Blind Clinical Trial to Study the Safety and Efficacy of Ceftolozane/Tazobactam (MK-7625A) Plus Metronidazole Versus Meropenem in Pediatric Subjects With Complicated Intra-Abdominal [NCT03217136]	Phase 2	94 participants (Actual)	Interventional	2018-04-03	Completed
Role of Prophylactic Antibiotics in Preventing Neonatal Sepsis in Neonates Born Through Meconium Stained Amniotic Fluid - A Randomized Controlled Trial [NCT01290003]		250 participants (Actual)	Interventional	2010-06-30	Completed
Rational Use of Broad-spectrum Antibiotics as Empiric Antibiotic Therapy in Febrile Neutropenia in Recipients of Allogeneic Hematopoietic Cell Transplantation [NCT03078010]	Phase 2	460 participants (Anticipated)	Interventional	2017-02-10	Recruiting
Comparison of the Nephrotoxicity of Vancomycin in Combination With Piperacillin/Tazobactam or Other Beta-lactams in Critically Ill Patients: A Retrospective, Multicenter Study in China [NCT03776409]		700 participants (Actual)	Observational	2018-12-12	Completed
Comparison of 9 Doses vs 3 Doses of Post Operative Antibiotics in Live Liver Donors: A Randomized Controlled Trial [NCT03765645]		126 participants (Actual)	Interventional	2018-10-04	Completed
Optimal Care of Complicated Appendicitis [NCT03159754]	Phase 4	40 participants (Actual)	Interventional	2017-06-29	Completed
Prospective Randomized Study to Compare Clinical Outcomes in Patients With Osteomyelitis Treated With Intravenous Antibiotics Versus Intravenous Antibiotics With an Early Switch to Oral Antibiotics [NCT02099240]	Early Phase 1	11 participants (Actual)	Interventional	2014-03-06	Terminated(stopped due to Not enough patient enrollment and lack of staffing)
A Randomized, Observer-blinded, Active-controlled, Phase Illb Study to Compare IV / Oral Delafloxacin Fixed-dose Monotherapy With Best Available Treatments in a Microbiologically Enriched Population With Surgical Site Infections [NCT04042077]	Phase 3	268 participants (Actual)	Interventional	2019-09-25	Terminated(stopped due to COVID-19 seriously affected the study execution as required by the protocol)
A Randomized, Double-blind, Multicenter, Phase2 Trial to Evaluate the Safety and Efficacy of YH1177 or YH1177-D Otic Soultion in Patients With Otitis Media and Otorrhea [NCT02817347]	Phase 1/Phase 2	135 participants (Actual)	Interventional	2016-06-30	Terminated(stopped due to Sponsor's decision for the Drug Development.)
Single Centre, Prospective, Comparative, Open-label, Randomised Study to Evaluate the Efficacy and Tolerability of the Combination of Moxifloxacin Plus Metronidazole Versus Piperacillin/Tazobactam for the Treatment of Patients With Intra-abdominal Abscess [NCT00629135]	Phase 3	180 participants (Actual)	Interventional	2005-11-15	Completed
A Phase 3, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Cefepime-AAI101 Compared to Piperacillin/Tazobactam in the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis. [NCT03687255]	Phase 3	1,043 participants (Actual)	Interventional	2018-09-24	Completed
An Investigator Initiated, Phase II Single-Center, Randomized, Open-Label, Prospective, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftolozane-Tazobactam Plus Vancomycin, Linezolid Versus Standard of Care Plus Vancomycin, Lin [NCT03485950]	Phase 2	100 participants (Actual)	Interventional	2018-05-16	Completed
The Feasibility of Ceftolozane/Tazobactam Continuous Infusion for Exacerbations of Cystic Fibrosis and Bronchiectasis Treated in an Outpatient Parenteral Antibiotic Therapy (OPAT) Setting [NCT06035055]	Phase 4	30 participants (Anticipated)	Interventional	2023-10-31	Not yet recruiting
Optimisation, Valorisation and Application of UPLC-MS/MS Based Monitoring of Antibiotic Concentrations in Sputum of Cystic Fibrosis Patients - Part 3: Non-blank Sputum Samples for Method Optimisation and Validation [NCT02840136]		40 participants (Actual)	Interventional	2016-02-29	Terminated(stopped due to Lack of staff)
Continuous Infusion Piperacillin-Tazobactam for the Treatment of Pulmonary Exacerbations in Patients With Cystic Fibrosis [NCT01694069]	Phase 4	6 participants (Actual)	Interventional	2012-09-30	Terminated(stopped due to Recruitment was not sufficient to complete the study)
Clinical Outcomes With Ceftolozane-tazobactam in Patients With Multi Drug Resistant (MDR) Pseudomonas Aeruginosa Infections [NCT03510351]		200 participants (Actual)	Observational	2017-02-01	Active, not recruiting
A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of Ertapenem Sodium (MK-0826) Versus Piperacillin/Tazobactam Sodium in the Treatment of Diabetic Foot Infections in Chinese Adults [NCT01370616]	Phase 3	565 participants (Actual)	Interventional	2011-09-02	Completed
A Randomized Controlled Trial Assessing Noninferiority of Three Antimicrobial Regimens for the Treatment of Grade III Open Fractures [NCT03560232]	Phase 4	17 participants (Actual)	Interventional	2018-07-09	Terminated(stopped due to Unable to recruit patients in a timely fashion and unable to recruit sufficient patients)
Efficacy and Safety of the Administration of Betalactam Antibiotics in Continuous or Extended Infusion Compared to Intermittent Infusion in Patients With Sepsis in Two Pediatric Third-level Care Hospitals [NCT03019965]		426 participants (Actual)	Interventional	2017-02-01	Completed
Randomized Controlled Trial of Meropenem Versus Piperacillin-Tazobactam for Definitive Treatment of Bloodstream Infections Due to Ceftriaxone Non-susceptible E. Coli and Klebsiella Species. [NCT02176122]	Phase 4	391 participants (Actual)	Interventional	2014-02-28	Terminated(stopped due to Secondary to third interim analysis by the study DSMB.)
Randomized, Double-Blind, Comparative Study to Evaluate the Safety and Efficacy of ZTI-01 vs Piperacillin/Tazobactam in the Treatment of cUTI/AP Infection in Hospitalized Adults [NCT02753946]	Phase 2/Phase 3	465 participants (Actual)	Interventional	2016-04-30	Completed
Is Combination Antibiotic Therapy Superior to Monotherapy in the Treatment of Acute Exacerbations of Chronic Obstructive Pulmonary Disease [NCT04879030]	Phase 2/Phase 3	170 participants (Actual)	Interventional	2020-01-01	Completed
Computer-basierte Dosierungsregime Von Antiinfektiva Bei eingeschränkter Nierenfunktion Und Kontinuierlichen Nierenersatztherapieverfahren (Computer-based Dosage Calculation for Antibiotics in Patients With Impaired Renal Function or Renal Replacement The [NCT03036826]		0 participants (Actual)	Observational	2019-06-30	Withdrawn(stopped due to due to organisational changes)
Efficacy of Extended Infusion of β-lactam Antibiotics for the Treatment of Febrile Neutropenia in Haematologic Patients: a Randomised, Multicentre, Open-label, Superiority Clinical Trial (BEATLE) [NCT04233996]	Phase 4	150 participants (Anticipated)	Interventional	2019-06-05	Recruiting
Model-based Dose Versus Empirical Dose of Piperacillin/Tazobactam in the Treatment of Late-onset Sepsis in Preterm Neonates: a Multicentre, Randomised, Open-label, Non-inferiority Study. [NCT05981079]	Phase 4	332 participants (Anticipated)	Interventional	2023-07-31	Recruiting
Randomized Control Trial: Two Different Antibiotics Versus One Antibiotic for Pediatric Perforated Appendicitis [NCT03289351]	Phase 4	162 participants (Actual)	Interventional	2017-05-22	Active, not recruiting
Therapeutic Drug Monitoring and Continuous Infusion of Beta-lactam Antibiotics in Patients With Bacteraemia [NCT03108690]	Phase 4	0 participants (Actual)	Interventional	2017-10-01	Withdrawn(stopped due to Logistics)
Piperacillin/Tazobactam Versus Carbapenems in Non-bacteremic Urinary Tract Infections Due to Extended-spectrum β-lactamase (ESBL)-Producing Escherichia Coli or Klebsiella Pneumoniae - (CAPITIS Study) [NCT03891433]	Phase 4	198 participants (Anticipated)	Interventional	2019-04-01	Recruiting
Efficacy and Safety of Antibiotics in the Treatment of Early Onset Neonatal Sepsis [NCT03932123]		500 participants (Anticipated)	Observational	2019-05-05	Recruiting
Randomized Phase II Trial of Total Gut Decontamination Followed by Fecal Microbiota Transplant (FMT), FMT-Alone or Standard of Care for Reduction in Acute Graft-Versus-Host Disease of the Gastrointestinal Tract in Patients Given Broad-Spectrum Antibiotics [NCT03862079]	Phase 2	0 participants (Actual)	Interventional	2020-06-01	Withdrawn(stopped due to Per PI's request)
Monitoring of Ceftolozane-Tazobactam Plasmatic Levels in Critical Patients [NCT04257812]		20 participants (Anticipated)	Observational	2020-02-15	Not yet recruiting
A Multicentre, Parallel Group Open-label Randomised Controlled Non-Inferiority Phase 3 Trial, of Ceftolozane-tazobactam Versus Meropenem for Definitive Treatment of Bloodstream Infection Due to Extended-Spectrum Beta-Lactamase (ESBL) and AmpC-producing En [NCT04238390]	Phase 3	0 participants (Actual)	Interventional	2022-01-31	Withdrawn(stopped due to The decision to withdraw the study was made due to delayed logistics of the supply chain of ceftolozane-tazobactam along with the immense complexities of conducting clinical research felt because of the COVID-19 pandemic.)
Comparing Oral Versus Parenteral Antimicrobial Therapy (COPAT) Trial [NCT05977868]	Phase 4	135 participants (Anticipated)	Interventional	2023-08-04	Enrolling by invitation
Beta-lactam Continuous Versus Intermittent Infusion and Associated Bacterial Resistance and Therapy Outcomes in Critically Ill Patients With Severe Pneumonia [NCT05102162]	Phase 4	35 participants (Actual)	Interventional	2021-12-17	Terminated(stopped due to Low recruitment.)
Pharmacokinetics of Piperacillin and Tazobactam in Critically Ill Patients - Finding the Best Predictor for Piperacillin-tazobactam Clearance [NCT03738683]		40 participants (Actual)	Observational	2019-02-01	Completed
A Double-Blind, Double-Dummy, Randomized, Moxifloxacin and Placebo Controlled, Four-Way Crossover Study of the Effects of a Single Intravenous Supra-Therapeutic Dose and Single Intravenous Therapeutic Dose of CXA-101/Tazobactam on the QT/QTC Intervals in [NCT02508753]	Phase 1	52 participants (Actual)	Interventional	2010-06-30	Completed
A Multicenter, Open-label, Noncomparative, Japanese Phase III Study to Assess the Efficacy and Safety of Ceftolozane/Tazobactam (MK-7625A) in Japanese Patients With Uncomplicated Pyelonephritis and Complicated Urinary Tract Infection [NCT02728089]	Phase 3	115 participants (Actual)	Interventional	2016-04-14	Completed
Target Attainment and Pharmacokinetics of Antimicrobials in Non-critically Ill Surgery Patients [NCT03120663]		120 participants (Anticipated)	Observational	2016-11-30	Recruiting
First Dose Pharmacokinetics for Piperacillin and Meropenem in ICU Patients [NCT05134298]		50 participants (Anticipated)	Observational	2019-11-01	Recruiting
Prospective Unblinded Randomized Trial to Examine Short vs Prolonged Antibiotic Treatment for Hospitalized Hemato-oncology Patients With Febrile Neutropenia [NCT02463747]	Phase 4	110 participants (Anticipated)	Interventional	2015-06-30	Not yet recruiting
A Multi-centre Study to Define Novel Individualised Dosing Regimens to Maximise Antibiotic Effectiveness for Treatment of Pneumonia in Intensive Care Units [NCT04986254]		80 participants (Anticipated)	Observational	2019-10-17	Recruiting
A Phase III Multicenter, Open Label Randomized Controlled Trial of Cefoxitin Versus Piperacillin-Tazobactam as Surgical Antibiotic Prophylaxis in Patients Undergoing Pancreatoduodenectomy [NCT03269994]	Phase 3	962 participants (Actual)	Interventional	2017-11-21	Active, not recruiting
Antibiotic Dosing in Pediatric Intensive Care [NCT02456974]		640 participants (Anticipated)	Observational [Patient Registry]	2012-05-31	Recruiting
A Pilot Study of Ceftolozane-Tazobactam in Conjunction With Rapid Molecular Diagnosis for Directed Treatment of Pseudomonas Aeruginosa Bacteremia and Pneumonia in Patients With Hematological Malignancies and Hematopoietic Stem Cell Transplantation [NCT04673175]	Phase 1/Phase 2	20 participants (Anticipated)	Interventional	2022-07-20	Recruiting
"Antibioprophylaxis for Excision-graft Surgery in Burn Patient: a Multicenter Randomized Double-blind Study: A2B Trial" [NCT04292054]	Phase 3	506 participants (Anticipated)	Interventional	2020-10-11	Recruiting
Early Versus Late Stopping of Antibiotics in Children With Cancer and High-risk Febrile Neutropenia [NCT04948463]	Phase 4	312 participants (Anticipated)	Interventional	2021-11-15	Recruiting
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia [NCT02735707]	Phase 3	10,000 participants (Anticipated)	Interventional	2016-04-11	Recruiting
A Multicenter, Open-label, Noncomparative, Japanese Phase III Study to Assess the Efficacy and Safety of Ceftolozane/Tazobactam (MK-7625A) Used in Combination With Metronidazole in Japanese Patients With Complicated Intra-abdominal Infection. [NCT02739997]	Phase 3	100 participants (Actual)	Interventional	2016-04-08	Completed
Population Pharmacokinetics and Pharmacodynamics Study of Piperacillin/Tazobactam During Early Phase in Critically Ill Patients With Severe Sepsis [NCT02730624]	Phase 4	50 participants (Actual)	Interventional	2014-03-31	Completed
Procalcitonin as a Marker of Antibiotic Therapy in Patients With Lower Respiratory Tract Infections. Can Measurement of Procalcitonin Reduce the Use of Antibiotics? [NCT02171338]	Phase 4	55 participants (Anticipated)	Interventional	2013-10-31	Active, not recruiting
Piperacllin Versus Placebo in Patients Undergoing Surgery for Acute Cholecystitis [NCT02619149]	Phase 3	100 participants (Actual)	Interventional	2009-03-31	Completed
Antibiotic Pharmacokinetics in Critically Ill Patients [NCT02609646]		1,500 participants (Actual)	Observational	2016-01-31	Completed
Samu Save Sepsis: Early Goal Directed Therapy in Pre Hospital Care of Patients With Severe Sepsis and/or Septic Shock [NCT02473263]	Phase 3	398 participants (Actual)	Interventional	2016-05-09	Completed
Prospective Study Evaluating Plasma Exposure of Optimized Antibiotic Therapy According to TDM in Patients With Subarachnoid Haemorrhage (ES) and Cerebral Haemorrhage (EC) [NCT04132115]		104 participants (Anticipated)	Observational	2019-10-01	Recruiting
A Comparison of Standard Vs Renal Dosing of Piperacillin/Tazobactam in Acute Renal Failure and Septic Shock [NCT00816790]	Phase 4	20 participants (Anticipated)	Interventional	2009-01-31	Terminated(stopped due to Study stopped because of study personel movement to another institution.)
Monitoring of Piperacillin-Tazobactam and Meropenem Plasmatic Levels in Critical Patients [NCT04257838]		200 participants (Anticipated)	Observational	2020-02-15	Not yet recruiting
Validation of Uncertainty Quantifying Machine Learning Models to Predict Beta-lactam Antimicrobial Concentrations in ICU Patients [NCT06026852]		600 participants (Anticipated)	Interventional	2023-12-20	Not yet recruiting
A Prospective, Randomized, Double Dummy, Double Blind, Multinational, Multicenter Trial Comparing the Safety and Efficacy of Sequential (Intravenous/Oral) Moxifloxacin 400 mg OD to Intravenous Piperacillin/Tazobactam 4.0/0.5 g Every 8 Hours Followed by Or [NCT00402727]	Phase 3	813 participants (Actual)	Interventional	2006-09-30	Completed
A Single-Dose Pharmacokinetics Study of Tapimycin Injection(Piperacillin 4 g + Tazobactam 0.5 g Powder for Injection) Administered Under Fasting Conditions to Healthy Adult Subjects [NCT00924742]		12 participants (Actual)	Interventional	2009-03-31	Completed
Population Pharmacokinetics and Dosage Individualization of Biapenem,Meropenem,Piperacillin and Tazobactam,Tigecycline,Levofloxacin .Etc in Elderly Patients Who Was Hospitalized in Intensive Care Unit [NCT04799626]		500 participants (Anticipated)	Observational [Patient Registry]	2021-04-01	Recruiting
[NCT02709382]	Phase 1	48 participants (Actual)	Interventional	2016-03-31	Completed
Low Doses of Lung Radiation Therapy in Cases of COVID-19 Pneumonia: Prospective Multicentric Study in Radiation Oncology Centers [NCT04394182]		15 participants (Anticipated)	Interventional	2020-04-21	Suspended(stopped due to lack of recruitment)
Pharmacokinetics and Pharmacodynamic (PK/PD) of Extended-infusion Meropenem, Piperacillin-tazobactam and Cefepime in the Early Phase of Septic Shock [NCT02820987]	Phase 3	129 participants (Anticipated)	Interventional	2016-09-01	Recruiting
Randomized, Multicenter, Phase III, Controlled Clinical Trial, to Demonstrate the no Inferiority of Reduced Antibiotic Treatment vs a Broad Spectrum Betalactam Antipseudomonal Treatment in Patients With Bacteremia by Enterobacteriaceae [NCT02795949]	Phase 3	344 participants (Actual)	Interventional	2016-10-31	Completed
Pharmacokinetics of Piperacillin and Tazobactam in Anuric Septic Patients Treated by Continuous Veno Venous Hemodiafiltration [NCT00703144]	Phase 4	10 participants (Actual)	Interventional	2008-06-30	Completed
Antibiotic Treatment in Ventilator Associated Tracheobronchitis (VAT): A Randomized, Controlled Trial [NCT01027832]	Phase 2/Phase 3	100 participants (Anticipated)	Interventional	2009-09-30	Recruiting
Effects on the Emergence and Transmission of Vancomycin-Resistant Enterococci After Changes in Antibiotic Use in a Hematology Unit. [NCT00167960]		1,500 participants	Observational	2005-01-31	Completed
A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Piperacillin/Tazobactam in Subjects With Hospital-Acquired Bacterial Pne [NCT02493764]	Phase 3	537 participants (Actual)	Interventional	2015-11-24	Completed
Targeted AntiBiotics for Chronic Pulmonary Disease: Can Targeted Antibiotic Therapy Improve the Prognosis of Pseudomonas Aeruginosa Infected Patients With Chronic Pulmonary Obstructive Disease, Non-cystic Fibrosis Bronchiectasis and Asthma? A Multicenter, [NCT03262142]	Phase 4	51 participants (Actual)	Interventional	2018-01-10	Terminated(stopped due to Slow recruitment)
A Multicenter, Double-Blind, Randomized, Phase 2 Study to Compare the Safety and Efficacy of Intravenous CXA 101/ Tazobactam and Metronidazole With That of Meropenem in Complicated Intraabdominal Infections [NCT01147640]	Phase 2	122 participants (Actual)	Interventional	2010-06-25	Completed
Piperacillin Tazobactam Versus Meropenem for Treatment of Bloodstream Infections Caused by Cephalosporin-resistant Enterobacteriaceae- a Non-inferiority Randomized Controlled Trial [NCT03671967]	Phase 4	1,084 participants (Anticipated)	Interventional	2019-05-01	Recruiting
An Investigator Initiated, Phase IV Single-Center, Randomized, Open-Label, Prospective Study to Determine the Impact of Serial Procalcitonin on Improving Antimicrobial Stewardship and on the Efficacy, Safety, and Tolerability of Imipenem - Relebactam Plus [NCT04983901]	Phase 2	100 participants (Actual)	Interventional	2021-09-14	Active, not recruiting
Effects of Piperacillin-Tazobactam Use on the Prevalence Rate of Extended-Spectrum Beta-Lactamase (ESBL) Producing Escherichia Coli and Klebsiella Pneumoniae in Hematology and Oncology Units. [NCT00167999]		200 participants	Observational	2005-02-28	Completed
Empirical Meropenem Versus Piperacillin/Tazobactam for Adult Patients With Sepsis (EMPRESS) Trial [NCT06184659]	Phase 4	5,800 participants (Anticipated)	Interventional	2024-03-01	Not yet recruiting
Appropriate Antimicrobial Therapy in Critical Care: A Pilot Randomized Controlled Trial [NCT00438269]	Phase 2	80 participants	Interventional	2003-02-28	Completed
Association of Antibiotic Utilization Measures and Control of Extended-Spectrum β-Lactamases (ESBLs) Producing Bacteria [NCT00488189]	Phase 4	134 participants (Actual)	Interventional	2007-05-31	Completed
Antimicrobial Pharmacokinetics in High Risk Infants (Urinary Proteomics in Antimicrobial/Antifungal-Treated Newborns - add-on Study) [NCT00491426]		450 participants (Actual)	Observational	2006-01-31	Completed
A Phase 1, Open-label, Non-comparative, Multicenter Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Ceftolozane/Tazobactam (MK-7625A) in Pediatric Participants With Nosocomial Pneumonia [NCT04223752]	Phase 1	40 participants (Anticipated)	Interventional	2020-04-17	Recruiting
Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care [NCT01431326]		3,520 participants (Actual)	Observational	2011-11-30	Completed
Antibiotic Plasma Concentrations During Continuous Renal Replacement Therapy With a High Adsorption Membrane (oXiris®) [NCT04033029]		20 participants (Actual)	Observational	2021-01-01	Completed
Pharmacokinetics and Safety of Piperacillin-tazobactam in Neonates [NCT00873327]	Phase 1	32 participants (Actual)	Interventional	2009-10-31	Completed
Comparison of Medical and Surgical Treatment of Uncomplicated Acute Appendicitis in Children [NCT02991937]	Phase 4	39 participants (Actual)	Interventional	2016-12-31	Completed
Antimicrobial Therapy for Ventilator-associated Pneumonia Among Patients Colonized With Extended-spectrum Beta-lactamase-producing Enterobacteriaceae : Efficacy of a Strategy Using Piperacillin-tazobactam as Empirical Treatment. [NCT04276480]		30 participants (Anticipated)	Interventional	2022-02-16	Recruiting
Observed Pharmacokinetic of Piperacillin/Tazobactam in ICU Patients Compared to Therapeutic Drug Monitoring of Amikacin [NCT03990467]		60 participants (Anticipated)	Interventional	2021-01-28	Recruiting
eXtended Antibiotic Prophylaxis for Intermediate- and High-risk Glands After Pancreatoduodenectomy to Reduce Clinically Relevant PostOperative Pancreatic Fistula: A Phase 2 Randomized Control Trial (X-POPF) [NCT05753735]	Phase 2	96 participants (Anticipated)	Interventional	2023-12-20	Recruiting
Monotherapy With Piperacillin-tazobactam Versus Combination Therapy With Piperacillin-tazobactam Plus Glycopeptide as an Initial Empiric Therapy for Fever in Neutropenic Patients. An Observational Prospective Study. [NCT00195533]		801 participants (Actual)	Observational	2001-07-31	Completed
Antibiotic Concentrations in Serum and Epithelial Lining Fluid Under Continous Infusion [NCT00435305]		40 participants (Anticipated)	Observational	2006-11-30	Terminated(stopped due to difficulties by enrolling patients fundings consumed, no staff could be recruited and payed to continue enrolling patients,)
Pharmacokinetic of Doripenem and Piperacillin/Tazobactam in More Than 120 kg Critically Ill Patients [NCT01517815]		50 participants (Actual)	Interventional	2012-02-29	Completed
An Open-label, Randomized Study Comparing the Efficacy and Safety of Piperacillin/Tazobactam and Ampicillin/Sulbactam Administered Intravenously in the Empirical Treatment of Foot Infections in Diabetic Inpatients [NCT00044746]	Phase 4	314 participants (Actual)	Interventional	2000-10-31	Completed
A Prospective, Multicenter, Double-Blind With In-House Blinding, Randomized, Comparative Study to Evaluate the Efficacy, Safety, and Tolerability of Ertapenem Sodium Versus Piperacillin/Tazobactam in the Treatment of Complicated Intra-Abdominal Infections [NCT00389987]	Phase 3	300 participants	Interventional	2001-09-30	Completed
A Randomized, Open-Label, Multi-Center, Comparative Study of the Efficacy and Safety of Piperacillin/Tazobactam to Cefepime for the Empiric Treatment of Neutropenic Fever in Patients With a Hematologic Malignancy or Lymphoma [NCT00044759]	Phase 3	0 participants	Interventional		Completed
Standard vs. Biofilm Susceptibility Testing in CF [NCT00153634]		75 participants (Actual)	Interventional	2004-03-31	Completed
Randomized, Open-label, Comparative Study of Zosyn (Pip/Tazo [12g/1.5g]) Administered by Daily 24hr Continuous Infusion vs Zosyn (Pip/Tazo) [3g/0.375g]) q6h for the Treatment of Hospitalized Patients With Complicated Intra-abdominal Infection [NCT00044928]	Phase 4	262 participants (Actual)	Interventional	2002-07-31	Completed
Study of the Safety and Efficacy of Piperacillin/Tazobactam in the Treatment of Patients With Complicated Urinary Infections. [NCT00195286]		180 participants (Actual)	Observational	2004-06-30	Completed
Optimized Treatment for Uncomplicated Acute Appendicitis; Active Observation With or Without Antibiotic Treatment [NCT03985514]	Phase 4	126 participants (Actual)	Interventional	2018-05-15	Completed
[NCT02620774]	Phase 1	16 participants (Actual)	Interventional	2016-02-19	Completed
A Prospective, Multicenter, Double-Blind With In-House Blinding, Randomized, Comparative Study to Evaluate the Efficacy, Safety, and Tolerability, of Ertapenem Versus Piperacillin/Tazobactam in the Treatment of Diabetic Foot Infections in Adults. [NCT00229112]	Phase 3	400 participants	Interventional	2001-04-30	Completed
An Open-Label, Multicenter, Multinational, Centrally Randomized, Two-Arm Parallel-Group Study to Demonstrate the Non-Inferiority in Clinical Efficacy of Levofloxacin 750mg od in Comparison With Piperacillin/Tazobactam 4g/500mg Every 8 Hours in the Treatme [NCT00253955]	Phase 3	460 participants (Actual)	Interventional	2003-06-30	Completed
Ceftolozane-tazobactam for the Treatment of Respiratory Infections Due to Extensively Drug-resistant Pseudomonas Aeruginosa Among Critically Ill Patients: a Retrospective Study. [NCT04352855]		55 participants (Actual)	Observational	2018-01-18	Active, not recruiting
Continuous-infusion Anti-pseudomonal β-lactams for the Treatment of Acute, Infective Pulmonary Exacerbations in Cystic Fibrosis [NCT01667094]	Phase 4	50 participants (Actual)	Interventional	2012-09-30	Active, not recruiting
Pharmacokinetics of Antibiotics During Extracorporeal Membrane Oxygenation (ECMO) Support [NCT03922451]		4 participants (Actual)	Observational	2019-08-27	Terminated(stopped due to COVID-19 - study and recruitment not feasible)
Nosocomial Infections in Patients With Acute Respiratory Distress Syndrome Treated With Extracorporeal Membrane Oxygenation [NCT05566665]		200 participants (Anticipated)	Observational	2023-01-01	Recruiting
Piperacillin-tazobactam and Temocillin as Carbapenem-alternatives for the Treatment of Severe Infections Due to Extended-spectrum Beta-lactamase-Producing Gram-negative Enterobacteriaceae in the Intensive Care Unit [NCT05565222]	Phase 3	600 participants (Anticipated)	Interventional	2023-03-11	Recruiting
Piperacillin/Tazobactam for Prophylaxis in Patients of Neutropenia After Hematopoietic Stem Cell Transplantation - A Pilot Study [NCT01714557]		150 participants (Anticipated)	Interventional	2012-09-30	Not yet recruiting
A Prospective, Randomized, Open Label Study of Piperacillin/Tazobactam Versus Imipenem/Cilastin for Empirical Therapy of Febrile Patients With Neutropenia After Hematopoietic Stem Cell Transplantation [NCT01714570]		123 participants (Actual)	Interventional	2012-11-30	Completed
A Phase 1, Open-label, Randomized, 2-period, Crossover Study to Assess the Effect of Intravenous Infusion of Piperacillin/Tazobactam on the Pharmacokinetics of Orally Administered Lumicitabine (JNJ-64041575) in Healthy Adult Subjects [NCT03441529]	Phase 1	18 participants (Actual)	Interventional	2018-02-09	Completed
Assessing the Longitudinal Outcomes of Piperacillin/Tazobactam Versus ceftriAxone and Metronidazole for Children With Perforated Appendicitis (ALPACA): a Randomized Controlled Trial [NCT05943223]	Phase 2	16 participants (Anticipated)	Interventional	2024-01-31	Not yet recruiting
Per Oral Versus Intravenous Postoperative Antibiotics After Surgery for Complicated Appendicitis: A Cluster Randomized Cluster Crossover Non-Inferiority Study. [NCT04803422]		2,631 participants (Anticipated)	Interventional	2021-05-01	Recruiting
A Prospective, Multicenter, Open-Label Study to Assess Population Pharmacokinetics and Safety of Intravenous Ceftolozane/Tazobactam in Adult Cystic Fibrosis Patients Admitted With Acute Pulmonary Exacerbation [NCT02421120]	Phase 4	21 participants (Actual)	Interventional	2015-09-30	Completed
Antibiotic Safety in Infants With Complicated Intra-Abdominal Infections (SCAMP Trial) [NCT01994993]	Phase 2/Phase 3	260 participants (Actual)	Interventional	2013-12-31	Completed
A Prospective Pharmacokinetic Evaluation of the Plasma and Cerebrospinal Fluid Concentrations of a Single Dose Ceftolozane/Tazobactam in Infected Critically Ill Patients With an Indwelling External Ventricular Drain [NCT03309657]	Phase 1/Phase 2	10 participants (Actual)	Interventional	2018-02-01	Completed
Pilot RCT of Meropenem Versus Piperacillin-Tazobactam for Definitive Treatment of Bloodstream Infections Caused by AmpC Beta-lactamase Producing Enterobacter Spp., Citrobacter Freundii, Morganella Morganii, Providencia Spp. or Serratia Marcescens. in Low- [NCT02437045]	Phase 4	100 participants (Anticipated)	Interventional	2015-04-30	Completed
A Prospective, Randomized, Double-Blind, Multicenter, Phase 3 Study to Assess the Safety and Efficacy of Intravenous Ceftolozane/Tazobactam Compared With Meropenem in Adult Patients With Ventilated Nosocomial Pneumonia [NCT02070757]	Phase 3	726 participants (Actual)	Interventional	2014-09-02	Completed
A Phase 3, Multicenter, Double-blind, Randomized, Active-controlled Clinical Study to Evaluate the Efficacy and Safety of Ceftolozane/Tazobactam (MK-7625A) Plus Metronidazole Versus Meropenem in Chinese Participants With Complicated Intra-abdominal Infect [NCT03830333]	Phase 3	268 participants (Actual)	Interventional	2019-03-20	Completed
Safety and Pharmacokinetics of Piperacillin-Tazobactam Extended Infusions in Infants and Children [NCT02466438]	Phase 1	141 participants (Anticipated)	Interventional	2016-01-31	Recruiting
TAID Study - A Prospective Interventional Trial on Antibiotics Continuous Infusion at Home [NCT04816968]	Phase 1	50 participants (Anticipated)	Interventional	2021-09-30	Not yet recruiting
Pharmacokinetics of Ceftolozane/Tazobactam in Patients With Burns [NCT03002506]	Phase 4	6 participants (Actual)	Interventional	2017-08-21	Terminated(stopped due to Much slower recruitment than anticipated)
Efficacy and Safety of Piperacillin-Tazobactam Continuous Infusion vs Intermittent Infusion for Complicated or Nosocomial Pseudomonas Aeruginosa Infection or Suspected Infection [NCT01577368]	Phase 3	76 participants (Actual)	Interventional	2011-05-31	Completed
Vancomycin Versus Placebo in Persistently Febrile Granulocytopenic Patients Given Piperacillin/Tazobactam [NCT00003805]	Phase 3	859 participants (Actual)	Interventional	1997-11-30	Completed
Phase III, Randomized, Double-Blind, Study Evaluating Efficacy/Safety/Tolerability of Meropenem-Vaborbactam Compared to Piperacillin/Tazobactam in Adult Patients With Complicated Urinary Tract Infections, Including Acute Pyelonephritis [NCT02166476]	Phase 3	550 participants (Actual)	Interventional	2014-11-20	Completed
CEFtolozane-Tazobactam for the Empiric Anti-bacterial Treatment of Neutropenic Fever in Hematology Patients; a Single-arm, Single-center, Open-label Clinical Trial (CEF-10 Study) [NCT05061654]	Phase 4	0 participants (Actual)	Interventional	2022-08-31	Withdrawn(stopped due to Administrative constraints)
Population Pharmacokinetic Modeling to Optimize the Dosage of the Piperacillin / Tazobactam Combination in Patients With Sepsis in Intensive Care [NCT03748095]		90 participants (Anticipated)	Observational	2019-03-12	Recruiting
Amplification and Selection of Antimicrobial Resistance in the Intestine II [NCT03140826]		60 participants (Actual)	Observational	2018-01-30	Completed
Postoperative Anti-infective Strategy Following Pancreaticoduodenectomy in Patients With Preoperative Biliary Stent [NCT06123169]	Phase 3	326 participants (Anticipated)	Interventional	2024-03-31	Not yet recruiting
In Vitro Activity of Ceftolozane/Tazobactam and Imipenem/Relebactam in Clinical Isolates of Pseudomonas Aeruginosa and Enterobacterales Collected From Hematology and Oncology Patients [NCT04196608]		1,005 participants (Anticipated)	Observational	2019-11-01	Recruiting
Clinical and Microbiological Effects of Local and Systemic Antimicrobials as an Adjunctive Therapy in Periodontitis Stages 2 and 3 [NCT05608564]		40 participants (Actual)	Interventional	2022-01-17	Active, not recruiting
A Phase 1, Non-comparative, Open-label Study to Characterize the Pharmacokinetics of a Single Intravenous Dose of Ceftolozane/Tazobactam in Pediatric Patients Receiving Standard of Care Antibiotic Therapy for Proven or Suspected Gram-negative Infection or [NCT02266706]	Phase 1	43 participants (Actual)	Interventional	2014-09-17	Completed
Extended-infusion Piperacillin-Tazobactam Versus Intermittent-Infusion Dosing Strategy in Critically Ill Patients With Suspected or Confirmed Bacterial Infections. [NCT04895657]	Phase 4	56 participants (Actual)	Interventional	2018-07-27	Completed
Phase Ⅱ, Randomized, Double-Blind,Double-Dummy Study Evaluating Safety,Tolerability,Efficacy of Meropenem-FL058 in Adult Patients With Complicated Urinary Tract Infections, Including Acute Pyelonephritis [NCT05060419]	Phase 2	150 participants (Anticipated)	Interventional	2021-10-08	Not yet recruiting
A Multicenter, Open-Label, Randomized Study to Compare the Safety and Efficacy of Intravenous Ceftolozane/Tazobactam With That of Piperacillin/Tazobactam in Ventilator Associated Pneumonia [NCT01853982]	Phase 3	4 participants (Actual)	Interventional	2013-06-14	Terminated(stopped due to Terminated to focus on a larger study within the clinical development program.)
A Phase IIIb, Multicenter, Double-Blind, Randomized, Comparative Study to Evaluate the Efficacy, Safety, and Tolerability of Meropenem-Vaborbactam Versus Piperacillin/Tazobactam in the Treatment of Hospital-Acquired Bacterial Pneumonia and Ventilator-Asso [NCT03006679]	Phase 3	0 participants (Actual)	Interventional	2018-08-31	Withdrawn(stopped due to Sponsor Decision)
PipEracillin/Tazobactam vs mERoPENem for Treatment of AmpC-producing Bloodstream Infections: an Extension of the Original PETERPEN Trial [NCT05355350]	Phase 4	1,000 participants (Anticipated)	Interventional	2022-07-01	Recruiting
A Phase 1, Prospective, Multi-center, Open-label Study to Assess the Plasma Pharmacokinetics and Lung Penetration of Intravenous (IV) Ceftolozane/Tazobactam in Critically Ill Patients [NCT02387372]	Phase 1	37 participants (Actual)	Interventional	2015-02-05	Completed
A Single-Center, Randomized, Open-label, Prospective, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime-Avibactam (CAZ-AVI) Plus Vancomycin or Linezolid Versus Standard of Care Plus Vancomycin or Linezolid as Empiric The [NCT02732327]	Phase 2	2 participants (Actual)	Interventional	2016-05-17	Terminated(stopped due to No longer aligned with the revised clinical development plan and commercial strategy)
A Single-center, Multi-arm, Open-label, Randomized, 3-period, Crossover, Phase 1 Study to Evaluate the DDI, PK, Safety, and Tolerability of Single Doses of SPR741 Co-administered With Three Different Antibiotics in Healthy Volunteers [NCT03376529]	Phase 1	27 participants (Actual)	Interventional	2017-11-10	Completed
Population Pharmacokinetic of Piperacillin/Tazobactam in Maternal and Neonatal Populations With High Risk for EOS [NCT06076200]		50 participants (Anticipated)	Observational	2023-09-30	Recruiting
Pharmacokinetics and Pharmacodynamics of High-Dose Piperacillin/Tazobactam in Obese Patients [NCT01923363]		29 participants (Actual)	Interventional	2014-02-25	Completed
Efficacy of Oral Antibiotic Therapy Compared to Intravenous Antibiotic Therapy for the Treatment of Diabetic Foot Osteomyelitis (CRO-OSTEOMYELITIS) [NCT02168816]	Phase 2	30 participants (Actual)	Interventional	2014-03-19	Terminated(stopped due to The study was stopped for feasibility (i.e., low recruitment))
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00402727 (12) [back to overview]	Percentage of Participants Assessed as Improvements by the Data Review Committee (DRC) at the During Treatment Day 3-5 in the Intent to Treat (ITT) Population
NCT00402727 (12) [back to overview]	Percentage of Participants Assessed as Resolution by the Data Review Committee (DRC) at End of Therapy in the Per Protocol (PP) Population
NCT00402727 (12) [back to overview]	Percentage of Participants With Bacteriological Success (BS) After 14 - 28 Days After Last Dose of Study Medication in the ITT Population With Causative Organisms
NCT00402727 (12) [back to overview]	Percentage of Participants With Bacteriological Success (BS) After 14 - 28 Days After Last Dose of Study Medication in the Microbiological Valid (MBV) Population
NCT00402727 (12) [back to overview]	Percentage of Participants With Bacteriological Success (BS) After 7 - 21 Days of Treatment in the ITT Population With Causative Organisms
NCT00402727 (12) [back to overview]	Percentage of Participants With Bacteriological Success (BS) After 7 - 21 Days of Treatment in the Microbiological Valid (MBV) Population
NCT00402727 (12) [back to overview]	Percentage of Participants With Bacteriological Success (BS) at 3 to 5 Days After Start of Treatment in the ITT Population With Causative Organisms
NCT00402727 (12) [back to overview]	Percentage of Participants With Bacteriological Success (BS) at 3 to 5 Days After Start of Treatment in the Microbiological Valid (MBV) Population
NCT00402727 (12) [back to overview]	Percentage of Participants Assessed as Resolution by the Data Review Committee (DRC) at End of Therapy in the Intent to Treat (ITT) Population
NCT00402727 (12) [back to overview]	Percentage of Participants Assessed as Improvements by the Data Review Committee (DRC) at the During Treatment Day 3-5 in the Per Protocol (PP) Population
NCT00402727 (12) [back to overview]	Percentage of Cured Participants as Determined by the Data Review Committee (DRC) at Test of Cure Visit in the Per Protocol (PP) Population
NCT00402727 (12) [back to overview]	Percentage of Cured Participants as Determined by the Data Review Committee (DRC) at Test of Cure Visit in the Intent to Treat (ITT) Population
NCT00873327 (1) [back to overview]	Piperacillin Pharmacokinetics (PK)
NCT01147640 (2) [back to overview]	Clinical Response of CXA 101/Tazobactam and Metronidazole at Test of Cure (TOC) Visit in the Microbiological Modified Intent to Treat (mMITT) Analysis Population
NCT01147640 (2) [back to overview]	Microbiological Response of CXA 101/Tazobactam and Metronidazole at the TOC Visit in the Microbiologically Evaluable (ME) Population
NCT01370616 (9) [back to overview]	Percentage of Participants With Favorable Microbiological Response Assessments at FUA Day 10 of Post-antibiotic Study Therapy
NCT01370616 (9) [back to overview]	Percentage of Participants With Favorable Clinical Response Assessments at Follow-up Assessment (FUA) Day 10 of Post-antibiotic Study Therapy
NCT01370616 (9) [back to overview]	Percentage of Participants With Serious AEs (SAEs)
NCT01370616 (9) [back to overview]	Percentage of Participants With One or More Adverse Events (AEs)
NCT01370616 (9) [back to overview]	Percentage of Participants Who Discontinued Treatment Due to an AE
NCT01370616 (9) [back to overview]	Percentage of Participants With Both Favorable Clinical and Microbiological Response Assessments at FUA Day 10 of Post-antibiotic Study Therapy
NCT01370616 (9) [back to overview]	Percentage of Participants With Drug-related AEs
NCT01370616 (9) [back to overview]	Percentage of Participants With Favorable Clinical Response Assessments at Day 5 of IV Study Therapy
NCT01370616 (9) [back to overview]	Percentage of Participants With Favorable Clinical Response Assessments at Discontinuation of Intravenous (IV) Study Therapy (DCIV)
NCT01923363 (4) [back to overview]	Half-life of Piperacillin
NCT01923363 (4) [back to overview]	Volume of Distribution of Piperacillin
NCT01923363 (4) [back to overview]	Serum Minimum Concentrations of Piperacillin
NCT01923363 (4) [back to overview]	Serum Maximum Concentrations for Piperacillin
NCT01994993 (11) [back to overview]	Number of Participants With Feeding Intolerance
NCT01994993 (11) [back to overview]	Number of Participants With Therapeutic Success at Day 30
NCT01994993 (11) [back to overview]	Number of Participants With Short Bowel Syndrome
NCT01994993 (11) [back to overview]	Number of Participants With Seizure
NCT01994993 (11) [back to overview]	Number of Participants With Positive Blood Cultures
NCT01994993 (11) [back to overview]	Number of Participants With Intestinal Stricture
NCT01994993 (11) [back to overview]	Number of Participants With Intestinal Perforation
NCT01994993 (11) [back to overview]	Number of Participants With Grade 3 and/or Grade 4 Intraventricular Hemorrhage (IVH)
NCT01994993 (11) [back to overview]	Death
NCT01994993 (11) [back to overview]	Number of Participants Progressed to a Higher Stage of Necrotizing Enterocolitis (NEC), if NEC is the Cause of the Complicated Intra-abdominal Infection
NCT01994993 (11) [back to overview]	Number of Participants With Gastrointestinal Surgeries
NCT02070757 (13) [back to overview]	Percentage of Participants With All Cause Mortality in the Microbiological Intent-to-Treat (mITT) Population - Day 28
NCT02070757 (13) [back to overview]	Percentage of Participants With All Cause Mortality in the Intent-to-Treat (ITT) Population - Day 28
NCT02070757 (13) [back to overview]	Percentage of Participants Who Report 1 or More Adverse Event (AE)
NCT02070757 (13) [back to overview]	Percentage of Participants Discontinuing Study Drug Due to an Adverse Event (AE)
NCT02070757 (13) [back to overview]	Percentage of Participants With Any Serious Adverse Event (SAE)
NCT02070757 (13) [back to overview]	Percentage of Participants With Microbiological Response of Eradication or Presumed Eradication, by Pathogen, at the Test-of-Cure (TOC) Visit in the Microbiologically Evaluable (ME) Population (>=10 Isolates at Baseline)
NCT02070757 (13) [back to overview]	Percentage of Participants With Per-Participant Microbiological Response of Cure or Presumed Cure at the Test-of-Cure (TOC) Visit in the Microbiologically Evaluable (ME) Population
NCT02070757 (13) [back to overview]	Percentage of Participants With Per-Participant Microbiological Response of Cure or Presumed Cure at the End-of-Therapy (EOT) Visit in the Microbiologically Evaluable (ME) Population
NCT02070757 (13) [back to overview]	Percentage of Participants With Clinical Response of Clinical Cure at the Test-of-Cure (TOC) Visit in the Intent-to-Treat (ITT) Population
NCT02070757 (13) [back to overview]	Percentage of Participants With Clinical Response of Clinical Cure at the Test-of-Cure (TOC) Visit in the Clinically Evaluable (CE) Population
NCT02070757 (13) [back to overview]	Percentage of Participants With Clinical Response of Clinical Cure at the Late Follow-up (LFU) Visit in the Clinically Evaluable (CE) Population
NCT02070757 (13) [back to overview]	Percentage of Participants With Clinical Response of Clinical Cure at the End-of-Therapy (EOT) Visit in the Intent-to-Treat (ITT) Population
NCT02070757 (13) [back to overview]	Percentage of Participants With All-Cause Mortality in the Intent-to-Treat (ITT) Population - Day 14
NCT02166476 (15) [back to overview]	Proportion Of Participants With A Clinical Outcome Of Cure In The Clinical Evaluable (CE) Population
NCT02166476 (15) [back to overview]	Proportion Of Participants With A Clinical Outcome Of Cure In The ME Population
NCT02166476 (15) [back to overview]	Per-Pathogen Microbiological Outcome (EMA) In The m-MITT Population
NCT02166476 (15) [back to overview]	Proportion Of Participants In The ME Population Who Achieved A Microbiologic Outcome Of Eradication
NCT02166476 (15) [back to overview]	Per-Pathogen Microbiological Outcome (EMA) In The ME Population
NCT02166476 (15) [back to overview]	Proportion Of Participants In The Microbiological Modified Intent-To-Treat (m-MITT) Population Who Achieved Overall Success At The End Of Intravenous Treatment Visit
NCT02166476 (15) [back to overview]	Proportion Of Participants In The Microbiological Evaluable (ME) Population Who Achieved A Microbiologic Outcome Of Eradication At The TOC Visit
NCT02166476 (15) [back to overview]	Proportion Of Participants With A Clinical Outcome Of Cure In The m-MITT Population
NCT02166476 (15) [back to overview]	Proportion Of Participants In The m-MITT Population Who Achieved A Microbiologic Outcome Of Eradication At The Test Of Cure Visit
NCT02166476 (15) [back to overview]	Per-Pathogen Microbiological Outcome (FDA) In The m-MITT Population
NCT02166476 (15) [back to overview]	Per-Pathogen Microbiological Outcome (FDA) In The ME Population
NCT02166476 (15) [back to overview]	Pharmacokinetic (PK) Characterization Of Plasma Exposure Of Meropenem/Vaborbactam
NCT02166476 (15) [back to overview]	Proportion Of Participants In The m-MITT Population Who Achieved A Microbiologic Outcome Of Eradication
NCT02166476 (15) [back to overview]	Proportion Of Participants In The m-MITT Population With Overall Success
NCT02166476 (15) [back to overview]	Proportion Of Participants In The ME Population With Overall Success
NCT02266706 (20) [back to overview]	Number of Participants Who Discontinued the Study Due to an Adverse Event
NCT02266706 (20) [back to overview]	Elimination Half-life (t1/2) of Ceftolozane
NCT02266706 (20) [back to overview]	Elimination Half-life (t1/2) of Tazobactam
NCT02266706 (20) [back to overview]	Maximum Plasma Concentration (Cmax) of Ceftolozane
NCT02266706 (20) [back to overview]	Plasma Concentration at the Last Quantifiable Concentration (Clast) of Tazobactam
NCT02266706 (20) [back to overview]	Time of Last Sampling Point (Tlast) of Ceftolozane
NCT02266706 (20) [back to overview]	Maximum Plasma Concentration (Cmax) of Tazobactam
NCT02266706 (20) [back to overview]	Number of Participants With One or More Adverse Events
NCT02266706 (20) [back to overview]	Plasma Clearance (CL) of Ceftolozane
NCT02266706 (20) [back to overview]	Plasma Clearance (CL) of Tazobactam
NCT02266706 (20) [back to overview]	Plasma Concentration at the Last Quantifiable Concentration (Clast) of Ceftolozane
NCT02266706 (20) [back to overview]	Time of Last Sampling Point (Tlast) of Tazobactam
NCT02266706 (20) [back to overview]	Time to Maximum Plasma Concentration (Tmax) of Ceftolozane
NCT02266706 (20) [back to overview]	Time to Maximum Plasma Concentration (Tmax) of Tazobactam
NCT02266706 (20) [back to overview]	Volume of Distribution at Steady State (Vss) of Ceftolozane
NCT02266706 (20) [back to overview]	Volume of Distribution at Steady State (Vss) of Tazobactam
NCT02266706 (20) [back to overview]	Area Under the Plasma Concentration-Time Curve (AUC0-inf) of Ceftolozane
NCT02266706 (20) [back to overview]	Area Under the Plasma Concentration-Time Curve (AUC0-inf) of Tazobactam
NCT02266706 (20) [back to overview]	Area Under the Plasma Concentration-Time Curve (AUClast) of Ceftolozane
NCT02266706 (20) [back to overview]	Area Under the Plasma Concentration-Time Curve (AUClast) of Tazobactam
NCT02387372 (20) [back to overview]	Terminal Elimination Half-life (t1/2) of Ceftolozane or Tazobactam in Mechanically Ventilated Participants for the First and Last Dose of Ceftolozane/Tazobactam Treatment.
NCT02387372 (20) [back to overview]	Plasma Clearance (CL) of Ceftolozane or Tazobactam in Mechanically Ventilated Participants for the First and Last Dose of Ceftolozane/Tazobactam Treatment.
NCT02387372 (20) [back to overview]	Maximum Plasma Concentration (Cmax) of Ceftolozane or Tazobactam in Mechanically Ventilated Participants for the First and Last Dose of Ceftolozane/Tazobactam Treatment.
NCT02387372 (20) [back to overview]	Last Quantifiable Plasma Concentration (Clast) of Ceftolozane or Tazobactam in Mechanically Ventilated Participants for the First and Last Dose of Ceftolozane/Tazobactam Treatment.
NCT02387372 (20) [back to overview]	Epithelial Lining Fluid (ELF) / Plasma Ratio (Intrapulmonary Penetration) of Ceftolozane and Tazobactam Concentrations in Mechanically Ventilated Participants.
NCT02387372 (20) [back to overview]	AUC From the Time of the Dose to Infinity (AUC0-∞) of Ceftolozane or Tazobactam in Mechanically Ventilated Participants for the First and Last Dose of Ceftolozane/Tazobactam Treatment.
NCT02387372 (20) [back to overview]	Vss of Ceftolozane/Tazobactam in Critically Ill Participants With Augmented Renal Function.
NCT02387372 (20) [back to overview]	Tmax of Ceftolozane/Tazobactam in Critically Ill Participants With Augmented Renal Function.
NCT02387372 (20) [back to overview]	Tlast of Ceftolozane/Tazobactam in Critically Ill Participants With Augmented Renal Function.
NCT02387372 (20) [back to overview]	T1/2 of Ceftolozane/Tazobactam in Critically Ill Participants With Augmented Renal Function.
NCT02387372 (20) [back to overview]	Number of Participants With Adverse Events (AEs)
NCT02387372 (20) [back to overview]	Cmax of Ceftolozane/Tazobactam in Critically Ill Participants With Augmented Renal Function.
NCT02387372 (20) [back to overview]	CL of Ceftolozane/Tazobactam in Critically Ill Participants With Augmented Renal Function.
NCT02387372 (20) [back to overview]	AUC0-last of Ceftolozane/Tazobactam in Critically Ill Participants With Augmented Renal Function.
NCT02387372 (20) [back to overview]	Area Under the Concentration Time Curve (AUC) From the First to Time of the Last Dose (AUC0-last) of Ceftolozane or Tazobactam in Mechanically Ventilated Participants for the First and Last Dose of Ceftolozane/Tazobactam Treatment.
NCT02387372 (20) [back to overview]	AUC0-∞ of Ceftolozane/Tazobactam in Critically Ill Participants With Augmented Renal Function.
NCT02387372 (20) [back to overview]	Time of Maximum Plasma Concentration (Tmax) of Ceftolozane or Tazobactam in Mechanically Ventilated Participants for the First and Last Dose of Ceftolozane/Tazobactam Treatment.
NCT02387372 (20) [back to overview]	Volume of Distribution at Steady State (Vss) of Ceftolozane or Tazobactam in Mechanically Ventilated Participants for the First and Last Dose of Ceftolozane/Tazobactam Treatment.
NCT02387372 (20) [back to overview]	Clast of Ceftolozane/Tazobactam in Critically Ill Participants With Augmented Renal Function.
NCT02387372 (20) [back to overview]	Time of Last Quantifiable Plasma Concentration (Tlast)) of Ceftolozane or Tazobactam in Mechanically Ventilated Participants for the First and Last Dose of Ceftolozane/Tazobactam Treatment.
NCT02421120 (5) [back to overview]	Ceftolozane Volume of Distribution (Central Compartment)
NCT02421120 (5) [back to overview]	Ceftolozane Probability of Target Attainment at 8 mcg/ml
NCT02421120 (5) [back to overview]	Ceftolozane Clearance
NCT02421120 (5) [back to overview]	Tazobactam Volume of Distribution (Central Compartment)
NCT02421120 (5) [back to overview]	Tazobactam Clearance
NCT02493764 (22) [back to overview]	Percentage of Participants in the CE Population With a FCR at OTX3 (Day 10)
NCT02493764 (22) [back to overview]	Percentage of Participants in the Clinically Evaluable (CE) Population With a FCR at On-therapy Visit 1 (OTX1) [Day 3]
NCT02493764 (22) [back to overview]	Percentage of Participants in the ME Population With a FMR at EFU Visit
NCT02493764 (22) [back to overview]	Percentage of Participants in the Microbiologically Evaluable (ME) Population With a FMR at EOT Visit
NCT02493764 (22) [back to overview]	Percentage of Participants in the MITT Population With a Favorable Clinical Response (FCR) at Early Follow-up (EFU) Visit
NCT02493764 (22) [back to overview]	Percentage of Participants in the MITT Population With a FCR at Day 28
NCT02493764 (22) [back to overview]	Percentage of Participants in the MITT Population With a FCR at EOT
NCT02493764 (22) [back to overview]	Percentage of Participants in the MITT Population With a FCR at OTX1 (Day 3)
NCT02493764 (22) [back to overview]	Percentage of Participants in the MITT Population With a FCR at OTX2 (Day 6)
NCT02493764 (22) [back to overview]	Percentage of Participants in the MITT Population With a FCR at OTX3 (Day 10)
NCT02493764 (22) [back to overview]	Percentage of Participants in the mMITT Population With a Favorable Microbiological Response (FMR) at End of Treatment (EOT) Visit
NCT02493764 (22) [back to overview]	Percentage of Participants in the mMITT Population With a FMR at EFU Visit
NCT02493764 (22) [back to overview]	Percentage of Participants With ≥1 Adverse Event (AE)
NCT02493764 (22) [back to overview]	Percentage of Participants With ACM at EFU in the MITT Population
NCT02493764 (22) [back to overview]	Percentage of Participants With ACM at EFU in the mMITT Population
NCT02493764 (22) [back to overview]	Percentage of Participants With ACM in the Microbiological Modified Intention-to-treat (mMITT) Population
NCT02493764 (22) [back to overview]	Percentage of Participants With All-cause Mortality (ACM) Through Day 28 in the Modified Intention-to-treat (MITT) Population
NCT02493764 (22) [back to overview]	Percentage of Participants Discontinuing Study Therapy Due to an AE
NCT02493764 (22) [back to overview]	Percentage of Participants in the CE Population With a FCR at Day 28
NCT02493764 (22) [back to overview]	Percentage of Participants in the CE Population With a FCR at EFU Visit
NCT02493764 (22) [back to overview]	Percentage of Participants in the CE Population With a FCR at EOT Visit
NCT02493764 (22) [back to overview]	Percentage of Participants in the CE Population With a FCR at OTX2 (Day 6)
NCT02620774 (7) [back to overview]	Tazobactam AUC in Tissue
NCT02620774 (7) [back to overview]	Ceftolozane Area Under the Curve (AUC) in Tissue
NCT02620774 (7) [back to overview]	Ceftolozane Tissue Penetration
NCT02620774 (7) [back to overview]	Ceftolozane Total Drug AUC in Plasma
NCT02620774 (7) [back to overview]	Number of Participants With Adverse Events
NCT02620774 (7) [back to overview]	Tazobactam Total Drug AUC in Plasma
NCT02620774 (7) [back to overview]	Tazobactam Tissue Penetration
NCT02728089 (12) [back to overview]	Percentage of Participants With Microbiological Response of Eradication, by Pathogen at EOT
NCT02728089 (12) [back to overview]	Percentage of Participants With Microbiological Response of Eradication at End Of Therapy (EOT)
NCT02728089 (12) [back to overview]	Percentage of Participants With Clinical Response of Clinical Cure at TOC
NCT02728089 (12) [back to overview]	Percentage of Participants With Clinical Response of Clinical Cure at LFU
NCT02728089 (12) [back to overview]	Percentage of Participants With Clinical Response of Clinical Cure at EOT
NCT02728089 (12) [back to overview]	Percentage of Participants Who Report 1 or More Adverse Event (AE)
NCT02728089 (12) [back to overview]	Percentage of Participants Discontinuing Study Drug Due to an AE
NCT02728089 (12) [back to overview]	Percentage of Participants With Microbiological Response of Eradication by Pathogen at TOC
NCT02728089 (12) [back to overview]	Percentage of Participants With Microbiological Response of Eradication by Pathogen at LFU
NCT02728089 (12) [back to overview]	Percentage of Participants With Microbiological Response of Eradication at Test of Cure (TOC)
NCT02728089 (12) [back to overview]	Percentage of Participants With Microbiological Response of Eradication at Late Follow-up (LFU)
NCT02728089 (12) [back to overview]	Percentage of Participants With a Composite Response of Both Eradication and Clinical Cure at TOC
NCT02739997 (9) [back to overview]	Percentage of Participants With Clinical Response (Clinical Cure, Clinical Failure, or Indeterminate) at Test of Cure (TOC)
NCT02739997 (9) [back to overview]	Percentage of Participants With Clinical Response (Clinical Cure, Clinical Failure, or Indeterminate) at Late Follow-Up (LFU)
NCT02739997 (9) [back to overview]	Percentage of Participants With Clinical Response (Clinical Cure, Clinical Failure, or Indeterminate) at End Of Therapy (EOT)
NCT02739997 (9) [back to overview]	Percentage of Participants With Adverse Events (AEs)
NCT02739997 (9) [back to overview]	Percentage of Participants Discontinuing Study Drug Due to AEs
NCT02739997 (9) [back to overview]	Percentage of Participants With Microbiological Response (Eradication, Persistence, or Indeterminate) at TOC
NCT02739997 (9) [back to overview]	Percentage of Participants With Microbiological Response (Eradication, Persistence, or Indeterminate) at EOT
NCT02739997 (9) [back to overview]	Percentage of Participants With Microbiological Response (Eradication, Persistence, or Indeterminate) by Pathogen at EOT
NCT02739997 (9) [back to overview]	Percentage of Participants With Microbiological Response (Eradication, Persistence, or Indeterminate) by Pathogen at TOC
NCT02753946 (3) [back to overview]	Number of Patients With a Response of Microbiologic Eradication
NCT02753946 (3) [back to overview]	Number of Patients With a Response of Clinical Cure in Various Protocol Populations
NCT02753946 (3) [back to overview]	Number of Patients With an Overall Success
NCT02991937 (3) [back to overview]	Readmission Rates
NCT02991937 (3) [back to overview]	Incidence of Long-term Complications in Medical Therapy Group
NCT02991937 (3) [back to overview]	Pediatric Quality of Life Inventory (PedsQL) Generic Core Scale - Parent
NCT03002506 (1) [back to overview]	Ceftolozane Clearnace
NCT03019965 (2) [back to overview]	Number of Participants With Adverse Events
NCT03019965 (2) [back to overview]	Number of Participants With Clinical Response
NCT03159754 (9) [back to overview]	Recurrent Appendicitis
NCT03159754 (9) [back to overview]	Number of Percutaneous Drainage Procedures
NCT03159754 (9) [back to overview]	Parents Away From Work
NCT03159754 (9) [back to overview]	Quality of Life (PedsQL)
NCT03159754 (9) [back to overview]	Quality of Life (PedsQL)
NCT03159754 (9) [back to overview]	Complications
NCT03159754 (9) [back to overview]	Duration of Antibiotic Therapy
NCT03159754 (9) [back to overview]	Length of Stay
NCT03159754 (9) [back to overview]	Number of Radiographic Imaging Studies
NCT03217136 (6) [back to overview]	Number of Participants Who Discontinued Study Therapy Due to AE(s)
NCT03217136 (6) [back to overview]	Number of Participants Experiencing ≥1 Adverse Events (AEs)
NCT03217136 (6) [back to overview]	"Percentage of Participants With a Clinical Response of Cure at the End of Treatment (EOT) Visit"
NCT03217136 (6) [back to overview]	"Percentage of Participants With a Clinical Response of Cure at the Test of Cure (TOC) Visit"
NCT03217136 (6) [back to overview]	Percentage of Participants With Microbiological Eradication at the TOC Visit
NCT03217136 (6) [back to overview]	Percentage of Participants With Microbiological Eradication at the EOT Visit
NCT03230838 (6) [back to overview]	Percentage of Participants With a Clinical Response of Cure at the Test of Cure Visit
NCT03230838 (6) [back to overview]	Percentage of Participants With Microbiological Eradication of All Baseline Pathogens at the End of Treatment Visit
NCT03230838 (6) [back to overview]	Percentage of Participants With Microbiological Eradication of All Baseline Pathogens at the Test of Cure Visit
NCT03230838 (6) [back to overview]	Number of Participants Discontinuing Study Therapy Due to AE
NCT03230838 (6) [back to overview]	Percentage of Participants With a Clinical Response of Cure at the End of Treatment Visit
NCT03230838 (6) [back to overview]	Number of Participants With ≥1 Adverse Events (AEs)
NCT03309657 (4) [back to overview]	Unbound Ceftolozane Exposure in the CSF
NCT03309657 (4) [back to overview]	Unbound Ceftolozane Exposure in the Plasma
NCT03309657 (4) [back to overview]	Unbound Tazobactam Exposure in the CSF
NCT03309657 (4) [back to overview]	Unbound Tazobactam Exposure in the Plasma
NCT03485950 (24) [back to overview]	Number of Participants With Infection-related Mortality in the MITT Analysis Set at LFU
NCT03485950 (24) [back to overview]	Number of Participants With Favorable Microbiological Response in the mMITT Analysis Set at LFU.
NCT03485950 (24) [back to overview]	Number of Participants With Favorable Clinical Response in the ME Analysis Set at TOC
NCT03485950 (24) [back to overview]	Number of Participants With Favorable Clinical Response in the MITT Analysis Set at Late Follow-Up (LFU)
NCT03485950 (24) [back to overview]	Number of Participants With Favorable Microbiological Response in the ME Analysis Set at TOC.
NCT03485950 (24) [back to overview]	Number of Participants With Favorable Microbiological Response in the ME Analysis Set at LFU
NCT03485950 (24) [back to overview]	Number of Participants With Favorable Microbiological Response in the ME Analysis Set at EOIV.
NCT03485950 (24) [back to overview]	Number of Participants With Favorable Clinical Response in the mMITT Analysis Set at Test of Cure (TOC)
NCT03485950 (24) [back to overview]	Number of Participants With Favorable Clinical Response in the mMITT Analysis Set at Late Follow-Up (LFU)
NCT03485950 (24) [back to overview]	Number of Participants With Favorable Clinical Response in the MITT Analysis Set at TOC
NCT03485950 (24) [back to overview]	Number of Participants With Favorable Clinical Response in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set at EOIV.
NCT03485950 (24) [back to overview]	Number of Participants With Favorable Clinical Response in the ME Analysis Set at LFU.
NCT03485950 (24) [back to overview]	Number of Participants With Favorable Clinical Response in the ME Analysis Set at EOIV.
NCT03485950 (24) [back to overview]	Number of Participants With Favorable Clinical Response in the Clinically Evaluable (CE) Analysis Set at EOIV.
NCT03485950 (24) [back to overview]	Number of Participants With Favorable Clinical Response in the CE Analysis Set at TOC
NCT03485950 (24) [back to overview]	Number of Participants With Favorable Clinical Response at End of Inpatient Intravenous Therapy (EOIV)
NCT03485950 (24) [back to overview]	Favorable Microbiological Response in the mMITT Analysis Set at TOC.
NCT03485950 (24) [back to overview]	30 Day All-cause Mortality in the mMITT Analysis Set
NCT03485950 (24) [back to overview]	30 Day All-cause Mortality in the MITT Analysis Set
NCT03485950 (24) [back to overview]	Number of Participants With Favorable Microbiological Response in the mMITT Analysis Set at EOIV.
NCT03485950 (24) [back to overview]	Number of Participants With Infection-related Mortality the mMITT Analysis Set at TOC
NCT03485950 (24) [back to overview]	Number of Participants With Favorable Clinical Response in the CE Analysis Set at LFU.
NCT03485950 (24) [back to overview]	Number of Participants With Infection-related Mortality in the mMITT Analysis Set at LFU.
NCT03485950 (24) [back to overview]	Number of Participants With Infection-related Mortality in the MITT Analysis Set at TOC
NCT03830333 (9) [back to overview]	Percentage of Participants With Favorable Per-Participant Microbiological Response of Eradication or Presumed Eradication at TOC Visit: Expanded Microbiologically Evaluable (EME) Population
NCT03830333 (9) [back to overview]	Percentage of Participants With Favorable Microbiological Response of Eradication or Presumed Eradication, by Pathogen, at the TOC Visit: EME Population
NCT03830333 (9) [back to overview]	Percentage of Participants With Clinical Response (Clinical Cure, Clinical Failure, or Indeterminate) at TOC Visit: Intent to Treat (ITT) Population
NCT03830333 (9) [back to overview]	Percentage of Participants With Clinical Response (Clinical Cure, Clinical Failure, or Indeterminate) at EOT Visit: ITT Population
NCT03830333 (9) [back to overview]	Percentage of Participants With Clinical Response (Clinical Cure or Clinical Failure) at End of Therapy (EOT) Visit: CE Population
NCT03830333 (9) [back to overview]	Percentage of Participants Who Experienced 1 or More Adverse Events (AEs)
NCT03830333 (9) [back to overview]	Percentage of Participants With Clinical Response (Clinical Cure or Clinical Failure) at Test of Cure (TOC) Visit: Clinically Evaluable (CE) Population
NCT03830333 (9) [back to overview]	Percentage of Participants That Discontinued Study Treatment Due to an AE
NCT03830333 (9) [back to overview]	Percentage of Participants With Favorable Microbiological Response of Eradication or Presumed Eradication, by Pathogen, at the TOC Visit: EME Population
NCT04042077 (5) [back to overview]	Hospital Infection Related Length of Stay (IRLOS)
NCT04042077 (5) [back to overview]	Number of Participants Eligible to Switch to Oral Formulation According to Blinded Observer's Assessment
NCT04042077 (5) [back to overview]	Hospital Length of Stay (LOS)
NCT04042077 (5) [back to overview]	Number of Participants With Clinical Success at Test Of Cure Visit
NCT04042077 (5) [back to overview]	Microbiological Response
NCT05102162 (10) [back to overview]	Superinfection Between Patients Treated With Continuous and Intermittent Infusion Beta-lactam Regimens.
NCT05102162 (10) [back to overview]	Percent of Time Free Drug Concentrations Remain Above the Minimum Inhibitory Concentration (%fT>MIC) in the Dosing Interval Between Patients Treated With Continuous and Intermittent Infusion Beta-lactam Regimens
NCT05102162 (10) [back to overview]	Percent of Time Free Drug Concentrations Remain Above Four Multiples of the Minimum Inhibitory Concentration (%fT>4xMIC) in the Dosing Interval Between Patients Treated With Continuous and Intermittent Infusion Beta-lactam Regimens
NCT05102162 (10) [back to overview]	Microbiologic Eradication Between Patients Treated With Continuous and Intermittent Infusion Beta-lactam Regimens
NCT05102162 (10) [back to overview]	Mortality Between Patients Treated With Continuous and Intermittent Infusion Beta-lactam Regimens
NCT05102162 (10) [back to overview]	Clinical Cure at Day 7 of Therapy Between Patients Treated With Continuous and Intermittent Infusion Beta-lactam Regimens
NCT05102162 (10) [back to overview]	Clinical Cure at the End of Therapy Between Patients Treated With Continuous and Intermittent Infusion Beta-lactam Regimens
NCT05102162 (10) [back to overview]	Gram-negative Bacterial Resistance Emergence Between Patients Treated With Continuous and Intermittent Infusion Beta-lactam Regimens
NCT05102162 (10) [back to overview]	Hospital Length of Stay Between Patients Treated With Continuous and Intermittent Infusion Beta-lactam Regimens.
NCT05102162 (10) [back to overview]	Intensive Care Unit (ICU) Length of Stay Between Patients Treated With Continuous and Intermittent Infusion Beta-lactam Regimens

Percentage of Participants Assessed as Improvements by the Data Review Committee (DRC) at the During Treatment Day 3-5 in the Intent to Treat (ITT) Population

"Clinical response was evaluated by the investigator and graded as improvement in signs and symptoms, or failure to respond, or indeterminate at Day 3 to 5 after treatment start based on subject data for clinical signs and symptoms at each visit, concomitant medication, microbiology results, laboratory tests and interpretation of photographs" (NCT00402727)
Timeframe: 3 - 5 days after start of treatment

Intervention	percentage of participants (Number)
Moxifloxacin	97.2
PIP/TAZ-AMC	95.8

Intervention	percentage of subjects (Number)
CXA 101/Tazobactam and Metronidazole	83.6
Meropenem With Matching Saline Placebo	96.0

Intervention	percentage of subjects (Number)
CXA 101/Tazobactam and Metronidazole	90.6
Meropenem With Matching Saline Placebo	95.8

Intervention	hours (Mean)
	Group 1 (CrCl >/= 80 mL/min) on 3.375 grams	Group 1 (CrCl >/= 80 mL/min) on 4.5 grams	Group 1 (CrCl >/= 80 mL/min) on 6.75 grams	Group 1 (CrCl >/= 80 mL/min) on 9 grams	Group 2 (CrCl >/= 40 to < 80 mL/min) on 3.375 gram	Group 2 (CrCl >/= 40 to < 80 mL/min) on 4.5 grams	Group 2 (CrCl >/= 40 to < 80 mL/min) on 6.75 grams	Group 2 (CrCl >/= 40 to < 80 mL/min) on 9 grams	Group 3 (CrCl < 40 mL/min) on 2.25 grams	Group 3 (CrCl < 40 mL/min) on 3.375 grams	Group 3 (CrCl < 40 mL/min) on 4.5 grams	Group 3 (CrCl < 40 mL/min) on 6.75 grams	Group 4 (HD) on 2.25 grams	Group 4 (HD) on 3.375 grams	Group 4 (HD) on 4.5 grams	Group 4 (HD) on 6.75 grams
Standard Dose to High Dose Piperacillin/Tazobactam	1.2	1.5	1.8	0.9	3.9	2.7	3.8	2.5	4.3	10.7	6.2	5.5	9.8	8.6	9.1	7.4

Intervention	milligrams per liter (Mean)
	Group 1 (CrCl >/= 80 mL/min) on 3.375 grams	Group 1 (CrCl >/= 80 mL/min) on 4.5 grams	Group 1 (CrCl > 80 mL/min) on 6.75 grams	Group 1 (CrCl >/= 80 mL/min) on 9 grams	Group 2 (CrCl >/= 40 to < 80 mL/min) on 3.375 gram	Group 2 (CrCl >/= 40 to < 80 mL/min) on 4.5 grams	Group 2 (CrCl >/= 40 to < 80 mL/min) on 6.75 grams	Group 2 (CrCl >/= 40 to < 80 mL/min) on 9 grams	Group 3 (CrCl < 40 mL/min) on 2.25 grams	Group 3 (CrCl < 40 mL/min) on 3.375 grams	Group 3 (CrCl < 40 mL/min) on 4.5 grams	Group 3 (CrCl < 40 mL/min) on 6.75 grams	Group 4 (HD) on 2.25 grams	Group 4 (HD) on 3.375 grams	Group 4 (HD) on 4.5 grams	Group 4 (HD) on 6.75 grams
Standard Dose to High Dose Piperacillin/Tazobactam	136	190	237	332	144	214	244	191	176	296	265	299	158	223	275	397

Intervention	Percentage of Participants (Number)
	Gram-Negative	Pseudomonas aeruginosa	Enterobacteriaceae	Escherichia coli	Klebsiella pneumoniae	Proteus mirabilis	Haemophilus influenzae	Enterobacter cloacae	Klebsiella oxytoca	Serratia marcescens	Acinetobacter baumannii
Ceftolozane/Tazobactam	69.9	79.3	68.7	78.3	71.4	63.6	91.7	57.1	87.5	40.0	33.3
Meropenem	62.4	55.3	65.6	73.9	66.7	70.0	50.0	75.0	57.1	50.0	80.0

Intervention	Participants (Count of Participants)
	Day 3: Improvement	EOIVT: Cure	EOIVT: Improvement	EOT: Cure	EOT: Improvement	TOC: Cure	LFU: Cure
Meropenem-Vaborbactam	243	202	45	235	7	231	220
Piperacillin-Tazobactam	250	206	46	239	6	224	209

Intervention	Participants (Count of Participants)
	Day 3: E. cloacae	EOIVT: E. cloacae	EOT: E. cloacae	TOC: E. cloacae	LFU: E. cloacae	Day 3: E. faecalis	EOIVT: E. faecalis	EOT: E. faecalis	TOC: E. faecalis	LFU: E. faecalis	Day 3: E. coli	EOIVT: E. coli	EOT: E. coli	TOC: E. coli	LFU: E. coli	Day 3: K. pneumoniae	EOIVT: K. pneumoniae	EOT: K. pneumoniae	TOC: K. pneumoniae	LFU: K. pneumoniae
Meropenem-Vaborbactam	10	10	10	9	8	13	13	12	5	9	124	123	112	89	90	29	29	27	19	15
Piperacillin-Tazobactam	3	5	5	3	2	14	14	13	11	9	106	107	100	68	68	24	26	24	14	12

Intervention	Participants (Count of Participants)
	Day 3: FDA	EOIVT: FDA	EOT: FDA	TOC: FDA	LFU: FDA	Day 3: EMA	EOIVT: EMA	EOT: EMA	TOC: EMA	LFU: EMA
Meropenem-Vaborbactam	177	178	163	122	122	174	178	160	118	120
Piperacillin-Tazobactam	160	166	156	109	99	157	166	156	102	94

Intervention	ug·hour/mL (Mean)
	AUC0-24: Day 1	AUC0-24: Steady-State
Meropenem-Vaborbactam	803	798

Intervention	Participants (Count of Participants)
	EOIVT	TOC
Meropenem-Vaborbactam	189	143
Piperacillin-Tazobactam	171	128

Intervention	Participants (Count of Participants)
Cohort 1: ≥12 to <18 Years TOL/TAZ 1000/500 mg FDC	0
Cohort 2: ≥7 to <12 Years TOL/TAZ 18/9 mg/kg	0
Cohort 3: ≥2 to <7 Years TOL/TAZ 18/9 mg/kg	0
Cohort 3: ≥2 to <7 Years TOL/TAZ 30/15 mg/kg	0
Cohort 4: ≥3 Months to <2 Years TOL/TAZ 18/9 mg/kg	0
Cohort 4: ≥3 Months to <2 Years TOL/TAZ 30/15 mg/kg	0
Cohort 5: Birth to <3 Months TOL/TAZ 20/10 mg/kg	0
Cohort 6: Birth to <3 Months TOL/TAZ 12/6 mg/kg	0
Cohort 6: Birth to <3 Months TOL/TAZ 20/10 mg/kg	0

Intervention	Hours (Geometric Mean)
Cohort 1: ≥12 to <18 Years TOL/TAZ 1000/500 mg FDC	1.45
Cohort 2: ≥7 to <12 Years TOL/TAZ 18/9 mg/kg	1.29
Cohort 3: ≥2 to <7 Years TOL/TAZ 18/9 mg/kg	1.34
Cohort 3: ≥2 to <7 Years TOL/TAZ 30/15 mg/kg	1.48
Cohort 4: ≥3 Months to <2 Years TOL/TAZ 18/9 mg/kg	1.30
Cohort 4: ≥3 Months to <2 Years TOL/TAZ 30/15 mg/kg	1.63
Cohort 5: Birth to <3 Months TOL/TAZ 20/10 mg/kg	2.21
Cohort 6: Birth to <3 Months TOL/TAZ 12/6 mg/kg	3.14
Cohort 6: Birth to <3 Months TOL/TAZ 20/10 mg/kg	1.73

Intervention	Hours (Geometric Mean)
Cohort 1: ≥12 to <18 Years TOL/TAZ 1000/500 mg FDC	0.702
Cohort 2: ≥7 to <12 Years TOL/TAZ 18/9 mg/kg	0.544
Cohort 3: ≥2 to <7 Years TOL/TAZ 18/9 mg/kg	0.719
Cohort 3: ≥2 to <7 Years TOL/TAZ 30/15 mg/kg	0.770
Cohort 4: ≥3 Months to <2 Years TOL/TAZ 18/9 mg/kg	0.538
Cohort 4: ≥3 Months to <2 Years TOL/TAZ 30/15 mg/kg	0.815
Cohort 5: Birth to <3 Months TOL/TAZ 20/10 mg/kg	1.09
Cohort 6: Birth to <3 Months TOL/TAZ 12/6 mg/kg	3.03
Cohort 6: Birth to <3 Months TOL/TAZ 20/10 mg/kg	0.875

Intervention	μg/mL (Geometric Least Squares Mean)
Cohort 1: ≥12 to <18 Years TOL/TAZ 1000/500 mg FDC	63.5
Cohort 2: ≥7 to <12 Years TOL/TAZ 18/9 mg/kg	56.2
Cohort 3: ≥2 to <7 Years TOL/TAZ 18/9 mg/kg	51.4
Cohort 3: ≥2 to <7 Years TOL/TAZ 30/15 mg/kg	96.6
Cohort 4: ≥3 Months to <2 Years TOL/TAZ 18/9 mg/kg	50.5
Cohort 4: ≥3 Months to <2 Years TOL/TAZ 30/15 mg/kg	91.3
Cohort 5: Birth to <3 Months TOL/TAZ 20/10 mg/kg	45.0
Cohort 6: Birth to <3 Months TOL/TAZ 12/6 mg/kg	34.9
Cohort 6: Birth to <3 Months TOL/TAZ 20/10 mg/kg	45.2

Intervention	μg/mL (Geometric Mean)
Cohort 1: ≥12 to <18 Years TOL/TAZ 1000/500 mg FDC	0.232
Cohort 2: ≥7 to <12 Years TOL/TAZ 18/9 mg/kg	0.420
Cohort 3: ≥2 to <7 Years TOL/TAZ 18/9 mg/kg	0.137
Cohort 3: ≥2 to <7 Years TOL/TAZ 30/15 mg/kg	0.327
Cohort 4: ≥3 Months to <2 Years TOL/TAZ 18/9 mg/kg	0.224
Cohort 4: ≥3 Months to <2 Years TOL/TAZ 30/15 mg/kg	0.401
Cohort 5: Birth to <3 Months TOL/TAZ 20/10 mg/kg	0.657
Cohort 6: Birth to <3 Months TOL/TAZ 12/6 mg/kg	3.66
Cohort 6: Birth to <3 Months TOL/TAZ 20/10 mg/kg	0.266

Intervention	Hours (Median)
Cohort 1: ≥12 to <18 Years TOL/TAZ 1000/500 mg FDC	6.00
Cohort 2: ≥7 to <12 Years TOL/TAZ 18/9 mg/kg	6.01
Cohort 3: ≥2 to <7 Years TOL/TAZ 18/9 mg/kg	6.08
Cohort 3: ≥2 to <7 Years TOL/TAZ 30/15 mg/kg	5.77
Cohort 4: ≥3 Months to <2 Years TOL/TAZ 18/9 mg/kg	6.00
Cohort 4: ≥3 Months to <2 Years TOL/TAZ 30/15 mg/kg	6.00
Cohort 5: Birth to <3 Months TOL/TAZ 20/10 mg/kg	6.01
Cohort 6: Birth to <3 Months TOL/TAZ 12/6 mg/kg	6.40
Cohort 6: Birth to <3 Months TOL/TAZ 20/10 mg/kg	5.85

Intervention	μg/mL (Geometric Least Squares Mean)
Cohort 1: ≥12 to <18 Years TOL/TAZ 1000/500 mg FDC	14.0
Cohort 2: ≥7 to <12 Years TOL/TAZ 18/9 mg/kg	9.25
Cohort 3: ≥2 to <7 Years TOL/TAZ 18/9 mg/kg	15.7
Cohort 3: ≥2 to <7 Years TOL/TAZ 30/15 mg/kg	24.8
Cohort 4: ≥3 Months to <2 Years TOL/TAZ 18/9 mg/kg	11.6
Cohort 4: ≥3 Months to <2 Years TOL/TAZ 30/15 mg/kg	22.4
Cohort 5: Birth to <3 Months TOL/TAZ 20/10 mg/kg	11.7
Cohort 6: Birth to <3 Months TOL/TAZ 12/6 mg/kg	6.87
Cohort 6: Birth to <3 Months TOL/TAZ 20/10 mg/kg	12.1

Intervention	L/hour/kg (Geometric Mean)
Cohort 1: ≥12 to <18 Years TOL/TAZ 1000/500 mg FDC	0.146
Cohort 2: ≥7 to <12 Years TOL/TAZ 18/9 mg/kg	0.168
Cohort 3: ≥2 to <7 Years TOL/TAZ 18/9 mg/kg	0.181
Cohort 3: ≥2 to <7 Years TOL/TAZ 30/15 mg/kg	0.162
Cohort 4: ≥3 Months to <2 Years TOL/TAZ 18/9 mg/kg	0.176
Cohort 4: ≥3 Months to <2 Years TOL/TAZ 30/15 mg/kg	0.149
Cohort 5: Birth to <3 Months TOL/TAZ 20/10 mg/kg	0.118
Cohort 6: Birth to <3 Months TOL/TAZ 12/6 mg/kg	0.0723
Cohort 6: Birth to <3 Months TOL/TAZ 20/10 mg/kg	0.147

Intervention	L/hour/kg (Geometric Mean)
Cohort 1: ≥12 to <18 Years TOL/TAZ 1000/500 mg FDC	0.556
Cohort 2: ≥7 to <12 Years TOL/TAZ 18/9 mg/kg	0.886
Cohort 3: ≥2 to <7 Years TOL/TAZ 18/9 mg/kg	0.506
Cohort 3: ≥2 to <7 Years TOL/TAZ 30/15 mg/kg	0.519
Cohort 4: ≥3 Months to <2 Years TOL/TAZ 18/9 mg/kg	0.611
Cohort 4: ≥3 Months to <2 Years TOL/TAZ 30/15 mg/kg	0.502
Cohort 5: Birth to <3 Months TOL/TAZ 20/10 mg/kg	0.385
Cohort 6: Birth to <3 Months TOL/TAZ 12/6 mg/kg	0.0760
Cohort 6: Birth to <3 Months TOL/TAZ 20/10 mg/kg	0.452

Intervention	μg/mL (Geometric Mean)
Cohort 1: ≥12 to <18 Years TOL/TAZ 1000/500 mg FDC	4.01
Cohort 2: ≥7 to <12 Years TOL/TAZ 18/9 mg/kg	2.85
Cohort 3: ≥2 to <7 Years TOL/TAZ 18/9 mg/kg	2.47
Cohort 3: ≥2 to <7 Years TOL/TAZ 30/15 mg/kg	5.69
Cohort 4: ≥3 Months to <2 Years TOL/TAZ 18/9 mg/kg	2.53
Cohort 4: ≥3 Months to <2 Years TOL/TAZ 30/15 mg/kg	5.72
Cohort 5: Birth to <3 Months TOL/TAZ 20/10 mg/kg	8.70
Cohort 6: Birth to <3 Months TOL/TAZ 12/6 mg/kg	10.2
Cohort 6: Birth to <3 Months TOL/TAZ 20/10 mg/kg	6.26

tazobactam

Description

Cross-References

Synonyms (90)

Research Excerpts

Overview

Effects

Actions

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (3)

Drug Classes (2)

Protein Targets (38)

Inhibition Measurements

Other Measurements

Biological Processes (7)

Molecular Functions (13)

Ceullar Components (5)

Bioassays (335)

Research

Studies (1,274)

Market Indicators

Research Demand Index: 109.45

Study Types

Clinical Trials (139)

Trial Overview

Trial Outcomes

Percentage of Participants Assessed as Improvements by the Data Review Committee (DRC) at the During Treatment Day 3-5 in the Intent to Treat (ITT) Population

Percentage of Participants Assessed as Resolution by the Data Review Committee (DRC) at End of Therapy in the Per Protocol (PP) Population

Percentage of Participants With Bacteriological Success (BS) After 14 - 28 Days After Last Dose of Study Medication in the ITT Population With Causative Organisms

Percentage of Participants With Bacteriological Success (BS) After 14 - 28 Days After Last Dose of Study Medication in the Microbiological Valid (MBV) Population

Percentage of Participants With Bacteriological Success (BS) After 7 - 21 Days of Treatment in the ITT Population With Causative Organisms

Percentage of Participants With Bacteriological Success (BS) After 7 - 21 Days of Treatment in the Microbiological Valid (MBV) Population

Percentage of Participants With Bacteriological Success (BS) at 3 to 5 Days After Start of Treatment in the ITT Population With Causative Organisms

Percentage of Participants With Bacteriological Success (BS) at 3 to 5 Days After Start of Treatment in the Microbiological Valid (MBV) Population

Percentage of Participants Assessed as Resolution by the Data Review Committee (DRC) at End of Therapy in the Intent to Treat (ITT) Population

Percentage of Participants Assessed as Improvements by the Data Review Committee (DRC) at the During Treatment Day 3-5 in the Per Protocol (PP) Population

Percentage of Cured Participants as Determined by the Data Review Committee (DRC) at Test of Cure Visit in the Per Protocol (PP) Population

Percentage of Cured Participants as Determined by the Data Review Committee (DRC) at Test of Cure Visit in the Intent to Treat (ITT) Population

Piperacillin Pharmacokinetics (PK)

Clinical Response of CXA 101/Tazobactam and Metronidazole at Test of Cure (TOC) Visit in the Microbiological Modified Intent to Treat (mMITT) Analysis Population

Microbiological Response of CXA 101/Tazobactam and Metronidazole at the TOC Visit in the Microbiologically Evaluable (ME) Population

Percentage of Participants With Favorable Microbiological Response Assessments at FUA Day 10 of Post-antibiotic Study Therapy

Percentage of Participants With Favorable Clinical Response Assessments at Follow-up Assessment (FUA) Day 10 of Post-antibiotic Study Therapy

Percentage of Participants With Serious AEs (SAEs)

Percentage of Participants With One or More Adverse Events (AEs)

Percentage of Participants Who Discontinued Treatment Due to an AE

Percentage of Participants With Both Favorable Clinical and Microbiological Response Assessments at FUA Day 10 of Post-antibiotic Study Therapy

Percentage of Participants With Drug-related AEs

Percentage of Participants With Favorable Clinical Response Assessments at Day 5 of IV Study Therapy

Percentage of Participants With Favorable Clinical Response Assessments at Discontinuation of Intravenous (IV) Study Therapy (DCIV)

Half-life of Piperacillin

Volume of Distribution of Piperacillin

Serum Minimum Concentrations of Piperacillin

Serum Maximum Concentrations for Piperacillin

Number of Participants With Feeding Intolerance

Number of Participants With Therapeutic Success at Day 30

Number of Participants With Short Bowel Syndrome

Number of Participants With Seizure

Number of Participants With Positive Blood Cultures

Number of Participants With Intestinal Stricture

Number of Participants With Intestinal Perforation

Number of Participants With Grade 3 and/or Grade 4 Intraventricular Hemorrhage (IVH)

Death

Number of Participants Progressed to a Higher Stage of Necrotizing Enterocolitis (NEC), if NEC is the Cause of the Complicated Intra-abdominal Infection

Number of Participants With Gastrointestinal Surgeries

Percentage of Participants With All Cause Mortality in the Microbiological Intent-to-Treat (mITT) Population - Day 28

Percentage of Participants With All Cause Mortality in the Intent-to-Treat (ITT) Population - Day 28

Percentage of Participants Who Report 1 or More Adverse Event (AE)

Percentage of Participants Discontinuing Study Drug Due to an Adverse Event (AE)

Percentage of Participants With Any Serious Adverse Event (SAE)

Percentage of Participants With Microbiological Response of Eradication or Presumed Eradication, by Pathogen, at the Test-of-Cure (TOC) Visit in the Microbiologically Evaluable (ME) Population (>=10 Isolates at Baseline)

Percentage of Participants With Per-Participant Microbiological Response of Cure or Presumed Cure at the Test-of-Cure (TOC) Visit in the Microbiologically Evaluable (ME) Population

Percentage of Participants With Per-Participant Microbiological Response of Cure or Presumed Cure at the End-of-Therapy (EOT) Visit in the Microbiologically Evaluable (ME) Population

Percentage of Participants With Clinical Response of Clinical Cure at the Test-of-Cure (TOC) Visit in the Intent-to-Treat (ITT) Population

Percentage of Participants With Clinical Response of Clinical Cure at the Test-of-Cure (TOC) Visit in the Clinically Evaluable (CE) Population

Percentage of Participants With Clinical Response of Clinical Cure at the Late Follow-up (LFU) Visit in the Clinically Evaluable (CE) Population

Intervention	Hours (Median)
Cohort 1: ≥12 to <18 Years TOL/TAZ 1000/500 mg FDC	4.15
Cohort 2: ≥7 to <12 Years TOL/TAZ 18/9 mg/kg	3.10
Cohort 3: ≥2 to <7 Years TOL/TAZ 18/9 mg/kg	5.85
Cohort 3: ≥2 to <7 Years TOL/TAZ 30/15 mg/kg	5.72
Cohort 4: ≥3 Months to <2 Years TOL/TAZ 18/9 mg/kg	4.00
Cohort 4: ≥3 Months to <2 Years TOL/TAZ 30/15 mg/kg	5.02
Cohort 5: Birth to <3 Months TOL/TAZ 20/10 mg/kg	5.95
Cohort 6: Birth to <3 Months TOL/TAZ 12/6 mg/kg	6.40
Cohort 6: Birth to <3 Months TOL/TAZ 20/10 mg/kg	5.85

Intervention	Hours (Median)
Cohort 1: ≥12 to <18 Years TOL/TAZ 1000/500 mg FDC	1.00
Cohort 2: ≥7 to <12 Years TOL/TAZ 18/9 mg/kg	1.07
Cohort 3: ≥2 to <7 Years TOL/TAZ 18/9 mg/kg	1.02
Cohort 3: ≥2 to <7 Years TOL/TAZ 30/15 mg/kg	1.03
Cohort 4: ≥3 Months to <2 Years TOL/TAZ 18/9 mg/kg	1.00
Cohort 4: ≥3 Months to <2 Years TOL/TAZ 30/15 mg/kg	1.05
Cohort 5: Birth to <3 Months TOL/TAZ 20/10 mg/kg	1.08
Cohort 6: Birth to <3 Months TOL/TAZ 12/6 mg/kg	3.89
Cohort 6: Birth to <3 Months TOL/TAZ 20/10 mg/kg	1.07

Intervention	L/kg (Geometric Mean)
Cohort 1: ≥12 to <18 Years TOL/TAZ 1000/500 mg FDC	0.274
Cohort 2: ≥7 to <12 Years TOL/TAZ 18/9 mg/kg	0.296
Cohort 3: ≥2 to <7 Years TOL/TAZ 18/9 mg/kg	0.331
Cohort 3: ≥2 to <7 Years TOL/TAZ 30/15 mg/kg	0.312
Cohort 4: ≥3 Months to <2 Years TOL/TAZ 18/9 mg/kg	0.282
Cohort 4: ≥3 Months to <2 Years TOL/TAZ 30/15 mg/kg	0.340
Cohort 5: Birth to <3 Months TOL/TAZ 20/10 mg/kg	0.394
Cohort 6: Birth to <3 Months TOL/TAZ 12/6 mg/kg	0.344
Cohort 6: Birth to <3 Months TOL/TAZ 20/10 mg/kg	0.388

Intervention	L/kg (Geometric Mean)
Cohort 1: ≥12 to <18 Years TOL/TAZ 1000/500 mg FDC	0.474
Cohort 2: ≥7 to <12 Years TOL/TAZ 18/9 mg/kg	0.740
Cohort 3: ≥2 to <7 Years TOL/TAZ 18/9 mg/kg	0.488
Cohort 3: ≥2 to <7 Years TOL/TAZ 30/15 mg/kg	0.513
Cohort 4: ≥3 Months to <2 Years TOL/TAZ 18/9 mg/kg	0.421
Cohort 4: ≥3 Months to <2 Years TOL/TAZ 30/15 mg/kg	0.574
Cohort 5: Birth to <3 Months TOL/TAZ 20/10 mg/kg	0.668
Cohort 6: Birth to <3 Months TOL/TAZ 12/6 mg/kg	0.338
Cohort 6: Birth to <3 Months TOL/TAZ 20/10 mg/kg	0.667

Intervention	Hours*μg/mL (Geometric Least Squares Mean)
Cohort 1: ≥12 to <18 Years TOL/TAZ 1000/500 mg FDC	17.5
Cohort 2: ≥7 to <12 Years TOL/TAZ 18/9 mg/kg	10.2
Cohort 3: ≥2 to <7 Years TOL/TAZ 18/9 mg/kg	17.8
Cohort 3: ≥2 to <7 Years TOL/TAZ 30/15 mg/kg	28.9
Cohort 4: ≥3 Months to <2 Years TOL/TAZ 18/9 mg/kg	14.9
Cohort 4: ≥3 Months to <2 Years TOL/TAZ 30/15 mg/kg	29.9
Cohort 5: Birth to <3 Months TOL/TAZ 20/10 mg/kg	24.9
Cohort 6: Birth to <3 Months TOL/TAZ 12/6 mg/kg	77.6
Cohort 6: Birth to <3 Months TOL/TAZ 20/10 mg/kg	22.3

Intervention	Hours*μg/mL (Geometric Least Squares Mean)
Cohort 1: ≥12 to <18 Years TOL/TAZ 1000/500 mg FDC	17.3
Cohort 2: ≥7 to <12 Years TOL/TAZ 18/9 mg/kg	9.69
Cohort 3: ≥2 to <7 Years TOL/TAZ 18/9 mg/kg	17.6
Cohort 3: ≥2 to <7 Years TOL/TAZ 30/15 mg/kg	28.5
Cohort 4: ≥3 Months to <2 Years TOL/TAZ 18/9 mg/kg	14.8
Cohort 4: ≥3 Months to <2 Years TOL/TAZ 30/15 mg/kg	28.9
Cohort 5: Birth to <3 Months TOL/TAZ 20/10 mg/kg	21.3
Cohort 6: Birth to <3 Months TOL/TAZ 12/6 mg/kg	21.6
Cohort 6: Birth to <3 Months TOL/TAZ 20/10 mg/kg	21.9

Intervention	Hours (Geometric Mean)
	First Dose	Last Dose
Mechanically Ventilated -Tazobactam	2.15	2.33
Mechanically Ventilated- Ceftolozane	4.15	4.86

Intervention	Ratio (Mean)
	1 Hr Post-dose	2 Hr Post-dose	4 Hr Post-dose	6 Hr Post-dose	8 Hr Post-dose
Mechanically Ventilated - Ceftolozane	0.213	0.360	1.76	1.02	0.786
Mechanically Ventilated - Tazobactam	0.234	0.471	2.34	2.59	1.06

Intervention	Liter (Geometric Mean)
Critically Ill - Ceftolozane	30.2
Critically Ill - Tazobactam	51.6

Intervention	Hours (Median)
Critically Ill - Ceftolozane	7.95
Critically Ill - Tazobactam	7.85